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Summary 
Background:  
Respiratory conditions are prevalent and cause an enormous burden on society. In recent 
decades, there has been a global increase in asthma in children and adults, yet the 
diagnosis of asthma must be made on clinical grounds as the diagnostic use of 
pharmacological reversibility of airway obstruction remains controversial. It is possible 
however that tools exist from different medical paradigms that may assist in the clinical 
diagnosis of asthma. Tools such as Traditional Chinese Medicine (TCM) enquiry, Breath 
Holding Time (BHT) or Electro-Dermal Screening Test (EDST) may provide useful 
clinical information, yet their use has not been widely explored or validated. 
 
Integrative medicine may be considered to represent a new frontier in medicine where 
each therapy and diagnostic method is seen to have its own advantages and limitations 
and where an integration of both diagnostic and therapeutic techniques from conventional 
and complementary medicine is seen to produce the best results. However, while there is 
a high community use of complementary therapies for conditions such as asthma, there is 
also a need to maintain accepted standards of medical and scientific principles and foster 
high quality research into complementary therapies.  
 
Objectives:  
The current study sought to determine: 
•  If there is a correlation between conventional measures of lung function such as 
Forced Expiratory Volume in one second (FEV1) and less conventional measures such as 
airways expired NO level (eNO), electrodermal measures, TCM enquiry and BHT. 
• If any of the lung function measures are able to distinguish between asthmatic and 
healthy subjects.  
• If the use of a rye grass extract is better than placebo in improving requirements for 
bronchodilator medication, peak flow, forced expiratory volume in one second or quality 
of life in mild to moderate childhood asthma. 
 
Rational for carrying out two separate studies as one study; 
The author was interested on both the integration of diagnostic techniques as well as the 
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effect of the herbal extract on asthma so it was decided to use the opportunity and put 
both in one study. 
 
Method:  
A range of conventional and non-conventional measures were conducted in healthy and 
asthmatic children including demographic details, quality of life data, spirometry 
measures, airway nitric oxide levels, electro-dermal measures, TCM history enquiries, 
breath holding time, and skin prick tests. The data were analysed to determine any 
significant correlations between these measures. A double blind randomized controlled 
pilot clinical trial was also performed to assess the effect of using rye grass extract in 
asthmatic children aged 8 to 16 years. 
Results:  
There were significant correlations between forced expiratory volume in one second and 
active quality of life, TCM spleen score and fraction of exhaled nitric oxide 
measurements.  There were also statistically significant differences between asthmatic and 
healthy subjects in TCM history, breath holding time and exhaled nitric oxide. The use of 
rye grass extract did not produce any significant improvement over placebo in any of the 
asthma outcome measures.   
Conclusions:  
The use of inexpensive measures such as BHT and TCM enquiry may provide useful 
clinical information when assessing respiratory conditions such as asthma. However, 
further research is required in larger populations to confirm their use. The use of the rye 
grass extract at the dose given in this study did not provide any clinical benefit for the 
asthmatic children in this study.   
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Chapter One: Literature Review 
1.1 Respiratory Disease and Asthma 
Respiratory conditions cause an enormous burden on society. According to the WHO 
World Health Report 2000, the top five respiratory diseases account for 17.4% of all 
deaths and 13.3% of all Disability-Adjusted Life Years with lower respiratory tract 
infections, chronic obstructive pulmonary disease (COPD), tuberculosis and lung cancer 
being among the leading causes of death worldwide (WHO 2002). 
 
While asthma has a relatively low fatality rate compared to these other respiratory 
conditions, asthma is estimated to affect about 150 million people world-wide and is the 
most prevalent chronic disease in childhood. High prevalence of childhood asthma 
observed during the last decades predicts the growing prevalence of asthma in the near 
future unless appropriate preventive measures are implemented (WHO 2002). One of the 
points for establishing an effective prevention and control program is to develop globally 
accepted criteria for the diagnosis of Chronic Respiratory Diseases (CRDs); also 
identifying research priorities, which should include, in addition to diagnosis, prevention 
strategies, therapeutic regimens, alternative drug delivery systems, traditional medicine 
and alternative therapeutic approaches (WHO 2002).  
1.1.1 Definition and Epidemiology of Asthma 
Asthma is a heterogeneous disease with changeable signs and symptoms among patients. 
Bronchial asthma is not a disease entity but a nonspecific reaction of the lung 
characterised by recurrent reversible airway obstruction (Rieger 1983). It also presents 
significant individual variability over time (Stein and Martinez 2004). Asthma has been 
defined as  the narrowing of the air tubes in the lungs through muscle contraction, 
inflammation and production of excess mucus causing difficulty in breathing the inhaling 
and exhaling of air (Matheson, Wicking et al. 2003).  
 
Despite improvement of therapeutic regimens, allergic disorders are common and affect 
people from all social classes and ethnic groups and are significant burdens to the 
affected individual, management problems for the parent and physician and the economic 
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cost to the family and the nation (Gupta, Sheikh et al. 2004; O'Connell 2004).  
 
Asthma is the most common chronic childhood disease (Lowe, Custovic et al. 2003) and 
childhood asthma contributes significantly to morbidity among children (Dalheim-
Englund, Rydstrom et al. 2004). United States national data suggests that the asthma 
hospitalization rate grew by 1.4% per year from 1980 to 1999. Although childhood 
asthma deaths are rare, the asthma death rate increased by 3.4% per year from 1980 to 
1998. Children aged 0 to 4 years had the largest increase in prevalence and had greater 
health care use, but adolescents had the highest mortality (Akinbami and Schoendorf 
2002).  
1.1.2 Prevalence of Asthma 
An international report released on World Asthma Day (4th May 2004) reveals that a 
global increase in asthma has occurred in both children and adults in recent decades, 
asthma is estimated to affect as many as 300 million people worldwide and it has been 
suggested that this number could increase by a further 100-150 million by 2025 (Cassar 
2004). Approximately 15 million Americans including over 5 million children suffer 
from asthma (Kalantar-Zadeh, Lee et al. 2004). 2 Serial cross-sectional studies were 
performed 15 years apart on children aged 7 to 17 years,in Denmark, one in 1986 (n = 
527) and the second in 2001 (n = 480) suggests that the prevalence of asthma has 
increased, especially in industrialized countries (Thomsen, Ulrik et al. 2004).  
 
Most of the studies indicate that the prevalence of asthma and related symptoms in 
developing countries is as high and variable as described previously for industrialized or 
developed regions of the world and that the environmental risk factors, mainly related 
with poverty, lack of a clear biomedical definition and lack of treatment plan for illness 
could be responsible for the different clinical and functional presentations of asthma in 
children (Mallol 2004; Schwartz 2004; Sichletidis, Chloros et al. 2004). 
 
The International Study of Asthma and Allergies in Childhood (ISAAC)  demonstrated 
that the highest prevalence of asthma in the world is in English-speaking countries, 
including New Zealand (Pattemore, Ellison-Loschmann et al. 2004). In the United States 
according to the National Health Interview Survey for asthma and neurodevelopmental 
disorders the prevalence of children with asthma doubled between 1980 and 1995, from 
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3.6% in 1980 to 7.5% in 1995 (Woodruff, Axelrad et al. 2004).  
Robertson et al’s question based survey in Melbourne, Sydney, Adelaide in 1993 and 
Perth in 1994 of students attending a random sample of 272 schools, stratified by age and 
city reports that asthma is a growing medical concern and demonstrates an increase in 
asthma prevalence in Australian children and is higher among Australian-born children 
than among those born elsewhere (Robertson, Dalton et al. 1998; Knight, Stewart-Brown 
et al. 2001; Woolcock 2002). It has been reported that asthma effects approximately one 
in five Australian children and one in ten adults (Woolcock 1988).  
 
Again according to Wilson study surveys by telephone interview of the South Australian 
population, and interview of participants in their own homes by trained health 
interviewers demonstrated that the prevalence of doctor-diagnosed asthma has increased 
from 8% in 1990 to 12.8% in 2001 (Wilson, Adams et al. 2003). There were 
approximately 2.2 million people in Australia with asthma as a current and long term 
condition (Thomas 2001). The prevalence of wheezing illness and asthma in children has 
increased dramatically over the last 20 years (Woolcock, Bastiampillai et al. 2001).  
 
According to a questionnaire-based survey on asthma and allergy in childhood there has 
been a 26% reduction in the 12-month period prevalence of reported wheeze,  and there 
was a reduction from 27.2% in 1993 to 20.0% in 2002 and also there were reductions in 
the proportion of children attending an emergency department (ED) for asthma from 
3.6% to 2.3%, the proportion admitted to hospital from 1.7% to 1.1% and the proportion 
taking asthma medication from 18.5% to 13.4% in Melbourne schoolchildren, despite an 
increase in the proportion taking regular inhaled steroids and increase in the prevalence 
of eczema and allergic rhinitis (Robertson, Roberts et al. 2004). In Switzerland it is 
estimated that there was no increase in adolescent asthma and allergy rates during the 
1990s (Braun-Fahrlander, Gassner et al. 2004). There is also a reported decrease in 
asthma prevalence in Israeli children with suggestions that this may be due to an increase 
in the use of inhaled corticosteroids (Goldman, Rachmiel et al. 2000) and a better anti-
inflammatory treatment (Morad, Kandel et al. 2004).  
In a systematic international comparison of the prevalence of asthma studying 463,801 
children aged 13-14 years in 155 collaborating centers in 56 countries Australia is 
reported to have one of the highest rates of asthma after the United Kingdom in the world 
(ISAAC 1998). 
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The reasons underlying the high prevalence of asthma in Australia are not well 
understood, although genetics, westernized life style and high allergen exposure are 
considered to be important factors.  
1.1.3 Aetiology of Childhood Asthma 
The cause of asthma remains essentially unknown (Kaiser 2004) despite increasing 
evidence indicating that genetic and environmental factors have significant effects on 
airway development and function in early life (Kurukulaaratchy, Matthews et al. 2004). 
Current understanding of the natural history of asthma is limited (Lowe, Custovic et al. 
2003; Wilson, Adams et al. 2003; Cole Johnson, Ownby et al. 2004; Lowe, Custovic et 
al. 2004; Wilson, Lamprill et al. 2004).  
 
Asthma is related to atopy which is caused by the interaction between genetic and distinct 
environmental factors (allergens) that lead to various clinical manifestations. It is claimed 
that in most cases, asthma is mainly an allergic process, mediated by an IgE mechanism 
and that inhalation of allergens is considered the most important cause of the onset of 
asthma in predisposed children (Casas Vila 2004).  
 
Beneath the lining of the skin, gut, lungs, nose and eyes are mast cells that contain 
granules filled with irritant chemicals such as histamine. Mast cells are also armed with 
proteins called IgE antibodies, which act as remote sensors in the local environment. A 
person allergic to house dust mite, for example, will have IgE antibodies capable of 
recognizing the shape of dust mite allergens, in much the same way that a lock 
"recognizes" the shape of a key. When this happens, mast cells are triggered to release 
their contents into the tissues, triggering an allergic reaction (Grootendorst, Dahlen et al. 
2001). 
 
The early exposure to allergens or irritants is thought to be an important cause of asthma 
(Vermeire 1999). It is suggested that the presence of an allergen firstly gives rise to 
sensitization, with the formation of specific IgE. In subsequent exposures, mediators are 
released, with an inflammatory response of the airways and an increase in bronchial 
hyperreactivity. If the presence of the allergen is prolonged, inflammation and subsequent 
healing may lead to irreversible damage to the bronchial wall and permanent 
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deterioration of respiratory function (Casas Vila 2004).  
 
There are a number of allergens that can trigger an asthma attack, for example the 
sensitisation to moulds is a known risk factor for life threatening exacerbations of asthma 
and the prevalence of sensitization to moulds has been found to increase with increasing 
severity of asthma. It is unknown however, whether such sensitization is associated with 
severity of asthma (Zureik, Neukirch et al. 2002). 
 
Clinical and epidemiologic studies suggest that asthma manifestations in preschool 
children may significantly differ from those observed in older subjects and may be 
related to viral infections (Silvestri, Sabatini et al. 2004). According to Silvestri et al 
there is strong epidemiological evidence that approximately 2/3 of all children who 
wheeze in early life do so because of viral infections rather than atopy and therefore have 
a transient condition that tends to disappear during early school years (Silvestri, Sabatini 
et al. 2004).  
 
However in some studies quantification of risk showed that school children with atopic 
eczema had a 3-times risk of allergic rhinitis and a 5-times risk of allergic asthma 
compared with schoolchildren without atopic eczema. The severity of eczema was also 
directly related to that of asthma and rhinitis (Falade, Olawuyi et al. 2004; Martin 
Fernandez-Mayoralas, Martin Caballero et al. 2004). Allergen exposure may also 
increase the risk of atopic consequences, but the outcome is highly dependent on dose of 
the allergen, timing of exposure, and, most interestingly, the nature of the allergen in 
question. Endotoxin exposure during infancy has been associated with increased 
wheezing during the first years of life, but several studies indicate that early exposure 
may confer some protection against allergy later in life (Wright 2004). 
 
Wright et al also suggest that increased psychological stress in early childhood is 
associated with an atopic immune profile in these children predisposed to atopy-asthma 
(Wright, Finn et al. 2004). In some places like Japan asthma attack shows strong 
seasonality. Some studies suggest that specific climate conditions and other seasonal 
factors increase the prevalence of asthma in those places (Hashimoto, Fukuda et al. 2004; 
Weiland, Husing et al. 2004). In indigenous Latin American populations the prevalence 
of all the symptoms of asthma was higher in children with a family history, contact with 
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pets or living where open fires were used for cooking (Maia, Marcopito et al. 2004; 
Mallol 2004; Schei, Hessen et al. 2004). 
 
Data from the National Health and Nutrition Survey (NHNS) also suggests that increased 
Body Mass Index (BMI) may influence asthma prevalence in children. In this study after 
controlling for dietary intake, physical activity, and sociodemographic variables, asthma 
risk was three times higher for children aged 6-16 years than 2-5 years old (Romieu, 
Mannino et al. 2004). The use of synthetic bedding may also increase the prevalence of 
wheezing (Victoria. 2003; Ponsonby, Dwyer et al. 2004; Trevillian, Ponsonby et al. 
2004).  
 
Environmental exposures in the first year of life to wood or oil smoke, soot, or exhausts, 
cockroaches, herbicides or pesticides and farm crops, farm dust, or farm animals are 
associated with childhood asthma risk. The risk of asthma decreased with an increasing 
number of siblings, and day care attendance within the first 4 months of life (Salam, Li et 
al. 2004). It is possible that early life exposure to endotoxins might moderate the 
development of allergy and persistent asthma and this is consistent with the "Hygiene 
Hypothesis" of allergy and asthma (Liu 2004). However the prevalence of asthma among 
a random sample of homeless children in New York City is more than 6 times the 
national rate for children (McLean, Bowen et al. 2004).  
 
A screening survey conducted within the context of a community-based participatory 
research partnership in Detroit, Michigan identified large numbers of children with 
undiagnosed and/or undertreated moderate-to-severe asthma (Lewis, Robins et al. 2004). 
 
The 'hygiene hypothesis' (relation between frequent infection in infancy and early 
childhood and low prevalence of asthma and other atopic disease among children in 
developing countries) does not support the hypothesis that infection protects against 
atopic eczema or recurrent wheezing in the first 12 months of life (Kramer, Guo et al. 
2004). Some prevention studies have been done; although initial results look promising, 
further follow up of the ongoing cohorts is required before any recommendations can be 
made within the public health context (Simpson and Custovic 2004). 
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1.1.3.1 General Asthma Triggers 
The following are common trigger factors of Asthma:  
 
• All respiratory viruses may be implicated in the wheezing episodes, the principal 
being respiratory syncytial virus (RSV) and, with a lower frequency, adenovirus and 
parainfluenza viruses during the first 3 years of life, and rhinoviruses after that age. 
Infants and preschool children have on average 6-8 "colds" per year, but the illness tends 
to be limited to the upper respiratory tract alone in a considerable proportion of 
individuals, without causing symptomatic involvement of the lower respiratory tract. The 
variety of factors determining the different outcomes are only partially known, but 
complex interactions between the intrinsic pathogenicity of the virus and host factors, 
including the socio-economic conditions of the family, are central to define the type of 
manifestations and the severity of the process which may lead to asthma.(Silvestri, 
Sabatini et al. 2004).  
• A high birth weight may be a risk factor for asthma in childhood however; few 
studies have examined this relationship. All neonates born at term between, 1985, and 
1988, in Alberta/Canada (N = 83,595) were divided into three birth-weight categories: 
low, normal and high birth weight (>4.5 kg). The cohort was observed prospectively for 
10 years showed that the neonates born with a high birth weight had a significantly 
increased risk of emergency visits for asthma during childhood compared to normal and 
low weight neonates. It suggests that the birth weight is a risk factor for increased asthma 
symptoms during childhood with the risk increasing linearly beyond a birth weight of 4.5 
kg (Sin, Spier et al. 2004).  
• Even at low levels of exposure, cigarette smoking and environmental tobacco smoke 
are independently associated with asthmatic symptoms in childhood (Janson 2004; 
Sturm, Yeatts et al. 2004).  
•  Dust mite may have a role in the primary causation of asthma (Wickens, de Bruyne 
et al. 2004).  
•  Early vitamin supplementation during the infancy and childhood is associated with 
increased risk for asthma and food allergies in black children, exclusively formula-fed 
children (Milner, Stein et al. 2004). 
• Maternal intake of foods containing vitamin E and zinc during pregnancy is 
associated with differences in the risks of developing childhood wheeze and asthma 
(Devereux, Turner et al. 2006)  
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• Dietary intake, especially of antioxidant vitamins A, C, E, and the carotenoids, has 
been linked with the presence and severity of asthma. The Third National Health and 
Nutrition Examination Survey (NHANES III), conducted in the United States between 
1988 and 1994 indicates that low vitamin C and alpha-carotene intakes are associated 
with asthma risk in children (Harik-Khan, Muller et al. 2004) 
• The traffic related pollutants might have contributed to the asthma epidemic that has 
taken place during the past decades among children.(Zmirou, Gauvin et al. 2004).  
• Psychologic stress modifies immune function and cytokine production therefore 
increased stress in early childhood was associated with an atopic immune profile in these 
children predisposed to atopy-asthma (Wright 2004)}. 
• The heavy metal, lead, is a known developmental immunotoxicant and a perinatal 
risk factor for childhood asthma as well as other diseases (Dietert, Lee et al. 2004).  
 
Many of these triggers are associated with particular demographic groups and also 
socioeconomic and lifestyle factors, such as exposure to smoking, pets, personal journey 
lengths and modes, income, household occupancy and domestic fuel use, may have 
limited detectable effects on lung function (Crabbe, Barber et al. 2004).  
1.1.4 Pathophysiology of Asthma 
The airways smooth muscle is increased in amount in asthma and as the asthmatic 
condition progresses this inflammatory reaction becomes more severe. This is associated 
with sloughing of the epithelial layer and regeneration of the basal epithelial cells that 
leads to thickening of the epithelial basement membrane as well as goblet cell and 
squamous cell metaplasia (Hogg 1984). Recent studies also suggest that airway 
inflammation is one of the immediate causes of the recurrent episodes of airflow 
limitation in asthma (Andreadis, Hazen et al. 2003; Belvisi, Hele et al. 2004). From time 
to time an asthma-like inflammation, with increased inflammatory cells and thickening of 
the lung basement membrane, may be present also at a very early age (Martinez 1999).  
 
Chronic inflammation is a key feature in many lung diseases such as asthma. Currently 
the diagnoses and follow up of inflammatory lung disease are based largely on 
radiography and measurements of lung function. However, these methods do not measure 
the inflammatory process but secondary changes caused by it. Direct measure of 
inflammation would therefore provide more precise information on the underlying 
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pathogenetic process and the activity of the disease (Bousquet 2000). There are few 
studies relating airway physiology, inflammation and remodeling.  
Early  studies support the hypothesis of structural alterations and resulting caliber 
changes of respiratory airways could have important effects on airway physiology and 
reactivity (Kuhn, Homer et al. 2000). A later study suggests that airway wall thickening 
attenuates airway reactivity in patients with asthma (Niimi, Matsumoto et al. 2003) 
however a recent study proposes that  at baseline Reticular Basement Membrane (RBM) 
thickening is related to bronchoalveolar lavage mast cells and  airway endobronchial  
biopsy eosinophil counts and suggests that airway inflammation, remodeling, and 
bronchial hyperresponsiveness in asthma are inter-related and improved by inhaled 
corticosteroid therapy (Holmén, Blomqvist et al. 1997; Ward, Reid et al. 2005). 
 
Asthma characteristics are also categorized by their immunopathology on the basis of 
patterns of inflammation, specifically the presence or absence of particular inflammatory 
cell types—eg, eosinophils or neutrophils (Simpson, Scott et al. 2005).  
 
Allergy in patients with atopy is caused by clinical adverse reactions to environmental 
antigen, which is often associated with allergen-specific immunoglobulin (Ig)E 
production (Yang 2001). 
 
Recently the "hygiene hypothesis" suggests that lack of exposure to a childhood 
infection, endotoxin, and bacterial products is an important determinant regarding 
development of atopic disease (Liu 2004). It is clear that a family history (genetics) is the 
strongest risk factor for the development of clinical atopic disease but it is also clear that 
environmental issues play a significant role and that there is a lot we still do not know 
(Kaiser 2004). 
 
The observed striking increase in intrinsic asthma suggests the possibility of a more 
heterogeneous disorder, involving more important factors than atopy (Thomsen, Ulrik et 
al. 2004).   
1.1.5. Symptoms and Signs of Asthma 
The National Asthma Council (NAC) of Australia describes the signs and symptoms of 
asthma as wheezing, coughing, shortness of breath, chest tightness, airway inflammation, 
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and bronchoconstriction due to narrowing of the airways within the lungs.  
The symptoms associated with asthma differ from person to person (Berg 2002). The 
asthma could be defined by level of severity (from mild to severe), the frequency of 
exacerbations, the presence of chronic airflow restriction, and the age of asthma onset 
(Chesnutt 2002; Miranda, Busacker et al. 2004; Wenzel 2006). Phenotypes of asthma 
defined by response to treatment, such as resistance to steroids, can also be put in this 
category (Wenzel, Schwartz et al. 1999). Phenotypes can also be defined on the basis of 
their relation to specific triggers including exercise, environmental allergens, 
occupational allergens and irritants, drugs (such as aspirin), and menses (Bobb and Ritz 
2003; Williams, Schmidt et al. 2003). 
 
Typical asthma symptoms are respiratory symptoms; cough, wheeze shortness of breath, 
chest tightness and exercise induced symptoms. Wheezing is the cardinal symptom yet all 
that wheezes is not asthma (Tilles 2006). However patient can present with atypical 
symptoms such as recurrent vomiting and chest pain (Blasi 2004) . In asthmatic patients, 
the physical examination between exacerbations is often normal and a good number of 
cases may not present with wheeze but may have a cough variant asthma (Sethi 2001). 
 
Asthma can be triggered by allergens or induced by external irritants. Allergen-induced 
asthma usually appears in individuals before the age of 31 (Hypponen, Sovio et al. 2004). 
Non-allergic asthma occurs later, usually at middle age, and is triggered by exercise, 
weather changes, or viral infections (Schiappoli, Gani et al. 2003).  
 
Three phenotypes have been identified in children with asthma: transient wheezing, non-
atopic wheezing of the toddler and pre-school-aged child and IgE-mediated wheezing. 
Wheezing associated with evidence of allergic sensitisation has been identified as the 
'classic' asthma phenotype. Early allergic sensitisation is a major risk factor for persistent 
asthma (Stein and Martinez 2004). 
 
However asthma symptoms do not always correlate with the pathophysiology and differ 
from patient to patient (Baker, Friedman et al. 2002; Bobb and Ritz 2003; Tilles 2006), 
therefore the complementary investigations also are needed to monitor and assess  
treatment. 
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1.2. Diagnostics in respiratory medicine  
 
1.2.1. Clinical Assessment in Respiratory Disease in Children 
Effective communication with children and their parents about symptoms is a critical 
prerequisite to appropriate diagnoses on respiratory diseases. Standardized screening 
questionnaires, also more frequent routine visits for children are needed compared to 
adults (Yoos, Kitzman et al. 2005). Pharmacological reversibility of airway obstruction 
as a method of diagnosing asthma is controversial when dealing with infants and toddlers 
(Law, Ng et al. 2000). 
The International Study of Asthma and Allergies in Childhood (ISAAC) was the first one 
using a standardized methodology to evaluate the prevalence of diseases such as asthma, 
allergic rhinitis, and atopic eczema and to make comparisons within and between 
countries (Keil, Weiland et al. 1996; Carvalho, Fernandez-Benitez et al. 2000). It consists 
of clinical examination, measures of bronchial hyperresponsiveness, measures of atopy, 
measures of environmental exposure to aeroallergens, and genetic analyses (Stipic-
Markovic, Pevec et al. 2003).  
A clinical assessment of a respiratory illness on a patient, involves assessment of both 
subjective and objective measures by a physician. Subjective measures are overall health 
assessment both by the study physician and the child's mother and objective are 
measurements of forced expiratory volumes (FEV (t)) and maximal flow at functional 
residual capacity V (max) FRC) (Wildhaber, Dore et al. 2002). 
 
The ISAAC questionnaire has been used in many countries and has been validated 
previously. It is a reasonably sensitive tool for both epidemiologic and clinical studies of 
asthma when used in conjunction with a predictive model (Valery, Purdie et al. 2003). 
 
Early identification and treatment of patients with asthma is important to prevent chronic 
inflammation and airway remodeling (Frank, Frank et al. 2001). A careful evaluation of 
respiratory function associated with a clinical assessment is very useful to carry out a 
more appropriate therapy (Verini, Rossi et al. 2001). Clinically important discrepancies 
in assessing disease severity are uncommon, and underestimation of severity by parents 
is rare (Gorelick, Stevens et al. 2002).  
Clinical Practice Guidelines (CPGs) for asthma have been used successfully in the 
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pediatric Emergency Departments (EDs) and may provide an efficient management and 
treatment approach to acute exacerbations of childhood asthma. Systematic and concise 
clinical practice guidelines appear to be easily adhered to in a pediatric ED, with the 
exception of using PEF in the routine ED assessment (Goodman, Lozano et al. 1999; 
Scribano, Lerer et al. 2001). Critics of the use of CPGs in an ED setting however, believe 
that they are too cumbersome and time-consuming (Flores, Lee et al. 2000). 
 
Respiratory assessment of children with asthma or bronchiolitis is problematic 
(Eggleston, Diette et al. 2005) because both the components of the assessment and their 
relative importance vary among care providers. Liu and Colleagues believe that use of a 
systematic standard assessment process and clinical score may reduce interobserver 
variation. By standardizing respiratory assessments, use of a clinical score may facilitate 
care coordination by physicians, nurses, and respiratory therapists and thereby improve 
care of children hospitalized with asthma and bronchiolitis (Liu, Gallaher et al. 2004). 
 
And also, Haverkamp, Staab et al put forward that the measurement of psychosocial 
adaptation due to chronic diseases in childhood and adolescence, is shifted from a more 
reductionist and biomedical oriented disease-model towards a more integrated, 
biopsychosocial view of chronic diseases. There are three paradigms in measuring 
psychosocial adaptation; psychopathology, coping, and health related QoL: all three 
paradigms-(each measuring different aspects of psychosocial adaptation) should be 
simultaneously included to come to a more complex view of adaptation in chronic 
diseases in general and asthma bronchiale in particular (Haverkamp, Staab et al. 2004). 
Eastham, Fall  et al inform that the non-cystic fibrosis (CF) bronchiectasis are rare and 
progressive in children living in western societies (Eastham, Fall et al. 2004), however 
the diagnostic delay is a problem (Byrnes 2006). The most common association is a 
previous pneumonia. In this regard the chest radiography is of little diagnostic value, but 
resolution is possible on high resolution computed tomographic (HRCT) scanning 
(Tiddens 2006). Bronchiectasis is currently defined as a condition which is both 
permanent and progressive. This term is not necessarily appropriate for all paediatric 
patients and an alternative nomenclature has been suggested (Eastham, Fall et al. 2004). 
1.2.2 Diagnoses of Asthma  
In the past there has been uncertainty amongst doctors concerning the treating of chronic 
obstructive pulmonary diseases, and the guidelines were followed to a lesser extent 
(Kolle and Morkve 1998). There are over 40 guidelines such as; Global Initiative for 
Chronic Obstructive Lung Disease guidlines, Global Strategy for the Diagnosis, 
Management and Prevention of Chronic Obstructive Lung Disease Guidelines, British 
Thoracic Society (BTS) guidelines  and  so on. Most of them have been developed, 
mainly by local respiratory societies as a result of local expert consensus (Buist 2002), 
however, still childhood rhinitis and asthma seem to be frequently underdiagnosed and 
undertreated (Sichletidis, Chloros et al. 2004). 
The majority of pediatricians believe several common clinical factors such as recurrent 
wheeze, symptomatic improvement with a bronchodilator, recurrent cough, exclusion of 
alternative diagnoses, and suggestive peak flow findings establish a diagnosis of 
childhood asthma, but disagree over what combinations of these factors are important 
(Werk, Steinbach et al. 2000). 
Currently asthma is diagnosed based on history taking, including family history of 
asthma and/or atopy, symptoms rather than any diagnostic tests (Nair, Daigle et al. 2005). 
The history needs to be augmented by a thorough examination that will yield different 
results based on whether the person having an asthmatic episode or is currently 
asymptomatic. Most clinicians considered recurrent wheeze, symptomatic improvement 
with a bronchodilator, recurrent cough, exclusion of alternative diagnoses, and suggestive 
peak flow findings as important in diagnosing asthma (Horak 2004). 
 
Potential asthma guidelines organize diagnostic criteria in an easily understood format, 
like a decision tree, to facilitate early recognition of asthma in young children (Werk, 
Steinbach et al. 2000). Successful treatment depends on identification of the type of 
asthma according to causative factors such as allergens, respiratory tract infections, 
complicating factors (sinusitis, smoking parents) and the degree of severity (Miller, 
Johnson et al. 2005).  
 
Evaluation of asthma should include a detailed medical and environmental history and 
focus on potential allergic and nonallergic triggers. Other illnesses and medications may 
impact on the safety and effectiveness of treatment (Morris, Abramson et al. 1996; 
Becker 2002). The severity of asthma varies widely between patients with mild cases 
being characterized by normal lung function and patients being asymptomatic most of the 
time, while severe cases are characterized by permanently impaired lung function and 
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frequent exacerbations. Little is known about the factors associated with severity, but the 
identification of such factors is necessary for management and prevention (Zureik, 
Neukirch et al. 2002). 
1.2.3 Differential Diagnosis of Asthma 
Many conditions are easily misinterpreted as asthma, and appropriate identification can 
lead to a dramatic reorganization of the treatment plan. Conditions such as chronic 
bronchitis, vocal cord dysfunction, cystic fibrosis, congestive heart failure, extrapulmonic 
obstructive lesions, foreign bodies, immunodeficiency resulting in recurrent pneumonia, 
bronchopulmonary dysplasia, bronchiolitis obliterans, and allergic bronchopulmonary 
aspergillosis may present with asthmatic symptoms or complicate the course of asthma 
(Rachelefsky and Siegel 1985; Bernstein and Storms 1995; van Schayck, Levy et al. 
2004; Frith, Attewell et al. 2006; Kashef, Kashef et al. 2006). 
1.2.4 Investigations on Asthma Diagnosis 
The diagnosis of pulmonary disease may involve many different diagnostic 
investigations in addition to clinical history and examination including chest imaging, 
blood gas analyses, and cytologic and hematologic tests.  Diagnostic imaging techniques 
generally require specialized skills to perform and specialized equipment and their use is 
subsequently limited to hospital and acute care settings. There is a range of other tests 
however, that can be used effectively in community clinic settings (Spiropoulos, Trakada 
et al. 2003) with static and dynamic tests of lung function being performed by 
spirometry. Spiro-metric data such as forced vital capacity (FVC), forced expiratory 
volume in 1 second (FEV1), maximum voluntary ventilation (MVV), peak expiratory 
flow,(Lim, MacRae et al. 1998) and tests of compliance provide measures of airway 
restriction/obstruction and can be used to diagnose restrictive and obstructive lung 
disease and to monitor the effects of treatment (Laszlo, Lance et al. 1993).  
 
Other useful functional tests include pulmonary diffusing capacity, which measures the 
amount of gas entering the pulmonary blood per unit time per unit pressure differential 
across the alveolar-capillary membrane (Cerveri, Dore et al. 2004). Flow-volume loops 
are used to graphically represent the events occurring during forced inspiration and 
expiration and make it possible to diagnose central or peripheral airway obstruction 
(Filippone, Narne et al. 2000). Blood gas analysis is also used to determine the arterial 
partial pressure of oxygen (PO2), the alveolar-arterial oxygen {P (A-a)O2} and the partial 
                                                                                                                                                                   
  
23
pressure of carbon dioxide (PaCO2), which are sensitive indicators of the severity of 
respiratory function (Sadoul 1983) and can show deterioration in lung function when 
changes in FEV1 may be minimal.  
 
Arterial blood gas tensions and calculation of the P(A-a)O2 also foster early recognition 
of increased flow resistance in the early stages of peripheral airway obstruction 
(Cherniack 1985) and blood gases can be used to assess problems related to acid-base 
balance, ventilation, and the level of arterial oxygen saturation. Similarly, cytologic and 
hematologic tests are important in identifying respiratory infections and tumors. Gas 
analysis, particularly paO2, may help in predicting the presence of lung opacities in 
young patients, however, radiographic imaging may still be needed to define the actual 
extension of opacities (Pifferi, Caramella et al. 2005). 
1.2.4.1 Imaging 
The image age began in 1895, when Wilhelm Conrad Roentgen discovered X-rays while 
experimenting with cathode-ray tubes (Tubiana and Maurice 1995). Early radiology was 
rooted in morphology, chiefly skeletal morphology. Beginning with nuclear medicine 
powerful methods have been developed to examine bodily function. With this 
transformation has developed a capacity not merely to display the epiphenomena of 
disease (eg, tumour masses and sinus tracks) but also to reveal mechanisms of disease 
and treatment, even in the brain (Lentle and Aldrich 1997). The modern tomographic 
techniques all provide sectional images in one or more planes, avoiding the 
superimposition of structures that still characterize a chest radiograph. Some techniques 
also use computer image processing but do not capitulate sectional data (eg. digital 
subtraction angiography and magnetic resonance angiography). The chest radiographies 
is still the most common radiological procedure (Lentle and Aldrich 1997). Many 
children who experiencing acute asthmatic episodes having chest radiographs, may show 
lung hyperinflation, hypoinflation, or normal inflation. Lung hypoinflation may be a sign 
of respiratory fatigue and poor prognosis. In the Spottswood study hypoinflation on chest 
radiographs was significantly correlated with hospital admission for children aged 6-17 
years; therefore, hypoinflation is a poor prognostic sign and may warrant more 
aggressive therapy (Spottswood, Allison et al. 2004).  
 
CT (Computed Tomography), composite high-quality volume-rendered images with 
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multislice CT can provide more exact airway images in relationship to the surrounding 
cardiovascular structures (Choo, Lee et al. 2006).  
PET (Positron Emission Tomography)has been described as providing "autoradiographs 
in life" (Yochum 1995). According to recent studies PET has advantages in evaluation of 
lung lesions, and integrated PET and CT are recommended for detecting local lymph 
node metastasis (Wang, Li et al. 2005). 
 SPECT (Single Proton Emission Computed Tomography) uses the single gamma-rays 
emitted by radionuclides (Stytz and Frieder 1990). One or more gamma camera heads, 
mounted on a rotating gantry, circles the patient, and, by computer methods similar to 
those used in CT or PET, an image of tracer distribution in multiple organ sections is 
obtained (Yochum 1995).   
 
US (Ultrasound), today substitutes for conventional x-rays in the diagnosis of many 
conditions, however, ultrasound does not produce clear images of the lungs and other 
organs filled with gas or air (Nordenberg 1999). 
 
MRI (Magnetic Resonance Imaging) is especially useful in studying the brain and spinal 
cord, the soft tissues of the body, and the joints. Because this technique shows distinct 
contrast between normal and abnormal tissues, it is sometimes superior to CT scanning 
and other imaging methods in evaluating tumors, tissue damage, and blood flow 
(Nordenberg 1999).  
MRS (Magnetic Resonance Spectroscopy) complements magnetic resonance imaging 
(Kalyoncu, Selcuk et al.) as a non-invasive means for the characterization of tissue. 
While MRI uses the signal from hydrogen protons to form anatomic images, proton MRS 
uses this information to determine the concentration of brain metabolites(Arbor 2005). 
Dynamic MRI of respiratory mechanics is a promising technique which could offer 
complementary information in the assessment of respiratory diseases (Fink, Ley et al. 
2004). 
 
High spatial and temporal resolution are strong features of radiography, CT, MRI, and 
US; for high-contrast resolution PET, SPECT, MRI, and US perform best; and MRI is 
probably the most powerful single tool in all three contexts (Lentle and Aldrich 1997). 
(See table 1). 
 
Table 1: Use of electromagnetic radiation for diagnostic imaging (Lentle and 
Aldrich 1997)  
The Electromagnetic 
Spectrum 
Diagnostic Technology Treatment 
PET Linear accelerators 
Radionuclide imaging 60 Co treatment 
 
  X-ray & Gamma rays 
X-Ray imaging OrtovoltageX-ray therapy 
Ultraviolet Vision 
 
Superficial X-ray therapy  
UVB (Psoriasis)  
Visible 
 
Microscopy 
Diaphanography Photodynamic range 
 
Infrared Thermography 
Non-invasive infrared 
scanning 
Thermography 
Non-invasive infrared 
scanning 
Microwaves 
 
Microwave imaging 
 
Microwave Tomography 
Microwave imaging 
 
Microwave Tomography 
Radio –waves MRI 
MRS 
Radio frequency, tissue 
destruction 
Diathermy 
Electric Current Magnetic Source imaging 
Electric impedance 
tomography 
Electrocuatery 
Diathermy 
 
Sound waves 
 
US 
Tissue ablation 
Lithotripsy 
Diathermy 
Partcles;  Heavy Radiography Radiotherapy 
+ positrons PET  
Electron microscopy  
Magnetic source imaging 
- Electrons (Electric Currents) 
Electric impedance 
tomography 
Radiotherapy 
 
1.2.4.2 Quality of Life Assessment 
Respiratory diseases are known to have consequences on perceived health status and vice 
versa. A variety of studies exist as to methods of assessing QoL in respiratory disease 
and various health-related QoL (HRQoL) measures have been developed to complement 
traditional health measures such as prevalence, mortality and hospitalization as indicators 
of the impact of disease (Schmier, Chan et al. 1998; Chiang 2005). Health status (or 
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Health-Related QoL) measurement is an established method for assessing the overall 
efficacy of treatments for asthma and chronic obstructive pulmonary disease (COPD) and 
such measurements reflect the impact of the disease on the patient’s life and can be used 
to assess or monitor the effects of treatment. A range of HRQoL measurement 
instruments is available using scales such as the Borg Scale and Visual Analogue Scales 
(Cullen and Rodak 2002). In a systematic review for quality of life instruments, Badia 
Llach et al reviewed fourteen instruments of which six were generic instruments for 
children (CHQ, KINDL, PedsQL, FS-IIR, RAND and CHIP-AE) and eight were specific 
to children with asthma (SSES, ASDQ, AMA, CAQ, LAQCA, PACQLQ, PAQLQ and 
APBC). The generic instruments measured the four basic aspects of HRQOL (symptoms, 
physical, mental and social functioning). Validated versions of the PedsQL (generic) and 
PAQLQ (specific) instruments, were found to be useful instruments for asthmatic 
children (Badia Llach, Benavides Ruiz et al. 2001). 
 
Since the responsibility for treating children with asthma has gradually shifted from the 
medical health service to the family and parents, asthma impact on the physical, 
psychological and social domains of QoL (Wallerstedt and Bellanti 1998; Gustafsson, 
Olofsson et al. 2002; Rydstrom, Dalheim-Englund et al. 2005) and daily routines of both 
asthmatic children (Pop, Chereches-Panta et al. 2005) and their parents has increased 
(Halterman, Yoos et al. 2004). A study to investigate the QoL of parents of children with 
asthma found that although a child's asthma did not influence the parents' QoL to a 
greater degree, there was a significant association between fathers' lower QoL outcome 
and having a child with severe asthma  (Dalheim-Englund, Rydstrom et al. 2004).  
 
French, Carroll et al developed Australian forms of the Childhood Asthma 
Questionnaires (CAQs) to establish the conceptual, semantic and technical equivalence 
of these forms with the UK versions. Comparison with the UK data revealed that the 
non-asthmatic scores were higher for Australian than British children but that the scores 
for children with asthma did not differ between the two countries. It was only in the 
Australian sample that the group with asthma reported impaired HRQoL when compared 
to their healthy peers. These findings were interpreted in the context of cultural 
expectations of life quality and conclusions are presented regarding the importance of the 
gap between experience and expectations (French, Carroll et al. 1998). 
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In a study examining different methods for estimating the threshold of clinical 
significance for three widely used health status questionnaires for asthma and COPD: the 
Asthma QoL Questionnaire, Chronic Respiratory Questionnaire and St George's 
Respiratory Questionnaire, it was found that the results appeared to be fairly reliable; i.e. 
for a given questionnaire, similar estimates were obtained in different studies (Jones 
2002). 
1.2.4.3 Peak Flow Meters  
A Peak Flow Meter (PFM) is a portable, inexpensive, hand-held device used to measure 
how air flows from the lungs in one "fast blast." In other words, the meter measures the 
ability of the lungs to push air out with the Peak Expiratory Flow Rate (PEFR) being 
defined as the highest flow achieved at the mouth during a forced exhalation (Janson 
2005).  
 
Knowledge of asthma and medication, compliance to treatment and inhaler technique and 
how to use the PFMs and Spirometers all are part of asthma education programs (AEP) 
(Garcia-Marcos, Castro-Rodriguez et al. 2004; Prabhakaran, Lim et al. 2006). (See figure 
1). In support of PFM usage technique the American Lung Association (Reinke and 
Hoffman 2000) suggests: 
• Before each use, be sure that the sliding marker or arrow on the PFM is at the bottom 
of the numbered scale (zero or the lowest number on the scale). 
• Stand up straight. Remove gum or any food from your mouth. Take a deep breath (as 
deep as you can). Put the mouthpiece of the PFM into the mouth. Close lips tightly 
around the mouthpiece. Be sure to keep tongue away from the mouthpiece. In one breath 
blow out as hard and as quickly as possible. Blow a "fast hard blast" rather than "slowly 
blowing" until you empty out nearly all of the air from the lungs. 
• The force of the air coming out of the lungs causes the marker to move along the 
numbered scale. Note the number on a piece of paper 
• Repeat the entire routine three times.  
• Record the highest of the three ratings. Do not calculate an average. 
• Record your highest reading 
• Measure the Peak Flow Rate close to the same time each day. 
 
Peak expiratory flow rate (PEFR) is the greatest airflow velocity that can be produced 
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during a forced expiration that starts from fully inflated lungs (ATS 1995) thus, peak 
flow monitoring assesses airflow obstruction, so the PEFR will rise if the patient is 
responding to a drug or a dyspnea-reducing strategy. Peak flow monitoring is used to 
audit daily response to treatment; detect a build-up in airflow obstruction before it 
becomes more serious; assess the severity of an asthma attack; evaluate response to 
therapy during an asthma episode; and aid decisions about the need for 
hospitalization(Ressel 2003). A PFM can be used by children as young as 5 years of age 
(Reinke and Hoffman 2000). 
 
Several variables, including gender, age, and height, determine what peak flow numbers 
are considered normal. Many patients, however, attain peak flow values higher or lower 
than normal. Objectives for therapy, therefore, are usually based on each patient’s 
personal best, rather than on predicted values (Ressel 2003). It is essential to find patient 
predicted peak flow using a PEFR chart and a number of factors can make the reading 
inaccurately low or high. By selecting the highest reading, patients minimize effects of 
these sources of error. If the highest reading is less than 80% of the predicted value, more 
aggressive therapy and continued daily monitoring may be indicated, if values fall below 
50%, patients need to seek medical attention immediately (Reinke and Hoffman 2000). 
 
PFMs are often used to assess bronchial obstruction (Douma, Mark et al. 1997) and 
PEFR is frequently used in general practice as a substitute for FEV1 in the assessment of 
airway obstruction and Broncho Dilator Response (BDR), however its use has never been 
validated in children with asthma. (Kamps, Roorda et al. 2001; Slieker and van der Ent 
2003). 
 
It is suggested that PEFR provides a simple, quantitative, and reproducible measure of 
the existence and severity of airflow obstruction and that asthma control may be assisted 
by educating patients to use PFMs (Susan Janson 2005), PEFR is therefore believed to be 
useful for regular monitoring of asthmatic patients in order to improve their abilities to 
provide self-care (Plymat and Bunn 1985; Klements 2001). 
1.2.4.3.1 Limitations of PFMs 
Guidelines for management of asthma consistently recommend routine home monitoring 
of peak expiratory flow (Xiao, Karpefors et al. 1995) in each patient.  Roche, Morel et 
al’s (2005) ‘credit card plan’  and peak flow based asthma self-management plans have 
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been strongly supported in consensus statements (D'Souza, Crane et al. 1994; Stach 
2000). However there are many limitations of PEFR measures (Jones, Mullee et al. 
1995). Changes in PEF poorly reflect changes in asthma activity, PEF diaries are kept 
very unreliably, and self management programs including PEF monitoring are no more 
effective than programs solely based on education and symptom monitoring (Brand and 
Roorda 2003; Wensley and Silverman 2004). PFM assessments of the degree of airway 
obstruction in asthma are also known to be unreliable, and it is recommended that 
clinicians prescribing PEF meters should be responsible for checking the patient's meter 
as well as their PEFR readings at clinic visits (Milesa, Brighta et al. 1995) and that self-
management and the use of prescribed PFMs need to be tailored to individual 
circumstances (Jones, Mullee et al. 1995). 
 
Convincing evidence for the effectiveness of PEFR measures is also lacking (Adams, 
Boath et al. 2001; Wraight, Cowan et al. 2002). Rigid adherence to long term daily peak 
flow measurement in the management of mild asthma in general practice does not appear 
to produce large changes in clinical outcomes (Quirce, Contreras et al. 1995) and 
although there is evidence that education about PFM use improves the pattern of PEFR, 
this has not been found to translate into reduced emergency room use or admission to 
hospitals (Garrett, Fenwick et al. 1994; Lefevre, Piper et al. 2002). Furthermore, a 
knowledge of PEFR does not contribute to self-management decisions and does not 
enhance self- management even during acute asthma exacerbations (Wensley and 
Silverman 2004). 
 
PEF and the use of PEF diaries may still be useful in isolated cases of diagnostic 
uncertainty, in the identification of exacerbating factors, and in the rare case of children 
having poor perception of their airways obstruction and experiencing frequent and severe 
exacerbations (Reddel, Vincent et al. 2005). If a reliable assessment of airways 
obstruction in asthma is needed, forced expiratory flow-volume curves (using a 
spirometer) are preferred (Brand and Roorda 2003). 
 
 
 
 
 
 
Figure 1 Mini Wright Peak Flow Meter Standard Range (Miller 2004) 
 
 
1.2.4.4 Spirometry 
Spirometry is the primary pulmonary function test (PFT) used in clinical practice (Pierce 
2005; Zanconato, Meneghelli et al. 2005) and laboratory-based spirometry is the "gold 
standard" for the assessment of lung function, both in clinical and research protocols 
(Sethi 2001). This test measures the air flow-rate and volume obtained during a patient's 
maximum forced exhalation/inhalation (Forced Expiratory Volume in one second (FEV1) 
and Forced Vital Capacity (FVC) (Pierce 2005) (See figure 2). Spirometry can be used to 
identify the presence of lung disease including early detection, as well as to assess the 
severity of disease, the degree of disability, and the effects of therapy. Spirometry and 
peak expiratory flow rates help in objective assessment and are good tools for monitoring 
chronic patients (Sethi 2001). Yet despite improved clinical status with intensive 
treatment, pulmonary function tests have been found to remain abnormal in patients with 
asthma (Perin, Weldon et al. 1994). 
 
There is no firm evidence from randomized controlled trials that routine monitoring of 
lung function improves asthma control in children (Brand and Roorda 2003) however, 
improvement in FEV1 after the administration of a bronchodilator remains the single best 
spirometric test with which to assess airway responsiveness in asthmatics, the diagnosis 
of asthma is based on clinical assessment rather than any specific diagnostic tests 
(Yurdakul, Dursun et al. 2005). Spirometers, however, are neither practical nor 
affordable for home-based monitoring (Mortimer, Fallot et al. 2003) (See Figure 2 & 3). 
 
1.2.4.4.1 Indications for spirometry;  
In his article “Spirometry: an essential clinical measurement” Prof. Rob Pierce (2005) 
points out when it is necessary to evaluate the lung function by spirometry; 
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1.The detection of respiratory disease in patients presenting with symptoms of 
breathlessness either at rest or on exertion, wheeze, cough, stridor or chest tightness. 
Spirometry is useful in distinguishing respiratory from cardiac disease as the cause of 
breathlessness and can be used to screen for respiratory disease in certain high-risk 
situations (Evans and Scanlon 2003; Pierce 2005; Pierce 2005).  
2.The diagnosis of respiratory disease and differentiation of obstructive versus restrictive 
ventilatory defects, the identification of upper airway obstruction and diseases associated 
with weakness of the respiratory muscles (Evans and Scanlon 2003; Pierce 2005).  
3.Following the natural history and progression of respiratory and sometimes systemic 
and neuromuscular diseases (Pal, Groothoff et al. 2000; Pierce 2005) 
4. Assessment of response to treatment in these conditions (Pierce 2005).  
5. Assessment of impairment from respiratory disease in the workplace and in the 
settings of pulmonary rehabilitation and compensation for occupational disease 
(Raymond, Barringer et al. 2005). 
6. Pre-operative risk assessment before anesthesia and abdominal or thoracic surgery 
(Tikuisis, Zurauskas et al. 2003; Dienemann, Hoffmann et al. 2005; Pierce 2005). 
 
Portable spirometers are becoming more readily available and are making an important 
contribution to epidemiologic and clinical studies that require frequent measures of a 
broader range of pulmonary function parameters than can be provided by peak flow 
meters (Bastian-Lee, Chavasse et al. 2002; Mortimer, Fallot et al. 2003). 
 
Figur2: Normal Spirogram and Flow-volume curve showing the conventional 
measurements made (Pierce 2005) 
 
FEV1 = forced expiratory volume in 1 second FVC = forced vital capacity 
FIV1 = forced inspiratory volume in 1 second TLC = total lung capacity 
FVC = forced vital capacity RV = residual volume 
PEFR = peak expiratory flow rate PIFR = peak inspiratory flow rate 
TV = tidal volume ERV = expiratory residual volume 
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Figure 3: Types of ventilatory defect with typical spirograms and flow-volume curve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Examples of how various respiratory diseases affect the shape of the flow 
volume curve: Adapted from Pierce 2005. (Pierce 2005) 
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Bastian-Lee et al suggests that; the portable, logging spirometer, provides reasonably accurate, 
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Bastian-Lee et al suggests that; the portable, logging spirometer, provides reasonably accurate, 
reproducible measurements of PEF and FEV1, but intrinsic bias, particularly in PEF 
measurement needs to be taken into account. They further suggest that the potential to 
document longitudinal changes in lung function in children with respiratory disease at home 
needs further study (Bastian-Lee, Chavasse et al. 2002). Pierce (2005) further points out that, 
the use of spirometry by primary care physicians, practice nurses and physiotherapists is 
now practicable and supported by a comprehensive range of devices, training courses and 
reference materials. Systematic use of ventilatory assessment both in the clinic and with 
patient self monitoring of peak flow and FEV1 has the capacity to improve patient 
understanding, confidence in self management, and QoL for those with lung disease. 
Spirometry may also provide a useful modality for following the progress of those with 
neuromuscular disease and incipient respiratory muscle weakness and for the promotion of 
respiratory health in the community setting, however further research in all these areas is 
required (Pierce 2005). 
1.2.4.4.2 Calibration of spirometry 
The American Thoracic Society (ATS) and European Respiratory Society (ERS) came 
together and produced a modified statement on the standardization of lung function testing 
so that they were easier to use by both technical and clinical staff. It contains details about 
procedures that are common for many methods of lung function testing (Miller, Crapo et al. 
2005).  
 
There are internationally accepted performance standards for spirometry equipment which 
are required to carry proof of validation. To ensure consistency and reliability of the results, 
equipment must also be regularly calibrated and maintained (Houtveen, Groot et al. 2006; 
Walters, Wood-Baker et al. 2006). It is also important that individuals performing 
spirometry adequately be trained and demonstrate a high level of competence (Townsend, 
Hankinson et al. 2004). Subject preparation, testing and quality control of results must also 
be carried out according to published guidelines (Radeos and Camargo 2004). Finally, test 
results must be interpreted according to current diagnostic guidelines, taking into account 
the purpose of the test, appropriateness of reference values and the clinical evaluation (van 
Schalkwyk, Schultz et al. 2004) as well as patient factors such as age, height weight and 
gender (Radeos and Camargo 2004). 
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1.2.4.4.3 How to measure by spirometry 
Spirometry can be used for diagnosing asthma and COPD and monitoring the course of 
these diseases and their response to treatment (Dueck 2000). The two most important 
parameters measured by spirometry are; FEV1 and forced vital capacity FEV6 (FVC). The 
FEV1 represents the air flow while the FEV6 (FVC) represents the air volume (Ciappi, 
Corbo et al. 2003). 
 
The National Lung Health Education Program of America (NLHEP) (Petty 2005)points out 
that to measure the FEV1 and FEV6, the person is asked to hold the tube of a spirometer in 
the mouth, inhale as much air as possible, then exhale forcefully into the spirometer for six 
seconds or more. It is now known that the forced expiratory volume in six seconds FEV6 is 
an excellent surrogate for FVC (Swanney, Jensen et al. 2000). 
 
The National Asthma Education and Prevention Program (NAEPP 1998) identifies the 
importance of spirometry for the diagnosis of asthma, given that physicians have a limited 
ability to estimate the degree of obstruction (Shim and Williams 1980) or predict 
reversibility of the obstruction (Russell, Crichton et al. 1986).  
1.2.4.4.4 Airway Reversibility  
There is no single diagnostic test for asthma (Law, Ng et al. 2000) however international 
asthma guidelines recommend that reversibility of FEV1 in response to inhalation of short-
acting bronchodilators is indicative of asthma. While airway reversibility is seen as a 
hallmark of asthma, the degree of reversibility required to make the diagnosis varies 
between guidelines. The British Thoracic Society (Pinnock 2004) recommends at least 15% 
of baseline FEV1, the American Thoracic Society (ATS 1991) and the Global Initiative for 
Asthma (GINA) (Appleton, Adams et al. 2005) recommend at least 12% of baseline FEV1, 
and others recommend 9% of the predicted FEV1 (Calverley, Burge et al. 2003) if the 
change exceeds 200 mL (Appleton, Adams et al. 2005). 
 
Methods used to assess and interpret acute bronchodilator reversibility in lung-function 
laboratories in Australia and New Zealand vary considerably. This may have a significant 
effect on the diagnosis and management of patients. Laboratories should report the 
method used to assess bronchodilator response (Borg, Reid et al. 2004). 
 
In addition to assessing airway reversibility after bronchodilator use, it is possible to 
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detect airway hyperresponsiveness to various challenges such as hypertonic saline, 
exercise, distilled water, cold dry air and histamine or metacholine (Riedler, Reade et al. 
1994). Non-pharmacological bronchial challenges may seem more natural to children and 
more acceptable to parents than the use of pharmacological agents (Law, Ng et al. 2000).  
There is a need to develop and evaluate methods, in addition to spirometry, that could 
assess and monitor pulmonary diseases (Ulmer 1990) especially asthma (Tilles 2006), and 
for physician education on the prevention, diagnosis and management of pulmonary 
patients (Sethi 2001). Spirometry alone cannot characterize the impact of treatment and 
diagnoses on the whole variety of respiratory diseases (Spahn 2003). Thus, there is a need 
for new methods that help diagnoses and measure treatment success beyond FEV1 in 
pulmonary patients. Any such tools would not take the place of spirometry, but would 
complement lung-function measurements and be used for routine follow-up assessment.  
1.2.4.5. Nitric Oxide (NO) 
NO is a colorless gas at room temperature and pressure. It was first discovered as an 
endogenous signaling molecule in 1987 (Machado and Alcantara 1995). Since then this 
small gaseous molecule has been found to play a crucial role in human physiology and 
pathophysiology. NO is a significant regulator of blood pressure and platelet aggregation, 
it also functions as a neurotransmitter in both central and peripheral nervous systems and 
regulates immune responses (Lowenstein, Dinerman et al. 1994). NO is synthesized from 
amino acid L-arginine by a family of NO synthase (NOS) enzymes. Three NOS isoforms 
programmed by distinct genes are known to date, that is to say, neuronal NOS (nNOS), 
inducible NOS (iNOS) and endothelial NOS (eNOS) (Fleming and Busse 1999). While 
originally found in neuronal and endothelial cells, nNOS and eNOS are expressed in a 
variety of cells throughout the human body. 
 
nNOS and eNOS are so-called constitutive NO synthases (Lowenstein, Dinerman et al. 
1994). By contrast, iNOS is not typically present in the physiological state. Its expression 
is induced in many cell types by bacterial products and inflammatory cytokines such as 
IL-1, IFN-γ or TNF-α. iNOS differs from the constitutive enzyme forms also it is 
expressed by anti-inflammatory treatment with glucocorticoids, whereas eNOSs are not 
steroid sensitive (Forstermann, Burgwitz et al. 1987). 
 
NO has no specific receptor mediating its action, being a small gaseous molecule it 
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diffuses easily through cell membranes and modifies cell function by affecting cellular 
proteins (Pailler 1998). Signal transduction by NO can be divided into direct and indirect 
mechanisms (Grisham, Jourd'Heuil et al. 1999). 
1.2.4.5.1 Exhaled NO Measurement 
NO has been studied as a noninvasive marker of airway inflammation, and has been 
shown to be elevated in asthma patients (Meyts, Proesmans et al. 2003; Choi, Hoffman et 
al. 2006). It has been claimed that exhaled NO had a better correlation with lung function 
parameters and asthma control than exhaled carbon monoxide (CO) and acidity of 
exhaled breath condensate (EBC), in mild to moderate persistent childhood asthma 
(Rosias, Dompeling et al. 2004). It is further suggested however, that more studies are 
required on a wide range of asthma severity, and preferably with repeated measurements 
of markers and of asthma control before the clinical utility of exhaled markers in 
monitoring childhood asthma can be established (Rosias, Dompeling et al. 2004). 
 
Measures of exhaled nitric oxide (eNO) are not specific for asthma as the difference in 
eNO between non-asthmatic rhinitis and asthma at baseline was observed to be eliminated 
after allergen exposure due to a significantly greater increase in eNO in non-asthmatic 
rhinitis (Lopuhaä, Koopmans et al. 2003). Reduction in nitrites in breath condensates has 
also been observed after a high altitude climate therapy (Straub, Ehmann et al. 2004).  
 
NO, measured in the exhaled breath, is an elegant and non-invasive means to monitor 
inflammation of the upper and lower respiratory tract. In the normal upper airways, the 
bulk of exhaled NO originates from the paranasal sinuses (Gerlach, Rossaint et al. 1994; 
Artlich, Busch et al. 1998). Exhaled NO is increased in nasal allergy and decreased in 
cystic fibrosis, nasal polyposis and chronic sinusitis (Kharitonov and Barnes 2000). That 
NO production is increased in asthmatic airways is also well established (Kharitonov and 
Barnes 1996; Kharitonov and Barnes 2004). Studies suggest that the sampling of exhaled 
breath is a noninvasive procedure that can be performed easily in adults, children, and 
patients with respiratory disease (Profita, La Grutta et al.; Rutkowski and Rutkowski 
2005). Several studies have demonstrated increased exhaled NO in patients with 
pulmonary disease, including asthma (Berlyne, Parameswaran et al. 2000; Deykin, 
Massaro et al. 2002; Fischer, Folkerts et al. 2002). In addition, exhaled NO may be a 
well-designed tool for monitoring the environmental health effects of air pollution and the 
prevalence of atopy in epidemiological surveys (van Amsterdam, Nierkens et al. 2000; 
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 1996). 
Giroux, Bremont et al. 2002).  
 
Studies suggest that the assessment of the value of exhaled NO (eNO) may be an effective 
tool for studying pulmonary disease, considering its wide advantages (i.e., fast analysis, 
noninvasive sampling, ability to measure large numbers of subjects [including children], 
and inexpensive in use) (Steerenberg and van Amsterdam 2004; Montuschi 2005). 
Increased concentration of eNO have been observed in asthmatic patients' airway 
infections, allergic rhinitis, and bronchiectasis (Baraldi, Dario et al. 1999; Steerenberg 
and van Amsterdam 2004). During inflammation, specific and nonspecific stimuli elicit 
expression and de novo synthesis of inducible NO (iNOS) once generated in the 
bronchiolar cells, NO is released from the tissue and diffuses to the lumen of the 
bronchioles.  
 
Of the two sampling methods (on-line [Directly] and off-line [remotely]), the off-line 
method (was achieved by a gas collection tube system, which consisted of a flow control 
unit, a tube reservoir with one-way valves at both ends, and an interrupter valve allowing 
the trapping of gas inside the tube and eliminating the inclusion of "dead space." After 
clamping, the reservoir may store and transport the gas samples for delayed analysis) 
(Djupesland, Qian et al. 2001). It is suitable for monitoring environmental health effects 
of air pollution and for obtaining an impression of the prevalence of atopy in 
epidemiological surveys. In addition, measurement of eNO helps to understand the 
mechanisms of pulmonary disease and may be useful in detecting adverse effects of air 
pollution (van Amsterdam, Nierkens et al. 2000). 
1.2.4.5.2 Basic methodology of exhaled NO measurement 
The NO concentration in exhaled air is usually measured by the ozone-
chemiluminescence method (Lefevere, Willems et al. 2000). This approach is based on 
the reaction between NO and ozone (O ) forming nitrogen dioxide (NO ), some of which 
is in excited state (NO ). Red and infrared light (~640-3000nm) is produced as the 
excited form of nitrogen dioxide regains its stable ground
3 2
2
 state (NO2→NO2+h) (Hampl, 
Tristani-Firouzi et al. 1996; Hampl, Tristani-Firouzi et al.
 
Mouth pressure, the mucosa in the nasal cavity and paranasal sinuses produce 
considerable amounts of NO (Lundberg, Nordvall et al. 1996) which accumulates in high 
concentrations in nasal air compared with air from the lower respiratory tract (Kimberly, 
Nejadnik et al. 1996) (See figures 5 &6). 
Meyts et al study suggests that eNO measurements may be useful for monitoring asthma 
patients (Meyts, Proesmans et al. 2003).  
 
Figure 5: Based on patient's height the Deadspace is modifiable and can be regulated by 
exhalation time (fractions of a second), exhalation volume (ml) or by a calculated volume 
(ml). Deadspace is exhaled unrestricted, without flow regulation. 
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Figure 6: FENO value is calculated by creating an NO plateau for at least 3 seconds. 
Exhalation is set to 10 seconds, NO plateau set to between 70–100% of the exhalation 
(between 7 and 10 sec). The settings can be adjusted. 
 
 
 
 
 
 
 
 
1.Inhalation of NO free air (< 5 ppb) is recommended in exhaled NO measurement 
(American Society 1999), inhalation of air with a high NO concentration causes a high 
initial peak in the exhaled NO concentration curve (Silkoff, McClean et al. 1998). 
 
2.NO may be produced on the oral cavity not only by NOS enzymes but also in a non-
enzymatic reduction from nitrite. The salivary glands excrete nitrate from the circulation 
into salvia, and bacteria in the oval cavity convert nitrate to nitrite. In an acidic oral 
environment nitrite further reduced to form NO. Ingestion of potassium nitrate or a meal 
rich in nitrate prior to NO measurement has been shown to increase the exhaled NO level, 
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whereas rinsing the mouth with antibacterial or basic solution reduces the level 
(Zetterquist, Pedroletti et al. 1999; Olin, Aldenbratt et al. 2001; Olin, Stenfors et al. 
2001). 
3.Repeated forced vital capacity maneuvers with spirometry have been shown to lower 
exhaled NO levels, whereas inhaled β2 agonists after spirometry increase the level 
(Silkoff, McClean et al. 1998). Exhaled NO measurement should thus be performed prior 
to any possible measures of lung function.  
 
4.Cigarette smoking has been found to reduce exhaled NO levels, while discontinuation 
of smoking increases exhaled NO levels gradually towards normal levels (Persson, 
Zetterstrom et al. 1994; Steerenberg and van Amsterdam 2004). 
1.2.4.5.3 International Guidelines on exhaled NO measurement. 
Measurements of exhaled and nasal NO, in several different laboratories in Europe and 
USA have reported widely different values which reflecting differences in technological 
and/or measurement techniques (Kharitonov, Alving et al. 1997; Kharitonov, Alving et al. 
1997). To overcome this problem, international guidelines have been published to 
standardize the measurement technique.  
 
An abnormally high exhaled NO concentration is interpreted as a sign of ongoing 
inflammation in the lower respiratory tract. And it is suggested that the measurement of 
nitrites may be feasible to objectively assess airway inflammation in asthmatic children in 
order to detect ongoing inflammation in children with normal FEV1 but persistent 
symptoms (Straub, Ehmann et al. 2004). 
1.2.4.5.4 NO in asthmatic inflammation 
As compared with healthy subjects, increased inducible NOS (iNOS) expression has been 
reported in bronchial biopsies from asthmatic subjects, Furthermore, iNOS expression can 
be reduced by treatment with glucocorticoids (Saleh, Ernst et al. 1998; Redington, Meng 
et al. 2001). iNOS expression in asthmatic airways has been shown in epithelial cells, 
macrophages, eosinophils, neutrophils, vascular endothelium and smooth muscle cells 
(Saleh, Ernst et al. 1998; Redington, Meng et al. 2001). The increased amount of NO in 
the exhaled air of asthmatic subjects is largely produced by the iNOS pathway, as 
inhalation or an oral dose of selective iNOS inhibitors causes a significant reduction in 
exhaled NO level (Sugiura, Ichinose et al. 2003). High NO production by iNOS is thought 
to have many detrimental effects in asthmatic airways, for example edema formation by 
reduced vascular integrity, epithelial cell toxicity and increased hyperresponsiveness 
caused by peroxynitrite (Sadeghi-Hashjin, Henricks et al. 1996; Meyts, Proesmans et al. 
2003). 
 
Data from a study repoted in 2004 suggests that FENO may be a practical tool to evaluate 
asthma severity and asthma control over time and also FENO may be used as a marker of 
compliance with steroids even when FEV1 has not decreased significantly (Delgado-
Corcoran, Kissoon et al. 2004). In another study it is suggested that the measurement of 
nitrites may be feasible to objectively assess airway inflammation in asthmatic children in 
order to detect ongoing inflammation in children with normal FEV1 but persistent 
symptoms (Straub, Ehmann et al. 2004).  
 
Baraldi et al suggests that the measurement of eNO is significance for diagnosis of 
asthma (Zitt 2005; Baraldi, Giordano et al. 2006) and very useful for monitoring the 
inflammatory process (Taylor 2006). It is suitable for the control of effectiveness of the 
anti-inflammatory treatment. In some developing countries measurement of concentration 
of exhaled NO in asthmatic patients is already used in fields both research and clinical 
practice (Cap 2004). A study exploring the links between atopy, asthma, and exposure to 
chlorination products in indoor pools, found that the exhaled NO test could serve to detect 
the chronic airway inflammation associated with excessive exposure to trichloramine 
(Bernard, Carbonnelle et al. 2005). Lung-specific proteins measurable in serum and 
markers in exhaled air represent sensitive tools that can be used to assess non-invasively 
the effects of air pollutants on the respiratory tracts of children (Bernard, Carbonnelle et 
al. 2005), however, eNO measurement alone is not sufficient for diagnosing or 
monitoring asthma, but it can be a valuable addition to current clinical tools (Zitt 2005). 
1.2.4.6 Skin Prick Testing 
As allergy is central to the pathophysiology of asthma,  structured allergy evaluation and 
avoidance advice can improve lung function and the control of asthma  in primary care 
(Bobb and Ritz 2003). It is recommended that skin testing should be performed in all 
patients suspected of suffering from severe episodic or persistent asthma, as well as in 
those with suspected hay fever, or suspected allergic reactions to stinging venomous 
insects or food allergy (Paranos, Petrovic et al. 1998). Studies suggest that skin prick 
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testing (SPT) is the most convenient and least expensive method of allergy testing and 
results are available within 20 minutes (Paranos, Petrovic et al. 1998; Devenney and 
Falth-Magnusson 2000). Alternative methods to SPT are; scratch testing, intradermal skin 
testing, measuring total IgE, Radioallergosorbent test (Simoni, Lombardi et al.) blood 
testing, eosinophil counts, patch testing, and challenge testing (Ownby 1982; Ownby and 
Anderson 1982). 
 
A study that investigated the prevalence of skin prick test (SPT) reactivity to common 
aeroallergens among Malaysian asthmatic patients with and without rhinitis showed that 
the prevalence of SPT reactivity to common aeroallergens is high among asthmatics, 
particularly in those with an early age of onset and in those with coexisting rhinitis   
(Liam, Loo et al. 2002). Another study revealed that mould allergy diagnosed by SPTs 
was rare in students. Most reactions to moulds were in students older than 14 years with 
multiple SPT reactions to common allergens, and there was no significant association 
with asthma (Immonen, Meklin et al. 2001). In yet another study a significant correlation 
was found between atopic index to indoor allergens in childhood and the persistence of 
asthma at puberty. The findings indicate that significant modification of skin reactivity to 
common environmental allergens in atopic children with asthma in puberty can occur. 
However, no association between these changes and the persistence of asthma has been 
demonstrated (Kaleyias, Papaioannou et al. 2002). 
 
It is suggested that while SPT and measurement of specific IgE antibodies are helpful in 
the diagnosis of allergies, the testing for food-specific Immunoglobulin G (IgG ) 
continues to be an unproven or experimental test (Beyer and Teuber 2005). 
1.2.5 Introduction to Less/Non-Conventional Assessment Tools 
Conventional assessment of lung function is based on knowledge of the components of 
the breathing system and how they work together (Garcia Martinez 1999; Rosias, 
Dompeling et al. 2004). In addition to conventional measures there are also a number of 
‘less/or non- conventional’ measures that may assist in assessing the state of the airways and 
the presence or absence of airways disease. These unconventional or traditional methods 
are based on different knowledge systems such as Chinese Medicine, and electro dermal 
screening. They are based on experience or ancient knowledge, and while they may be 
commonly used in different populations, the accuracy and reliability of these methods in 
diagnosing and/or monitoring the health of the respiratory system is uncertain, and they 
                                                                                                                                                                   
  
43
have not been subject to scientific validation. 
1.2.5.1 Chinese Medicine History 
Traditional Chinese Medicine (TCM) is a complete system of healing that was developed 
in China about 3000 years ago, and has only changed slightly over the centuries. Siow et 
al in their study proclaims that the health of an individual, like the universe at large, is 
subject to constant battling between opposing forces such as heat and cold, yin and yang, 
and joy and sadness. All these factors manifest themselves in the body, and a good 
balance between them maintains health. An imbalance between any of these forces can 
cause a blockage in the flow of the body's qi, or vital energy, traveling throughout the 
body along invisible pathways known as meridians (Siow, Gong et al. 2005).  
Zheng Bausell et al state that TCM differs from its western counterpart in a number of 
ways. One of the more noticeable involves a conceptually oriented diagnostic system that 
relies more on the clinician's reading of the patient's symptoms and signs than on 
laboratory findings. Because highly individualized TCM treatment plans originate 
directly from its diagnostic system, a necessary condition for conducting clinically 
relevant TCM efficacy trials rests on the answer to a simple question “How consistent are 
different TCM practitioners at making the same TCM diagnoses and prescribing 
comparable treatment regimens for the same group of patients?” (Zhang, Bausell et al. 
2003). The first and perhaps one of the most important textbooks of TCM was completed 
in about 200 BC. This treatise, known as the Yellow Emperor's Classic of Internal 
Medicine (Huang Di Nei Jing Tai Su), provides the reader with theory and philosophy of 
TCM, as well as the therapeutic benefits of acupuncture and various herbal medicines. It 
also recommends diet and exercise treatments for the maintenance of health (Siow, Gong 
et al. 2005; Siow, Y et al. 2005). The theories of systematic correspondences between 
phenomena, known as the yin-yang and five-phases doctrines, were applied almost 
exclusively to map the human body, to explicate its normal and pathological functions, to 
clarify pulse diagnosis, and to guide needle treatment (acupuncture) (Unschuld 1999).  
Unschuld states; the 20th century has brought the further development of Chinese 
medicine within the boundaries of its traditional theoretical foundations to a complete 
halt. Over the past decades an empirical and scientific basis has been built to justify the 
modern application of Chinese medicine (Unschuld 1999).  
TCM diagnosis relies mostly on clinical enquiries; The Traditional Four Diagnostic 
Methods are Inspection, Auscultation and Olfaction, Interrogation, and Pulse feeling and 
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palpation. The information obtained from the four diagnostic methods results in diagnoses 
based on syndrome differentiation, and can also be differentiated according to the eight 
guiding principles, to etiology, to the theory of qi, blood, and body fluids or to the theory 
of the zang-fu organs (Jingfeng, Jian et al. 1995). 
 
Zhang et al (2003) state that the TCM diagnostic process relies entirely on clinical 
symptoms and signs that are differentiated by the practitioner with no technological aid to 
verify the findings. This is called "syndrome pattern diagnosis," and it, in turn, is the 
foundation of the individualized treatment that characterizes true TCM practice. At the 
core of the syndrome pattern diagnosis is the eight-principle differentiation, with which 
practitioners describe patients' disharmony in terms of 8 parameters. This differentiation 
identifies the disharmony that most interferes with a patient's optimal state of wellness. 
These eight parameters are broadly combined into four paired conceptual descriptions, 
namely, yin and yang, external and internal, deficiency and excess, and heat and cold. 
Specific diseases are diagnosed in terms of some combination of these eight parameters. 
Other patterns, which can be combined with these principles, include (1) Zang-Fu organ 
differentiation, which focuses on identifying disharmonies among the Zang (lung, heart, 
spleen, liver, and kidney) and Fu (large and small intestines, stomach, gallbladder, and 
bladder) organ systems and (2) Qi, (which can be loosely translated to energy-related 
disorders), and blood differentiation or disharmonies (Zhang, Bausell et al. 2003). 
Chan et al explain that the beginning of Chinese medicine has been attributed to three 
mythical emperors who gathered herbs for medicines. During the 2nd century BC, Han 
dynasty physicians developed cranial trephining and sedation with wine and herbs for 
anesthesia. Chiang Chung-Ching (142-212 AD) used the appearance of rashes in 
diagnosis, treated infections with anthelmintics and asthma with ephedra, described the 
symptoms of diabetes mellitus and expanded medical ethics. Sung Tse, who also 
advocated hand washing with sulfur and vinegar to avoid infection during autopsies, 
developed forensic medicine during the 10th century. The Daoist physicians used 
androgens and estrogens to treat hypogonadism with therapeutic preparations of 
placentas. They also had an advanced knowledge of alchemy, claiming to achieve 
'immortality' by their preservation techniques (Chan, Ahmed et al. 1994). Qualifying 
examinations for physicians were conducted by the Chinese state as early as the 1st 
century AD, and later incorporated philosophy and art to conform with the Confucian 
ideal. Throughout these eras, Chinese medicine profited from contact with western Asia. 
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In ancient Chinese medicine, the excretory function of the kidney was attributed to the 
bladder. 'Kidney weakness', which refers to somatized depression, was treated by 
acupuncture along the 'kidney channel'. Pulse examination was also used to give a 
measure of the imbalance of renal Yin and Yang (Chan, Ahmed et al. 1994). 
In the 1977 Encyclopedia of Traditional Chinese Medicinal Substances, 5,767 substances 
were identified as part of the traditional materia medica (Bensky and Gamble 1993). The 
enormous number of substances listed is a result of extensive research into the traditional 
folk applications of substances in different parts of rural China. A typical practitioner may 
routinely use between 200 and 600 substances (Ergil, Kramer et al. 2002). While TCM 
has always legitimised its practice on claims of empirical science based on the 
methodology of holism, it plays a unique role in advancing the development of life 
science and medicine (Feng, Wu et al.). The ever-increasing use of Chinese herbal 
medicine and acupuncture worldwide is a good indication of the public interest in TCM 
(Thomas, Nicholl et al. 2001; Honda and Jacobson 2005). It has not been validated justly 
with modern methods yet it has an immense potential for efficacy which needs to be 
explored. 
1.2.5.2 Breath Holding Time 
Respiration can be voluntarily inhibited for some time but eventually the voluntary 
control is overridden by the involuntary urge to breathe. The point at which breathing can 
no longer be voluntarily inhibited is called the breaking point (Ganong 2001). If a subject 
holds his/her breath, he or she can maintain voluntary apnoea for some time before 
reaching a “breaking point" at which the urgent desire to breathe becomes dominant 
(Kumar, Paudel et al. 2001). Voluntary BHT varies in duration at different times a day 
and its relationship with Delta P ACO2 (the difference between end-tidal partial pressure 
of CO2 [P CO2] and alveolar P CO2 [P ACO2)] at the breaking point) between the 
morning and evening hours (Bosco, Ionadi et al. 2004). The duration of breath holding is 
limited by several factors including the arterial partial pressure of oxygen (PO2) and 
carbon dioxide (PCO2), however, factors other than chemical are also involved. This is 
shown by the observation that if, at the breaking point of breath holding, a gas mixture is 
inhaled which raises the arterial pCO2 and lowers the pO2, a further period of breath 
holding is possible (Courteix, Bedu et al. 1993). Breath holding thus depends on the 
functional status of lungs, development of respiratory muscles, practice, age, sex and 
psychological factors.  
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Psychological factors play a key role, and subjects can hold their breath longer when they 
are motivated (Manley 1990; Van Hoeyweghen, Verbruggen et al. 1991). Boiten reported 
the effects of emotional behavior on components of the respiratory cycle (Boiten 1998). 
Studies indicate that required mental concentration stimulated the respiratory complex as 
part of a generalized central nervous system arousal (Stubbing, Ramsdale et al. 1983; El-
Manshawi, Killian et al. 1986). There are numerous studies reporting the effect of task 
and coping on the respiratory patterns. Two main factors (chemical and non-chemical 
factors) are involved in the determination of BHT. Studies have shown that chemical 
factors can be modified by training such as that used by deep sea divers. The non-
chemical factors increased significantly with BHT and were higher in the non-divers 
(Delapille, Verin et al. 2001). These adaptations in divers may modify the breath-hold 
breaking point and consequently increase BHT (Delapille, Verin et al. 2001). Breath-
holding induces cardiovascular responses, notably bradycardia and peripheral 
vasoconstriction, suggesting that apnoea training explained the greater oxygen 
conservation seen in the divers in both static and dynamic conditions (Delahoche, 
Delapille et al. 2005). 
 
Increased levels of exhaled carbon monoxide (fractional concentration of CO in expired 
gas [F ]), have been reported in patients with inflammatory airway disorders, such as 
asthma, rhinitis and cystic fibrosis (Zayasu, Sekizawa et al. 1997; Monma, Yamaya et al. 
1999). 
 
E,CO
 
It was illustrated that the concentration of carbon monoxide in expired gas is 
unaffected by alterations in flow rate, but increases with breath-holding (Zetterquist, 
Marteus et al. 2002). 
 
Breathing exercises and breathing retraining are often used in the management of asthma. 
One specific form of breathing therapy, known as the Buteyko breathing technique (BBT) 
has received considerable attention, and Bowler states that those practicing BBT reduced 
hyperventilation and their use of β2-agonists. A drift toward reduced inhaled steroid use 
and better QoL was observed in these patients without objective changes in measures of 
airway caliber (Bowler, Green et al. 1998). Patients with asthma are interested in the use 
of breathing exercises but their role is uncertain Cooper also affirms that the Buteyko 
breathing technique can improve symptoms and reduce bronchodilator use but does not 
appear to change bronchial responsiveness or lung function in patients with asthma 
                                                                                                                                                                   
  
47
(Cooper, Oborne et al. 2003). McHugh et al believe that BBT is a safe and efficacious 
asthma management technique. BBT has clinical and potential pharmaco-economic 
benefits that merit further study (McHugh, Aitcheson et al. 2003). 
 
However Bruton and Lewith on their review declare that; it is not known whether altering 
breathing patterns can raise carbon dioxide levels significantly, and there is currently 
insufficient evidence to confirm that this is the mechanism behind any effect that BBT 
may exert. Further research is necessary to establish unequivocally whether BBT is 
effective, and if so, how it may work (Bruton and Lewith 2005) or whether breath-
holding time can be used to diagonise asthma or respiratory illness. 
  
Recently a study completed by Nannini et al regarding the identification of asthmatic 
subjects with low perception of dyspnea that are at higher risk of hospitalization, near-
fatal and fatal asthma, found that the BHT could improve their management. They 
suggest that their method of the breath-holding test is simple and rapid and its process 
might exclude the probability of poor perception of dyspnea in subjects with stable 
asthma (Nannini, Zaietta et al. 2007). BHT also used on assessment of dysfunctional 
breathing (Courtney and Cohen 2006). More study should be done to determine the 
usefulness or otherwise of the BHT on diagnoses of pulmonary diseases, particularly 
asthma.  
1.2.5.3 Electrodermal Screening Test (EDST) 
According to TCM, a form of bodily energy called chi (Qi) flows throughout internal 
organs and circulates throughout the body, along a defined meridian system. Acupuncture 
points are points on the skin, usually located on meridians, where the circulation of qi can 
be controlled. These points have also been labeled organ projection areas (Szopinski, 
Pantanowitz et al. 1998). Szopinski et al inform that the electrical impedance of the 
projection areas corresponding to diseased organs is increased, relative to that of healthy 
organ-related skin zones (Szopinski, Pantanowitz et al. 2004). They further claim that the 
meridian energy flow also carries with it information about internal organs that can be 
used in diagnosis (Szopinski, Pantanowitz et al. 2004). Szopinski et al point out; that the 
difference in impedance is stated to be proportional to the intensity of the pathological 
process and this is the basis of the EDST. Electrodermal diagnostic equipment  which 
employs these electrical phenomena of the skin, are said to detect diseased organs and 
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estimate the extent of pathological process activity within these organs (Szopinski, 
Pantanowitz et al. 1998; Szopinski, Pantanowitz et al. 2004). Zimlichman et al update that 
the measurement of electroskin impedance of dermal-visceral zones has the potential to 
serve as a screening tool for inner organ pathologies and there is a significant correlation 
with cardiovascular, respiratory, gastrointestinal and genitourinary diseases compared to 
conventional diagnostic methods (Zimlichman, Lahad et al. 2005).  
 
The device used in the EDST is the electro dermal screening device (EDSD), which 
works by measuring electrical resistance and polarization at acupuncture points and 
meridians. Through these skin-level measurements, it is claimed that it is possible to 
analyze the bio-energy and bio-information produced by internal organs and systems 
(Chen 1996). The predecessor to the EDST and EDSD weas invented in the 1950's by the 
German doctor Reinhold Voll and is called EAV or (Electro Acupuncture According to 
Voll). Dr. Voll originally developed a system of acupuncture point electro-therapeutics, 
but then he claimed that when an internal organ's function or structure changes, the 
performance of the related meridian and acupuncture points also changes, and that this 
change could be measured using an electrical resistance measurement device (Voll 1975) 
.  
 
Dr.Voll and others have gathered clinical data suggesting that electrical conductance 
measurements taken at low resistance points on the body can be correlated to the bio-
energetic functional status of specific organs and tissue systems (Voll 1975). Many of the 
low resistance measurement points correlate with classical acupuncture points. Tsuei 
suggests that pathological disturbances of organ function established by conventional 
medical diagnostic procedures are frequently demonstrated by disturbed skin conduction 
values at corresponding points suggested by acupuncture theory (Tsuei 1996). 
 
Recently Prokhorov et al compared direct current and alternative current impedance 
measurements obtained in vivo in acupuncture points connected with healthy organs in 
Ukrainian and Mexican residents. They also studied the electrical characteristics of the 
APs connected with unhealthy organs as well as the skin around these points. They state 
that impedance measurements from acupuncture points can be used as an efficient and 
prompt non-invasive method for diagnostic purposes (Prokhorov, Prokhorova et al. 2006). 
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Electro acupuncture according to Voll (EAV) is perhaps the most commonly employed 
method and claims to be adaptable, precise and codified (Krop, Lewith et al. 1997). Voll 
used a device called the Dermatron, Kail (2001) believes that  similar devices can be used 
for diagnosis and medicine testing (Kail 2001). The core of the EDSD is an ohmmeter 
designed to deliver approximately 10-12 microamperes of direct electrical current at 1-
1.25 volts a very small and perfectly safe amount of energy. On the majority of the 
devices the meter is calibrated to read from 0 to 100 such that the standard skin resistance 
of 100 kilo-ohms reads 50 (Tsuei 1996). 
 
Many electrodermal devices are currently being used all over the world and have become 
increasingly popular, possibly because of their safety, non-invasive nature, and simplicity 
(see BMJ’s website for further details).  However there is little reliable information on the 
use of electro dermal testing. These devices are suggested to work through a number of 
different mechanisms that include pressure changes over the acupuncture point that are 
produced unconsciously by the examiner (Lewith, Broomfield et al. 2001) to more 
objective mechanisms that are independent of the operator and are summarized as 
“quantum biology” (Krop, Lewith et al. 1997; Lewith, Broomfield et al. 2001; Lewith 
2003).  
 
Studies have shown that a weak electrical direct current stimulus evokes three 
mechanisms in the body: electrical conduction, dielectric polarization, and self-regulation. 
The first two are physical; the third is biological. When a direct current of one volt is 
applied to the skin with electro dermal screening (EDS), electrons and ions propelled by 
the circuit begin to move through the body (Konrad Kail 2001).The mobility of electrons 
is influenced by cellular metabolism and the concentration of charged particles suspended 
in the body fluids. In addition to electrical conduction, the cells are polarized by the 
applied voltage. It is suggested that the body functions as a resistor during the first 50 
milliseconds (Chen 1996). It is also suggested that electromagnetic waves move faster 
through meridians than through non-meridian tissue, making the meridian system an 
efficient bio-information communication network (Konrad Kail 2001). 
 
According to Konrad Kail one of the most popular uses of EDST medicine testing is 
allergy testing (Konrad Kail 2001). However, the results of EDST allergy testing have 
been compared to standard diagnostic modalities (RAST, serum IgE, intra-dermal allergy 
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skin testing, food rechallenge testing, and allergy history analysis).by Beyer and Teuber 
(2005) who suggest that the controlled oral food challenges remain the gold standard in 
the diagnostic work-up of suspected food allergy. The skin prick test and measurement of 
specific IgE antibodies to food extracts, individual allergens or allergenic peptides are 
helpful in the diagnostic approach. The other alternative and complementary techniques 
such as EDST have no proven benefit and may endanger patients via misdiagnosis (Beyer 
and Teuber 2005). 
 
Lewith et al (2001) found that the results of the electrodermal tests did not distinguish 
between volunteers who had previously reacted positively on skin prick tests for allergy 
to some allergens and volunteers who had reacted negatively to those allergens. Moreover 
a study by Semizzi et al (2002) found that the bioelectrical method, under blind testing, 
could not correctly detect respiratory allergy (Semizzi, Senna et al. 2002). Furthermore 
another study suggested no single participant's atopic status was consistently correctly 
diagnosed by a vegatest device (Bresser 1993; Lewith, Broomfield et al. 2001). In more 
recent studies Passalacqua et al found that none of the alternative diagnostic techniques 
such as electrodermal testing, kinesiology, leukocytotoxic test, iridology, and hair 
analysis have been proved able to distinguish between healthy and allergic subjects or to 
diagnose sensitizations. Therefore it is suggested that these tests can lead to delayed or 
incorrect diagnosis and therapy (Passalacqua, Compalati et al. 2005) (See Figure 7). 
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Figure 7: Biological Energy Correlation and Energy Index & Energy level in comparison to norm (www.medec.com.au) 
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1.2.5.3.1 Use of EDST and Respiratory Function 
Lewith, Broomfield (2001) believe that it should be possible to design an appropriate trial to 
study the diagnostic usefulness of the Vegatest for food intolerance reported by patients, 
although it is difficult to envisage a unifying mechanism to explain how the test would be able 
to detect this heterogeneous group of disorders. Furthermore, they recognize that electrodermal 
testing was developed to aid the prescription of homoeopathic and herbal remedies and not 
primarily as an allergy test. The phenomena involved in electrodermal testing may also make it 
difficult to evaluate in an entirely blind manner (Semizzi, Senna et al. 2002), as the person 
conducting the test may be an important part of the process. Such issues can be addressed by 
appropriate randomized, controlled trials. They consider electrodermal testing to be unable to 
diagnose allergy to common aeroallergens such as cat dander and house dust mite allergens 
that have a strong association with atopic respiratory disorders such as asthma, rhinitis, 
eczema, and conjunctivitis (Lewith, Broomfield et al. 2001).  
 
Krop in his study comments that the electrodermal testing was a reliable method of 
differentiating between allergic and non-allergic substances in the context of their study (Voll 
1975; Krop, Lewith et al. 1997), however Semizzi believes that bioelectrical method , under 
blind testing, could not correctly detect respiratory allergy (Semizzi, Senna et al. 2002) 
therefore there is an urgent need for rigorous tests to be done to determine  the correlations 
between tests. Passalacqua suggests that  complementary diagnostic techniques are mainly 
used in the field of food allergy-intolerance (Passalacqua, Compalati et al. 2005). 
 
Each year many adults and children with allergic disease consult alternative practitioners 
(MacLennan, Wilson et al. 2002; Mullins, Heddle et al. 2005), some are going under unproven 
diagnostic allergy testing as used by some alternative medical practitioners. the potential for 
adverse outcomes from using unproven diagnostic techniques are potentially more serious than 
the more commonly debated issues surrounding costs (MacLennan, Wilson et al. 2002). 
1.3. Treatment and Management of Asthma 
Early intervention might optimize lung growth and immune development, and moderate 
asthma persistence and severity (Szefler 2004). "Early interventions" target asthma shortly 
after its onset, "Secondary preventions" aim to prevent lung targeting of disease processes in 
the vulnerable host, and "primary preventions" strive to promote healthful immune 
development and lung growth by keeping pro-asthmatic immune responses from occurring 
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(Liu 2004).  
 
Asthma is a disease of the airways with an underlying inflammatory component. Currently 
inhaled β2-adrenoceptor agonists and corticosteroids form the basis of the treatments available 
to alleviate the symptoms of asthma (Belvisi, Hele et al. 2004). It is reported that exposure to 
infectious diseases may reduce the development of asthma or allergy. In particular, the role of 
the BCG vaccine in modulating asthma or allergy has been a source of speculation. One study 
further supports the role of infectious agents in modulating asthma and allergy development 
(Townley, Barlan et al. 2004). 
 
Sawyer study “living with asthma Survey” suggests that national asthma management goals in 
Australia are not being achieved in a high proportion of patients, with evidence for both 
underprescribing and underusage of preventive medication. Also the traditional focus of 
asthma education is not sufficient. Asthma education for children should address their views 
of etiology and fears, in addition conversations with parents about their explanatory models 
and beliefs about medications and alternative therapies could assist in understanding and 
responding to parental concerns and choices about medications and help achieve better 
adherence (Handelman, Rich et al. 2004). Therefore close arrangements between medical and 
patient standpoint is an important goal of asthma education and management (Sawyer and 
Fardy 2003). Specially trained community pharmacists, using a pharmaceutical care-based 
protocol, can produce impressive improvements in clinical, economic and humanistic outcome 
measures in asthma patients (McLean, Gillis et al. 2003). Also, health care professionals can 
help by providing school educators with appropriate information about the risk and functional 
impact of childhood chronic health conditions (Olson, Seidler et al. 2004). 
 
Current asthma guidelines identify inhaled corticosteroids (Busse, Lenfant et al. 2002) as the 
preferred initial long-term control therapy even in young children (Liu and Szefler 2003). 
Inhaled corticosteroids (Holmén, Blomqvist et al. 1997) clearly improve asthma control in 
children with mild to moderate persistent asthma, but it is not clear that they can alter the 
natural history and progression of asthma (Konig and Shaffer 1996). 
 
Since administering inhaled therapy to younger children can be difficult, an oral agent such as 
ketotifen offers potential advantages. Ketotifen alone or in combination with other co-
interventions improves control of asthma and wheezing in children with mild and moderate 
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asthma. However due to the high proportion of children with atopy the results cannot 
necessarily be generalized to all asthmatic children and also it has minor side effects, namely 
sedation and weight gain (Schwarzer, Bassler et al. 2004).  
 
Also several behavioral medicine interventions, such as relaxation training and written 
emotional expression, have been proposed as effective supplemental treatments for 
individuals with chronic illnesses such as asthma. Whether these treatments are feasible 
or effective in a manual-based, self-administered format is unclear, and few studies have 
examined the effectiveness of such treatments presented in a complementary format. 
Hockemeyer and Smith (2002) examined the feasibility and effectiveness of a 4-week 
stress management treatment compared with a matched placebo intervention in young 
adults with asthma. The treatment group showed significant improvement in measures of 
lung function compared with the placebo group, but analysis revealed no differences in 
measures of perceived stress. These findings provide initial support for the feasibility of 
self-administered manual-based interventions and some evidence that they can produce 
health benefits in individuals with asthma and, perhaps, other chronic conditions 
(Hockemeyer and Smyth 2002). Regular follow-up care of asthmatic children at a 
specialized pediatric pulmonary outpatient clinic considerably reduces the morbidity of 
childhood asthma, thus reducing hospital costs for asthma and improving the QoL for 
asthmatic children and their families (Mihailidou, Paspalaki et al. 2004). 
 
It is suggested that the best way to minimize the symptoms is to avoid the triggers. 
Changing bed and pillow coverings once a month (Chen and Hsieh 1996), avoiding mold 
(Simoni, Lombardi et al. 2005), staying away from pets, avoiding the outdoors during 
windy days, and controlling allergic reactions to venomous insects and foods (Gries, 
Moffitt et al. 2000) are some of the lifestyle changes a person can make to eliminate the 
triggers. Exposure to tobacco smoke is reported as the major modifiable risk factor 
related to asthma morbidity in children (Maziak, von Mutius et al. 2004). There is also a 
strong  association with family history of asthma and rhinitis, the place of residence, 
having smokers as parents and early weaning from maternal breast milk (Mavale-Manuel, 
Alexandre et al. 2004). 
 
Accurate symptom perception on the part of the patient is a critical component of asthma 
management (Yoos, Kitzman et al. 2003). There is a commonly held view that asthma 
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usually remits during adolescence (Guerra, Wright et al. 2004). Several behavioral 
medicine interventions (e.g., relaxation training and written emotional expression) have 
been proposed as effective supplemental treatments for individuals with chronic illnesses 
such as asthma (Hockemeyer and Smyth 2002). 
 
According to Wensley the knowledge of PEF does not enhance self- management even 
during acute exacerbations (Wensley and Silverman 2004) however; the sustain theory-
based educational program has a good effect on self-management behaviors (Chiang, 
Huang et al. 2004). In some country primary care groups are taking on increasing 
responsibility for monitoring the health of their population, commissioning health 
services, and meeting government targets. Admission rates for primary care are strongly 
associated with measures of chronic illness and deprivation (Majeed, Bardsley et al. 
2000). 
 
In conclusion, the interventions and the practice guidelines for asthma control are useful 
for preventing and controlling asthma (Mo, Robinson et al. 2004). While there is 
presently no cure for asthma, correct diagnosis and adequate management of the 
condition will allow the majority of people with asthma to lead a full and active life style. 
To improve asthma management requires additional study beside the present asthma 
guidelines and information activities. 
1.3.1. Asthma Conventional Medication 
Asthma is a disease of remission and exacerbation but the combination of optimal 
interval (Bowler and Mitchell 1983). The goal of asthma therapy is to control symptoms, 
optimize lung function, and minimize days lost from school. Courtney et al updates that 
acute care of an asthma exacerbation involves the use of inhaled β2 agonists delivered by 
a metered-dose inhaler with a spacer, or a nebulizer, supplemented by anticholinergics in 
more severe exacerbations. The use of systemic and inhaled corticosteroids early in an 
asthma attack may decrease the rate of hospitalization (Courtney, McCarter et al. 2005). 
Chronic care focuses on controlling asthma by treating the underlying airway 
inflammation. Inhaled corticosteroids are the agent of choice in preventive care, but 
leukotriene inhibitors and nedocromil also can be used as prophylactic therapy. Long-
acting β2 agonists may be added to one of the anti-inflammatory medications to improve 
control of asthma symptoms. Omalizumab, a newer medication for prevention and 
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control of moderate to severe asthma, is an expensive option (Courtney, McCarter et al. 
2005). The therapy of asthma is twofold; one is to reduce chronic inflammation and 
enhance hyperresponsiveness with so-called anti-inflammatory medication, second; to 
overcome acute persistent asthma is now considered an inflammatory airways disease 
(Lalloo 2002).  
  
• Inhaled corticosteroids are recognized as the preferred long-term control medication 
(Szefler 2004). Recent updates in the asthma guidelines advise clinicians to 
consider intervention with anti-inflammatory therapy, preferably inhaled 
corticosteroids, in children who have frequent asthma exacerbations and a risk 
profile for persistent asthma (Szefler 2004). Continued research is needed to 
identify asthma at a very early stage so that interventions can be directed to 
interrupting the development of this disease. For asthmatic children inhaled 
corticosteroids are more beneficial than as-needed use of β2 agonists, long-acting β2 
agonists, theophylline, cromolyn sodium, nedocromil, or any combination of those 
(Kallstrom 2004). Therefore inhaled corticosteroids (Holmén, Blomqvist et al.) 
(Holmén, Blomqvist et al. 1997) are considered first-line therapy for persistent 
asthma in children (Angus 2002). Major safety concerns about long-term ICS 
therapy include suppression of adrenal function, growth, and bone development. 
Proper interpretation of ICS safety studies requires knowledge of differences 
between various ICS drug/delivery device systems (Allen 2004).  
 
• A phenotype-specific treatment approach may also help to define which add on 
therapy e.g. long-acting beta agonist, leukotriene receptor antagonist, theophylline 
is best for children with moderate asthma not controlled by moderate dose (400 
mcg/day) inhaled corticosteroids (Bush 2004). 
• Leukotriene modifiers are an alternative but not a preferred treatment; they should 
be considered if the medications need to be administered orally rather than via 
inhalation (Kallstrom 2004). 
• Leukotriene antagonists are seen to be well tolerated, efficacious, and of benefit to 
some children with exercise induced asthma (Moraes and Selvadurai 2004).  
• Cromolyn sodium and nedocromil are effective long-term asthma-control 
medications, but they are not as effective as inhaled corticosteroids (Sekerel, 
Saraclar et al. 1999; Kallstrom 2004).There is insufficient evidence to determine 
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whether cromolyn benefits maintenance of childhood asthma (Bartels and 
Farrington 1994). Cromolyn sodium and nedocromil are alternatives, but not 
preferred treatments for mild persistent asthma. Cromolyn may be useful as a 
preventive therapy prior to exertion or unavoidable exposure to allergens 
(Kallstrom 2004). Regular inhalation of corticosteroids controls asthma 
significantly better than as-needed β2 agonists(Kallstrom 2004). No studies have 
examined the long-term impact of regular inhaled corticosteroids on lung function 
in children less than 5 years old (Kallstrom 2004). As monotherapy, inhaled 
corticosteroids are more effective than long-acting β2 agonists. The asthma-control 
benefit of inhaled corticosteroids decidedly outweighs the risks from inhaled 
corticosteroids (Eid 2004). There is no high-level evidence that low-to-medium-
dose inhaled corticosteroids have ocular toxicity or important effects on 
hypothalamic-pituitary-adrenal function in children (Kallstrom 2004). 
• Antibiotic therapy has no role in asthma management unless there is a bacterial 
comorbidity, but further research is needed on the relationship between sinusitis and 
asthma exacerbation (Herrera and deShazo 1990). The asthma care plan should 
include a written asthma action plan for the patient, but there is inadequate evidence 
as to whether the asthma action plan should be based on symptoms or on peak flow 
monitoring (Lung and Lung 2003). There is low-level evidence that helium-oxygen 
mixture (heliox) may be of benefit in the first hour of an acute asthma attack but 
less advantageous after that first hour.(Rabbat and Laaban 2001; Kallstrom 2004) 
Metered-dose inhalers are no more or less effective, overall, than other aerosol-
delivery devices for the delivery of β2 agonists or inhaled corticosteroids, so the 
least expensive delivery method should be chosen (Kallstrom 2004). In the US, 
subcutaneous administration of Omalizumab is indicated for adults and adolescents 
(age greater than or equal to 12 years) with allergic asthma that is moderate to 
severe and inadequately controlled with inhaled corticosteroids. Further evaluation 
on Omalizumab needs to be done in the pediatric population (Hadj Tahar 2004; 
Walker, Monteil et al. 2004). (See Table 2) 
 
Table 2: Asthma drug’s names, action, clinical usage and their possible side effects 
(Galbraith, Bullock et al. 1999) 
 
Drug/Name Action and Clinical Uses Side Effects 
Sympathomimetics Isoproterenol, 
Ephedrine, Bronkosol, Alupent, 
Brethine, Proventil, Ventolin  
 
Decrease intracellular 
calcium; smooth muscle 
relaxation; bronchodilation 
Tachycardia, palpitations, GI 
distress, nervousness, headache, 
dizziness 
Methylxanthines Amnodur, 
elixophyllin, Theodur, Choladril 
Increase cAMP; block the 
decrease of cAMP 
Agitation, hypotension, chest 
pain, nausea, tachycardia, 
palpitation, GI distress, 
nervousness, headache, dizziness 
 
Parasympatholytics Atrovent, 
Atropine sulphate 
Block parasympathetic 
stimulation and prevents 
increase in cGMP; prevents 
bronchoconstriction 
Central nervous system 
stimulation with low doses and 
depression with high doses; 
delirium, hallucinations, 
decreased GI activity 
 
Glucocorticoids Prednisone, Cortisol, 
Azmacort, Vancer 
Decrease inflammatory 
response; bronchodilation 
Obesity, growth suppression, 
hyperglycemia and diabetes, 
mood changes, irritability, or 
depression, thinning of skin, 
muscle wasting 
Cromolyn sodium Intal, Fivent Prevents influx of calcium 
ions, thus blocking mast cells 
release of mediators 
responsible for 
bronchoconstriction; 
bronchodilation 
Throat irritation, hoarseness, dry 
mouth, cough, chest tightness, 
bronchospasm 
 
1.3.2 Immunotherapy for Asthma 
Specific allergen immunotherapy, although being performed for almost 100 years, 
(Fornadley 1998; Akdis and Akdis 2006) is still being addressed in clinical trials (Wahn 
2002). Wahn suggests that sublingual immunotherapy is not yet sufficient to recommend 
this mode of treatment in clinical practice (Wahn 2002). However the Bufe, Ziegler-
Kirbach et al (2004) inform that in children, sublingual allergen application has gained 
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considerable interest. Recent findings suggest that specific allergen immunotherapy has 
the capacity to modify the natural history of allergic airway disease by reducing the 
incidence of new sensitivities non-specifically, reducing allergic symptoms years after 
discontinuation and preventing the incidence of asthma (Marogna, Spadolini et al. 2005; 
Tonnel 2005).  
1.4 Introduction to Complementary Medicine 
Most of the complementary therapies have their own diagnostic methods. These 
diagnostic methods need to be concerted with the diagnostic methods of orthodox 
medicine (Byass 1999).  
 
The World Health Organization strategies, “Integrated Management of Childhood Illness 
and Practical Approach to Lung health” provide assessment and management guidelines 
for health workers in developing countries (Nelson, Olukoya et al. 2004). Whitehead 
(2003) suggests that the benefits and safety of herbal and dietary supplements in 
respiratory disorders need to be considered. In the United States, the legal status of these 
therapies is uncertain at the present caused by variation of practice and manufacturing 
procedures of these products and it has been suggested that there is a need to accelerate 
the integration of conventional and traditional medicine, with standardization of practice 
and manufacturing procedures of these products (Whitehead 2003). Ernst (1998) informs 
that asthma patients are prime candidates to employ complementary medicine (CM) for 
their conditions. Breathing techniques, homoeopathy, and herbalism were the three most 
prevalent treatments. The majority of respondents perceived these therapies as 
moderately useful with only little difference between various treatments. CM is 
frequently used for asthma. Therefore, this area of healthcare would seem to warrant 
more rigorous investigation (Ernst 1998). 
1.4.1. What is non- conventional medicine? 
According to the World Health Organization (WHO) Traditional Medicine Resolution 2002-
2005; Traditional medicine is the “sum total of the knowledge, skills, and practices based on 
the theories, beliefs, and experiences indigenous to different cultures, whether explicable or 
not, used in the maintenance of health as well as in the prevention, diagnosis, improvement 
or treatment of physical and mental illness.” In some countries the terms ‘complementary 
medicine’ or ‘alternative medicine’ are used inter-changeably with traditional medicine to 
refer to a broad set of health care practices that are not part of that country's own tradition and 
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are not integrated into the dominant health care system (WHO 2002). Ernst et al define 
complementary medicine as diagnosis, treatment and/or prevention which complements 
conventional medicine by contributing to a common whole, by fulfilling a demand not met 
by orthodoxy or by diversifying the conceptual frameworks of medicine (Ernst, Resch et al. 
1995).  
 
The National Center for Complementary and Alternative Medicine (NCCAM) in the 
United States defines CAM as; “a group of diverse medical and health care systems, 
practices, and products that are not presently considered to be part of conventional 
medicine” and classifies CAM therapies into five categories; Alternative Medical 
Systems, Mind-Body Interventions, Biologically Based Therapies, Manipulative and 
Body-Based Methods and Energy medicine (NCCAM 2002; NCCAM 2002; NCCAM 
2004) . 
 
The list of what is considered to be CAM changes continually, as those therapies that are 
proven to be safe and effective become adopted into conventional health care and as new 
approaches to health care emerge (NCCAM 2002). While scientific evidence exists 
supporting the efficacy and safety of some CAM therapies, for most there are key 
questions that are yet to be answered through well-designed scientific studies. Key 
questions include whether complementary therapies are safe and efficacious for the 
diseases or medical conditions for which they are used and whether diagnostic systems 
arising from different paradigms can provide useful clinical information (Rosenthal and 
Dean-Clower 2005).  
1.4.2 Use of Complementary Medicine 
The use of Complementary and Alternative Medicine (CAM) including the use of both 
complementary therapies (CTs) and complementary medicines (CMs) is one of the most 
visible and fastest growing areas of health care (Makowski 2004) and patients actively seek 
and use a wide variety of CAM therapies (Milan, Landau et al. 1998). 
 
 In the United States it is estimated that 36%of the adult population were using some 
form of CAM in 2002 (Barnes, Powell-Griner et al. 2004; Tindle, Davis et al. 2005) and 
if megavitamin therapy and prayer for health reasons were included the number rose to 
62% (NCCAM 2004). In another US study, 53% of pediatric patients attending Odense 
University Hospital during a 2 week period in the autumn of 2001 had tried CAM at least 
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once and 23% had tried CAM within the previous month (Madsen, Andersen et al. 2003).  
 
In India, a study done in the Punjab found that 76% of patients who visited an internal 
medicine outpatient department over a period of 6 months had used one or more 
unconventional therapies in the previous year with homeopathy being the most frequently 
used (Malhotra, Bhatia et al. 2001). This study found that digestive problems, backache, 
joint pains and bronchial asthma were the most frequent conditions for which alternative 
therapies were used and that most patients used alternative therapies on their own, 
without visiting a provider of such therapies (Malhotra, Bhatia et al. 2001). 
 
The results of a South Australian survey suggest that at least 50% of the population use at 
least one complementary therapy with greatest use being in women with higher income 
and education levels and therapies being used mostly to maintain general health 
(MacLennan, Myers et al. 2006). Study further suggests that the 50% of the CAM users 
used conventional medicines on the same day and more than 50% did not report the use 
of CAMs to their doctor (MacLennan, Myers et al. 2006). In another Australian study 
performed in rural NSW more than 70% of the population were found to be using one or 
more types of complementary therapies (Wilkinson and Simpson 2001).  
 
The most popular form of CAM therapies varies depending on the time and place. For 
instance in rural NSW, vitamin/ mineral therapy, chiropractic and massage therapy were 
the most frequently used therapies respectively, vitamin C and multivitamins were the 
most commonly used complementary medicines with garlic and Echinacea being the 
most used herbal products (Wilkinson and Simpson 2001). In contrast Madsen et al 
suggest that in the US the most common CMs were herbal medicines used to strengthen 
the immune system and the most common treatment was homeopathy (Madsen, Andersen 
et al. 2003). According to Donnelly the most common treatments were chiropractic 
followed by homoeopathy/naturopathy, acupuncture and herbal medicine (Donnelly, 
Spykerboer et al. 1985). Italian National institute of statistic (ISTAT)in collaboration 
with WHO data collected from 9 million  Italian (15.6% of population) in1997 to 1999 
over a three-year period, established that CAM therapies most often used in Italy were 
homeopathy, followed by manual treatments, phytotherapy, acupuncture, and others 
(Sanitaria, Zhang et al. 2003). 
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1.4.2.1 Use of CAM on children and adolescents 
It has been reported that children may be more frequent users of CAM than adults and 
there is evidence to suggest that it is frequently undertaken by parents without the 
knowledge or advice of their pediatrician (Ottolini, Hamburger et al. 2001). Reznik et al 
reveals that the prevalence of CAM use by adolescents in a study population of 3800 
registered students aged 13 to 18 years in an inner-city high school in US was twice the 
national average for adults (Reznik, Ozuah et al. 2002). The prevalence of CAM use 
among patients admitted to hospital also appears to be high, but documentation of this 
usage is low (Cockayne, Duguid et al. 2005).  
 
Schafer suggests that the users and nonusers of alternative medicine with allergies can be 
distinguished by psychosocial characteristics such as health focus of control and quality 
of life (QoL) (Schafer, Riehle et al. 2003). 
 
It is suggested that health professionals need to be aware of the high rates of usage of CM 
and CT in asthmatic children and of parental attitudes to conventional and alternative 
therapies (Shenfield, Lim et al. 2002). It has also been suggested that healthcare 
professionals need to be able to make informed decisions when advising or referring their 
patients who wish to use CAM. This has led to calls for pediatric patients to be 
interviewed about their use of complementary/alternative medicine with regard to side-
effects, interactions or lack of compliance with conventional medicine (Madsen, 
Andersen et al. 2003). It is further suggested that medical practitioners might benefit 
from advice by CAM-providers as to which treatment can be recommended for which 
condition (Long, Huntley et al. 2001). This is paralleled by calls for training in CAM to 
be included in the undergraduate and continuing education of health professionals 
(Wilkinson and Simpson 2001; Wilson, Adams et al. 2003).  
1.4.2.2 Evidence and CAM 
While there have been criticisms of the scientific basis for CAM therapies the evidence 
base supporting the use of CAM is growing. According to Linde et al (2001), a large 
number of systematic reviews on acupuncture exist and the majority of systematic 
reviews for homeopathy seem to report positive results, however not all trials are well 
designed (Linde, Hondras et al. 2001). Systematic reviews are also available on a broad 
range of herbal preparations prescribed for defined conditions. There is very little 
evidence however on the effectiveness of herbalism as practiced by specialist herbalists 
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who combine herbs and use unconventional diagnostic techniques (Linde, Riet et al. 
2001) and there are calls for increased funding of CAM research and the conduct of well-
designed, large clinical trials (Linde, Vickers et al. 2001). 
1.4.2.3 An overview of CAM use in asthma 
Despite concerted efforts in comprehensive management, the incidence and severity of 
asthma are increasing and more families are looking to CAM for help in treating 
persistent childhood asthma. It seems that people are turning to therapies such as 
homeopathy, acupuncture and herbal therapy (Andrews, Lokuge et al. 1998; Schafer, 
Riehle et al. 2002; Felix Berumen, Gonzalez Diaz et al. 2004) and it has been estimated 
that around 55% of children from a children's hospital in South Australia use alternative 
therapies for asthma management. Furthermore these therapies appear to have wide 
appeal as it has been reported that there are no significant differences in the age, asthma 
severity, and length of time since diagnosis or presence of another illness amongst 
children who do or do not use alternative therapies for asthma. In the US, CAM therapies 
such as prayers, rubs, and massage have a very high rate of CAM use among inner-city 
children with asthma (Braganza, Ozuah et al. 2003).  
 
It is further estimated that roughly half of asthmatic families consulted an alternative-
medicine practitioner at some time (Donnelly, Spykerboer et al. 1985) yet there is 
evidence that people use these treatments to complement conventional therapy and not 
replace it (Bielory, Chiaramonte et al. 2003). It is suggested however, that a very high 
proportion of parents perceived the therapies to be as effective as pharmacotherapy and 
use them as first line treatment of acute asthmatic exacerbations, and did not inform a 
physician of doing so (Bielory, Chiaramonte et al. 2003; Braganza, Ozuah et al. 2003).  
 
It appears that there are many barriers to optimal treatment for asthmatics including a 
failure to recognize warning symptoms, belief in a permanent cure, not continuing 
treatment and undertreatment (Singh, Sinha et al. 2002). According to Shenfield et al the 
most common reasons for using CM and CT in Australia for asthmatics were 
dissatisfaction with conventional therapies and concerns about steroid side effects 
(Shenfield, Lim et al. 2002). In some cases whom the disease is not well controlled are 
more likely to use CAM as complementary therapy (Orhan, Sekerel et al. 2003). It needs 
to be stressed, those families who wish to try alternative therapies along with 
conventional care need to have open lines of communication and cooperation between 
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their providers, both conventional and unconventional therapists (Doerr 2001). 
1.4.2.4 Overview of research in to CAM for asthma 
In a review of Randomized Controlled Trials (RCT) published in English between 
years1997-2002 Markham and Wilkinson (2004) suggest that some CAM therapies 
have shown minimally significant improvements in asthma QoL (breathing exercises) 
or pulmonary function (relaxation) and immune function (relaxation and acupuncture) 
in selected asthma populations. However, the trends for improvement, notably in QoL 
measurements, are encouraging (Holloway and Ram 2004). Although CAM therapy is 
being regularly used in the management of asthma, more research is needed to assist in 
determining the efficacy of CAM therapies (Holloway and Ram 2004; Markham and 
Wilkinson 2004). while individuals are using CAM therapies to help manage their 
asthma, there is no clear direction in the current guidelines for the use of CAM in 
asthma (Markham and Wilkinson 2004). Steurer-Stey et al disclose in their study that 
up to now evidence is lacking that alternative form of medicine are more effective than 
placebo in asthma. However, lack of evidence does not always mean that treatment is 
ineffective, but it could mean that effectiveness has not been adequately investigated as 
in conventional therapy. Research should be fostered in complementary medicine 
(Steurer-Stey, Russi et al. 2002). High quality research studies published since June 
2002 on CAM in bronchial asthma reviewed by Gyorik revealed that the use of 
homeopathy, air ionizers, manual therapy, or acupuncture for asthma could not be 
supported on the basis of evidence (Gyorik and Brutsche 2004). However antioxidant 
dietary supplementation (Sienra-Monge, Ramirez-Aguilar et al. 2004; Wood, Garg et 
al. 2005), and some natural anti-inflammatory and immunomodulatory remedies might 
have some effects, but their effects are not clearly established (Gyorik and Brutsche 
2004).  
1.4.2.4.1. Chinese Herbal Medicine 
There are many individualized formulae in Chinese herbal medicine administration on 
treating asthma. According to the National Asthma Council Australia (NACA) several of 
these are possibly effective in improving breathing capacity in people with asthma. As there 
is no definitive evidence for any of the herbal preparations showed is effective on clinical 
trials. Considering the popularity of herbal medicine with asthma patients, there is urgent 
need for rigorously designed clinically relevant randomized clinical trials for herbal 
preparations in the treatment of asthma. However; commonly used Chinese herbal 
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preprations in chronic disease such as respiratory illness; Ginkgo biloba extract 
(ginkgolides), Ligusticum wallichii (also called chuan xiong in China and senkyu in Japan), 
Chanbei Kechuanping, Xuan Fei Ding Chuan Wan and Xiao Chuan Gu Ben Wan, 
Reinforcing kidney and invigorating spleen decoction, Invigorating kidney for preventing 
asthma tablets, Strengthening body decoction mahuang Ephedra sinica mixture, mahuang 
(Ephedra) Wenyang Tongulo mixture (WTM), all are preparations for asthma, (Marks, Marc 
Cohen et al.). Also there are some formulas, which have been investigated, by randomised 
clinical trials (RCT) such as 
Xiao-Qing-Long Tang (XQLT), a Chinese herbal medicine that has been used to treat 
bronchial asthma and allergic rhinitis for centuries. It is suggested that the administration of 
XQLT has the immunomodulatory effect of reducing bronchial inflammation in allergen-
sensitized mice. However, the therapeutic mechanisms of this medication are still far from 
clear (Kao, Wang et al. 2000). 
 
Shinpi-To (Formula divinita; TJ-85) is another herb used in treating childhood asthma, and 
it is suggested that Shinpi-To inhibits leukotriene C4 synthesis by inhibiting phospholipase 
A2 and 5-lipoxygenase activities without affecting the mobilization of [Ca2+]i (Hamasaki, 
Kobayashi et al. 1997). 
 
The Chinese herbal medicine formula MSSM-002, derived from TCMs used to treat 
allergic asthma, exhibits anti-airway hyperresponsiveness, anti-airway inflammation, and 
immunoregulatory effects on T (H)1/T(H)2 responses, which may be useful for treatment of 
allergic asthma (Li, Huang et al. 2000). 
 
HAN fang Ji (Tetrandrine) is another TCM drug used for the treatment of asthma. This 
drug has an anti-inflammatory, antifibrogenetic, immunomodulating effects, antioxidant 
effects, and also presents anti-allergic effects, inhibitory effects on pulmonary vessels and 
airway smooth muscle contraction, and platelet aggregation. Consequently it has potential to 
treat asthma, pulmonary hypertension and chronic obstructive pulmonary disease 
(COPD)(Qiang-Min, Hui-Fang et al. 2002; Xie, Tang et al. 2002) 
 
Acacia ancistrocarpa leaves, Ficus racemosa bark, Clematis pickeringii stem, Acacia 
adsurgens leaves, Tinospora smilacina stem and Morinda citrifolia fruit powder have also 
been traditionally used. In Australia some plants are used in aboriginal medicine and also 
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used in TCM for the treatment of various diseases that are considered as inflammatory in 
nature, e.g. asthma, arthritis, rheumatism, fever, edema, infections, snakebite and related 
inflammatory diseases investigated. All these herbs have exhibited inhibition of Cox-1. 
Aspirin and indomethacin used as the reference Cox-1 inhibitors in this study inhibited Cox-
1 in some degree (Li, Myers et al. 2003). 
 
Other medicinal therapies include: traditional Ayurvedic (Indian) medicines are 
Boswelliaserrata, Coleus forskohlii (forskolin), Picrorrhiza kurroa, Solanum xanthocarpum/ 
S. trilobatu (kantakari), and TylophoraIndica. Traditional Japanese medicines; Tsumura 
saiboku-to (TJ-96). Medicinal therapies: herbs (miscellaneous), Ivy leaves dried (Hedera 
helix L.) (Marks, Marc Cohen et al.).  
1.4.2.4.2. Acupuncture treatment for asthma 
Acupuncture has traditionally been used to treat asthma in China and is used increasingly for 
this purpose internationally (Linde, Jobst et al. 2000). It is one of the alternative therapies 
that is quickly gaining popularity and acceptance among both patients (Altshuler and Maher 
2003; Foltz, St Pierre et al. 2005)  and doctors (Altshuler and Maher 2003). The National 
Institute of Health (NIH) has supported its use for many conditions, alone or as adjunctive 
therapy to conventional methods (Altshuler and Maher 2002; Goddard 2005). Research has 
now demonstrated several physiological mechanisms to explain acupuncture's benefits 
(Altshuler and Maher 2002). However, there are many different schools of acupuncture and 
methodology and techniques vary widely, all contributing to the success or failure of 
acupuncture treatment (White, Resch et al. 1999; Altshuler and Maher 2002). With proper 
use, acupuncture can be an effective treatment for a variety of medical conditions, (Altshuler 
and Maher 2002) however, in the light of recent research there does not appear to be  enough 
evidence to make recommendations about the value of acupuncture in asthma treatment 
(Linde, Jobst et al. 2000; Steurer-Stey, Russi et al. 2002; McCarney, Brinkhaus et al. 2004). 
Further research needs to consider the complexities and different types of acupuncture 
(McCarney, Brinkhaus et al. 2004). 
1.4.2.4.3. Homeopathy treatment for asthma  
Homeopathy involves the use, in dilution, of substances which cause symptoms in their 
undiluted form. It is one of the most widespread forms of complementary medicines and it is 
also used to treat asthma (Felix Berumen, Gonzalez Diaz et al. 2004). In western societies an 
increasing number of patients with asthma and allergy combine conventional and 
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complementary and alternative treatment indicating that there is a need for bridge building 
between conventional and alternative health care (Launso and Rieper 2005). Regarding 
homeopathy McCarney study puts forward that there is not enough evidence to reliably 
assess the possible role of homeopathy in asthma. They suggest that in addition to 
randomised trials, there is a need for observational data to document the different methods of 
homeopathic prescribing and how patients respond. This will help to establish to what extent 
people respond to a 'package of care' rather than homeopathic intervention alone (McCarney, 
Linde et al. 2004). Ponvert proposed that individualized homeopathy, as an adjunct in the 
treatment of childhood asthma, is not superior to placebo in improving the QoL of children 
with mild to moderate asthma (Ponvert 2004). However the reasons for choosing, continuing 
or termination of patient treatment by general practitioner (Townley, Barlan et al. 2004) 
patients' and classical homeopath (CH) depends on the importance of health providers' 
insight into GP patients' and CH patients' different reflections to adverse events, the patients' 
different understandings of asthma and allergy, and the different learning processes that GP 
patients and CH patients might be involved in while living with asthma and allergy 
(Jorgensen and Launso 2005). Hassed advises that the informed GP plays a vital role in 
supervision, educating patients about valid and safe treatment options, decision making, and 
supporting legitimate patient empowerment in their own management. An evidence based 
integrative approach offers the best potential outcomes for doctor, patient and family 
(Hassed 2005). 
1.4.2.4.4. Breathing retraining for dysfunctional breathing in asthma: 
There is much anecdotal evidence in eastern and western literature describing benefits for 
patients with asthma when treated with breathing interventions. The term 'breathing exercise, 
training and retraining' has numerous interpretations depending on the nature of the therapy, 
therapist and cultural background (Mota, Guell et al.; van Dixhoorn 1998; Liaw, Lin et al. 
2000; Maguire, Walsh et al. 2004; Geddes, Reid et al. 2005; Trummer, Mueller et al. 2006). 
No reliable conclusions can be drawn concerning the use of breathing exercises for asthma in 
clinical practice. However trends for improvement, notably in QoL measurements, are 
encouraging and further studies including full descriptions of treatment methods and 
outcome measurements are required (Holloway and Ram 2004). Functional breathing 
disorders complicate asthma and impair QoL (Thomas, McKinley et al. 2003). In a 
randomised controlled trial with 23 participants, over half the patients were treated for 
asthma in the community with symptoms suggestive of dysfunctional breathing showed a 
clinically relevant improvement in QoL following a brief physiotherapy intervention. This 
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improvement was maintained in over 25% six months after the intervention (Thomas, 
McKinley et al. 2003). Breathing exercises have been found to improve lung function and 
QoL in different studies (Gyorik and Brutsche 2004). Strategies influencing breathing 
technique or perception, such as breathing or retraining exercises, need to be studied to 
establish their additive role in the treatment of asthma.  
1.4.2.4.4.1 Breath Holding Time and Asthma  
Two main factors (chemical and non-chemical factors) are involved in the determination of 
BHT (Honda, Hayashi et al. 1981; Delapille, Verin et al. 2001). By training both factors can 
be modified and consequently increase BHT (Delapille, Verin et al. 2001). Either an increase 
in PaCO(2) or a decrease in PaO(2), can affect respiratory stimulation through respiratory 
centers, thus influencing BHT (Morooka, Wakasugi et al. 2000).  
Voluntary BHT has a circadian rhythm and varies along with the relationship with Delta P 
ACO2 between the morning and evening hours but changes in alveolar and arterial gases are 
not the same at different times of the day (Bosco, Ionadi et al. 2004). Breath-Holding 
Capability (BHC) has been shown to be low in asthmatics when their airflow resistance was 
high and to rise when the airflow resistance fell as the result of treatment (Allen and Stretton 
1984) breathing oxygen at rest was high in the asthmatics before treatment and fell after 
bronchodilator drugs were administered (Allen and Stretton 1984). The fall in respiratory 
drive which followed bronchodilatation in the asthmatic subjects cannot be solely explained 
in terms of the resulting fall in the viscous and elastic work of breathing. Vagal afferent 
signals arising in the airways might play a part in modifying respiratory drive in such 
circumstances (Allen and Stretton 1984). Dysfunctional breathing in asthma is identifiable 
and appears to be correctable through therapeutic intervention such as the BBT (Thomas, 
McKinley et al. 2001; Morgan. 2002). 
 
Breathing retraining turns out to be an effective therapy for difficult to treat psychosomatic 
patient who have dyspnea  and a wide variety of symptoms (Han, Zhu et al. 2004).  McHugh, 
Aitcheson et al. (2003) suggest that BBT is promoted as a drug-free asthma therapy. They 
put forward that it is a safe and efficacious asthma management technique. BBT has clinical 
and potential pharmaco-economic benefits that merit further study (McHugh, Aitcheson et 
al. 2003). It is based on the premise for raising blood PaCO2 through hypoventilation and 
can treat asthma (Opat, Cohen et al. 2000) ,however Increased airway CO2 alone is an 
unlikely mechanism for the reported benefits of BBT (Al-Delaimy, Hay et al. 2001). 
Buteyko's theory relating to carbon dioxide levels and airway calibre is an attractive one, and
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 need for alternative healing while monitoring for potential allergic reactions (Frieri 
2001).  
) 
has some basis in evidence from experimental studies (Bruton and Lewith 2005). Studies 
inform that, those practicing BBT reduced hyperventilation and their use of β2-agonist
trend toward reduced inhaled steroid use and better QoL was observed in these patients 
without objective changes in measures of airway caliber. These results warrant further 
investigation (Bowler, Green et al. 1998; Opat, Cohen et al. 2000; Cooper, Oborne et al. 
2003). However, it is not known whether altering breathing patterns can raise carbon dioxide
levels significantly, and there is currently insufficient evidence to confirm that this is the 
mechanism behind any effect that BBT may exert. Further research is necessary to establish 
unequivocally whether BBT is effective, and if so, how it may work (Bru
005). 
1.4.2.4.5. Herbal Remedies Integration into Conventional Medicine 
There is a high prevalence of usage of herbal medicine to treat asthma (Huntley and E
2000; Szelenyi and Brune 2002). Despite growing health care costs and very limited 
evidences of efficacy of most CAM therapies their use has grown substantially over the las
decade in Europe, US and Australia (Eisenberg, Davis et al. 1998). The use of plants is as 
old as humankind and it has been steadily increasing. Plant-based remedies are now o
the most popular complementary treatments (Szelenyi and Brune 2002). There is no 
conclusive answer as to why patients seek CAM, but it seems that they feel more empowere
by the process, more actively involved in the decision making and more in control of their 
illness (Furnham and Kirkcaldy 1996). Interest in herbal medicine has been facilitated by 
multiple factors, including the perception that pharmaceutical medications are expensive, 
overprescribed and may often be dangerous (Szelenyi and Brune 2002). Alternatively, herbal 
medicine is often perceived as being "natural" and therefore is considered safe (Bauer 2000
However, the scientific literature supporting the efficacy of herbal therapies is incomplete 
(Szelenyi and Brune 2002). There are few well-controlled studies that support the e
herbal remedies in the treatment and clinical improvement of patients with asthma 
(Passalacqua, Compalati et al. 2005). Available scientific evidence has not yet confir
validity of their popular role in the treatment of asthma (Szelenyi and Brune 2002). 
Conventional physicians should question their patients about their use and be knowledge
about toxicity. The allergist-immunologist should meet the challenge to understand the 
patient's
 
A review of seventeen RCTs of herbal medicine for asthma by Huntley and Ernst (2000
                                                                                                                                                                   
  
70
leaf 
levant RCTs for herbal preparations in the 
tr untley and Ernst 2000).  
 
found that six trials concerned the use of traditional Chinese herbal medicine and eight 
described traditional Indian medicine, of which five investigated Tylophora indica. Three 
other randomised trials examined a Japanese Kampo medicine, marihuana, and dried ivy 
extract. Nine of the 17 trials reported a clinically relevant improvement in lung function 
and/or symptom scores; however there was no definitive evidence for any of the herbal 
preparations. Considering the popularity of herbal medicine with asthma patients, there is 
urgent need for rigorously designed clinically re
eatment of asthma (H
1.4.2.4.5.1. Ryegrass 
The Columbia Encyclopedia, Sixth Edition, (2001) describes; the ryegrass as a short-lived
perennial, leafy, tufted plant belonging to the family Gramineae (grass family) (Bartleby 
2001). In Finland Prof. Herman Aldercreutz discoverd the significant health benefits
the consumption of rye products by a statistically large group of Finnish people. He 
succeeded in isolating and identifying phytoestrogens in the rye plant and has been working 
with them for the past 30 years (Aldercreutz and Dessypris 1974). Only one study suggests 
that ryegra
 from 
ss extract has a beneficial effect on restricted airway function (Cooper, Rogers et 
ng 
 
d rye 
ide valuable raw materials for health-
promoting foods (Lampi, Moreau et al. 2004). 
xtract 
al. 2002). 
There is not much formal study on rye grass and human consumption as a medication. 
However there are studies that state rye bread is effective in reducing serum total and LDL 
cholesterol concentrations in men with elevated serum cholesterol. Good compliance with 
consuming a relatively large amount of rye bread in the usual diet indicates that rye bread 
offers a practical dietary means of reducing serum cholesterol in men (Leinonen, Poutanen et 
al. 2000). Also high-fiber rye bread appears to enhance insulin secretion, possibly indicati
improvement of b cell function (Juntunen, Laaksonen et al. 2003). In another study fiber 
from rye appears more effective than that from wheat in overall improvement of biomarkers 
of bowel health (McIntosh, Noakes et al. 2003). A recent study revealed that rye bread was a
good source of dietary selenium (Bryszewska, Ambroziak et al. 2005). Also barley an
are a good source of phytosterols and thus prov
 
In Australia the makers of “rye grass extract” (Cooper, Rogers et al. 2002) strongly believe 
in the healing effect of the rye grass sprouts suggesting that they developed a way to e
the hormones, protectants and polysaccharides, phyto-estrogens, and so on which are 
possessed by rye as part of its natural biochemical immune complement. Their extract, 
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the effects of manual therapies on clinically relevant outcomes (Hondras, Linde 
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d scientific principles and foster high quality research into complementary 
therapies. 
 
Oralmat Drops, has been used by a broad cross-section of the community in Australia and 
world wide including many asthmatic patients. They also claim that rye grass extract ha
wound-healing effec
eneral well being. 
1.4.2.4.6. Hypnotherapy in treatment of asthma 
In a research study hypnotherapy was offered to 303 pediatric subjects who were thought to
have pulmonary symptoms due to psychological issues, discomfort due to medications, or 
fear of procedures. Improvement was observed in 80% of patients with persistent asthma, 
chest pain/pressure, habit cough, hyperventilation, shortness of breath, sighing, and vocal 
cord dysfunction, Therefore, hypnotherapy ma
atients in a pediatric practice (Anbar 2002
1.4.2.4.7. Manual therapies for asthma 
A variety of manual therapies with similar postulated biologic mechanisms of action such as
physiotherapy and chiropractic are commonly used to treat patients with asthma (Hond
Linde et al. 2005). Manual therapy practitioners include physiotherapists, respiratory 
therapists, chiropractic and osteopathic physicians. A Cochrane review of clinical trial 
evidence for the effects of manual therapies for treatment of patients with bronchial asthma
suggests that there is currently insufficient evidence to support or refute the use of manual 
therapies for patients with asthma and that there is a need to conduct adequately sized RCTs 
that examine 
  
 
 
1.5 Summery Of the Literature Review 
Respiratory conditions are prevalent and cause an enormous burden on society. There has
been a global increase in asthma in children and adults, there is a high community use of 
complementary therapies for conditions such as asthma, each therapy and diagnostic meth
have its own advantages and limitations there is a need to maintain accepted standards
medical an
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Chapter Two: Research Methods 
This chapter outlines the methodology used for the research. The first section outlines the 
methodology used for the study of nonconventional respiratory measures while the 
second section of this chapter outlines the methodology used for the randomized 
controlled trial.  
The randomized controlled trial were initiated in the Monash University and funded by 
the Oralmat production company. Later the study transferred to RMIT University and 
nonconventional respiratory measures study were added and analyzed as one study. 
 The ethical approval was provided by RMIT Ethics Committee for both arms of the 
study. 
2.1 A Study into the Correlation between Conventional and 
Unconventional Measures of Respiratory Function  
A clinical study was conducted in order to determine if less/ non-conventional assessment 
tools correlate with more conventional assessment methods.  
 
2.1.1 Objectives of Study for non-conventional respiratory tests 
A range of conventional and non-conventional respiratory tests were performed on healthy 
and asthmatic children. 
The objectives of this study were: 
• To determine if there is a correlation between spirometry measures such as Forced 
Expiratory Volume in one second (FEV1) and Forced Vital Capacity (FVC) and less 
conventional measures such as Expired NO (eNO), electro dermal measures, Treditional 
Chinese Medicine (TCM ) enquiry and Breath Holdig Time (BHT) in asthmatic and healthy 
subjects 
• To determine if the results of Skin Prick Testing (SPT) influenced the correlation 
between other measures.  
 
 2.1.2 Study Design 
Table 3: Description of Design of Trial 
 
: 
 
 
 
 1 Brief details of study explained 
2 Inclusion /Exclusion Criteria checked 
3 Informed Consent signed by parent and child and a 
copy was given to the parents 
4 Baseline variables questionnaire asked 
5 Height and weight measured 
6 QoL Questionnaire 
7 Exhaled NO measurement 
8 Spirometry test 
9 Electro dermal Acupuncture Meridian Test 
10 BHT 
Advertise the study on local paper and 
Media &Schools Newsletters, Potential subjects 
Contact the Investigator 
Potential patient completes & returns the 
forms to the Investigator. If eligible, the patient was 
given an appointment to attend the RMIT research 
clinic for initial assessment. 
Patient letter, questionnaire, & Consent Form Sent 
To the 
Potential patient and participants 
Environemental allergen test was done at the 
second visit 
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2.1.2.1 Study Population  
The study was carried out in north region of Melbourne from April 2004 through to April 
2005.  The subjects included both healthy and asthmatic children between the ages of 8 and 
16.  
2.1.2.2 Inclusion and Exclusion Criteria 
Inclusion criteria for the healthy subjects were: 
? No previous history of asthma, chronic respiratory condition or other chronic disease 
? Written consent provided by parents/ guardian for their children participation in the 
study, child willing to participate in the study.  
? No other respiratory tract infection or hospitalization for any reason in the last four 
weeks. 
Inclusion criteria for asthmatic subjects were;  
? Previously diagnosed with asthma by medical practitioner  
? Asthma diagnosis confirmed by spirometry as indicated by a 12% improvement in 
FEV1 after bronchodilator 
? Using an inhaled β2 agonist three or more times a week. 
? Written consent provided by parents/ guardian to their children’s participation in the 
study, child willing to participate in the study.  
? No other respiratory tract infection or hospitalization for any reason in the last four 
weeks. 
? Not participating in another trial or study for asthma treatment. 
2.1.2.3 Recruitment  
Subjects were recruited from the community through advertisement in local papers, radio, 
television, as well as local general practice clinics. RMIT media services also placed 
advertisements in the RMIT News and sent out media releases to local papers. Permission 
from the Department of Education in Northern region was obtained to approach, schools many 
of which placed advertisements in their school newsletters. Appendix 1- (copy of 
advertisements/letters/media releases etc)  
 
Phone enquiries from the advertisements were captured on a telephone message bank. Phone 
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calls were returned and subjects were interviewed by phone to assess their eligibility and 
willingness to participate in the study. Appendix 2 (phone screening sheet). 
A plain language statement (PLS) was sent to potentially eligible parents or guardians and to 
the child, explaining the nature of the study. Children who agreed to participate in the study 
were invited to attend RMIT for an initial visit during which both the child and the 
parent/guardian were asked to sign a consent form. A copy of the consent form was then given 
to the participants. See PLS and consent form letters (Appendix 3) 
Subjects were provided with free parking space and offered free transport.  
2.1.3 Data Collection 
Eight main sets of data were obtained from each subject including;  
1. Demographics,  
2. QoL Questionnaire survey data   
3. Spirometry measurements   
4. Airways NO measurements,  
5. Acupuncture meridian function measures,   
6. TCM enquiries  
7. BHT 
8. Skin prick measures 
2.1.3.1 Demographics 
These included date of birth, sex, height, weight, ethnicity, smoking status, treatments used, 
prescription medication usage, over the counter medication usage (e.g. vitamins, minerals), use 
of other therapeutic methods (physiotherapy, acupuncture yoga), asthma severity index score, 
other coexisting conditions (e.g. hay fever). Current and past medical conditions were also 
recorded. Appendix 4- [Case Report Form (CRF)] 
2.1.3.2 Quality of Life Questionnaire survey data 
“The Childhood Asthma Questionnaire” designed for use in the clinical evaluation of new 
treatments for pediatric asthma was used to assess asthma-related QoL (French, Christie et al. 
1994; French, Carroll et al. 1998). This questionnaire has three sets of questioners: one for 
young ages till eight years old (The Childhood Asthma Questionnaire A), one designed for age 
8 to 11 (The Childhood Asthma Questionnaire B), and another for 12 to 16 years old (The 
Childhood Asthma Questionnaire C). This study used questionnaires B and C respectively 
(French, Christie et al. 1994; French, Carroll et al. 1998). During the completion of the 
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questionnaires if the subject did not understand any question or was uncertain regarding the 
answer, the researcher or the parent clarified it and the answer was filled by the subject on the 
questionnaire booklet (Appendix 5) (Childhood Asthma Questionnaire B & C). 
2.1.3.3 Airways NO Measurement 
The measurement of exhaled NO was obtained before each measurement of spirometry. 
Exhaled NO was measured using the online technique recommended by the American 
Thoracic Society (1999; ATS 1999) with the NIOX system (Aerocrine AB, Stockholm, 
Sweden US Patent 5,447,165). This records Fractional exhaled NO (FENO) values, FENO 
average (ppb) NO output (nl/min), Deadspace volume (ml) using Microsoft® Windows 
NT® Workstation 4.0 Application Software technology (Silkoff, Carlson et al. 2004) 
Fractional Exhaled NO (FENO) expressed in parts per billion (ppb) value which represents 
the mean NO level during the NO plateau (between 5–8 seconds of exhalation). The mean 
value of three consecutive FENO measurements is the FENO result. Appendix 4 (See CRF) 
 
The device required regular calibration every 14 days. Calibration involved a 2-point 
calibration at 0 ppb and 200 ppb, using NIOX calibration gas. NO in N2: 200 ±20 ppb 3 bar 
absolute (3–9 bar absolute) Manufactured by AGA Linde Healthcare. The NIOX® filter 
used was a disposable filter that was changed with every new patient.  
 
The measurement technique utilized a resistive device that provided a constant low 
expiratory flow rate and vellum closure. 
 
The procedure required to replace the NIOX® disposable mouthpiece Filter for each subject 
each session to avoid possible contagious of any kind of infection through contact and enter 
the patient's name, ID and examiner's name, The device included software that used a 
computer game involving a balloon so that children could visualize their respiratory effort.  
Subjects were seated (with no nose clip), then asked to exhale and place a disposable 
NIOX® Filter in their mouth, inhale to total lung capacity over 1 to 2 seconds, then exhale 
slowly, keeping constant flow with the aid of the balloon visualisation between 5 to 8 
seconds.  
They were asked to: 
• Have a deep breath in and  
• Put the filter in the mouth and  
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ndix 4) 
• Breath out slowly but constantly and continually  
• Lead the balloon as soon as you see it on the screen with your breath from one side of 
the river to the other side. 
• Keep blowing until I ask you to stop. 
• Repeat the procedure again 
The performance was repeated until three valid FENO measurements were obtained. The 
results obtained included, three values of FENO, AvFENO average (ppb), NO output 
(nl/min) these values were then recorded in the CRF (See Appe
2.1.3.4 Spirometry test 
The pulmonary function tests were performed by the researcher, using a Spiro Card PC 
Based Spirometer (QRS Spiro-Card, Made in USA SN 2001-85001377) connected to a 
Windows-based laptop. Equipment specifications and testing procedures for the maximal 
expiratory flow volume maneuvers met or exceeded American Thoracic Society 1994 
spirometry standards.(1995; ATS 1995; WEISS, NATTA et al. 2000) Age, sex, and 
ethnicity appropriate prediction equations were used to calculate the percent of predicted 
values for FEV1 and FVC (Wang, Dockery et al. 1993) spirometry was performed at least 4 
hours after the last use of a short-acting bronchodilator. In asthmatic subjects maximal post 
bronchodilator spirometry was performed 15 minutes after a total of 1 inhalation of 
Ventolin. 
 
The American Thoracic Society (ATS) guidelines for manoeuvre performance (1995; 
Arets, Brackel et al. 2001; Appleton, Adams et al. 2005) were used. The FVC manoeuvre 
was performed with maximum effort immediately following a maximum inspiration. The 
procedure was carefully explained to the patient, ensuring that he/she was sitting erect with 
feet firmly on the floor. Subjects were instructed to: “breathe in fully, seal your lips around 
the mouthpiece; blast air out 'as fast and as far as you can until your lungs are completely 
empty; breathe in again as forcibly and fully as possible.”  Subjects were urged to maintain 
a good seal on the mouthpiece and to perform a very vigorous effort right from the start of 
the manoeuvre, continuing until absolutely no more air can be exhaled as well as to sit erect 
and to lean forward during the test. This procedure was repeated until at least three 
technically acceptable manoeuvres were obtained and these values were recorded on the 
pulmonary function report form in the CRF (See Appendix 4). 
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2.1.3.5 Electro-Dermal Screening Test (EDST)  
Electro-dermal testing was performed using a MEDEC Biograph (Medec Perth, 2004) 
The procedure involved fixing an electrode to the forearm of the subject whilst placing a 
probe against the subject’s skin on various acupuncture points on the fingers and toes. 
Using a measuring electrode the researcher measured 40 endpoints on all fingers and toes 
(10 at each hand and each foot) that corresponded with the jing well acupuncture points. 
A low electric current (0.4 µA) was applied by the device for a second;  
• The subject was asked to take off his /her shoes and socks and any removable 
metal jewelry  
• Asked to relax, assured that there is not any kind of stimulus that they are going to 
feel. 
• The researcher entered the required data such as name, age, sex, address and the 
date of the test on the computer program which was connected to the biograph and then 
placed the probe on the jing well acupuncture points one by one as instactions appeared 
on the screen.  
• The data was saved on the computer and printed out to form part of the CRF as 
well as having selected data recorded separately on the subjects CRF (See Appendix 4). 
There were two kinds of data. One was recorded as energy level percentage to the norm, 
which was calculated by the biograph software, and also other organs excess and 
deficiencies, again by the software.  
• The energy level data as well as lung spleen and kidney organs data was selected 
to use on the statistical analysis appropriate to TCM theory (See Appendix 4). 
2.1.3.6 Traditional Chinese Medicine (TCM) Enquiries 
A questionnaire along with examination of the pulse and tongue was developed by the 
researcher (Chinese medicine and acupuncture practitioner) after consultation with other 
experienced TCM practitioners and classical Chinese references on the differential diagnosis 
of Zang Fu Syndromes some of which were translated from the Chinese with the assistance 
of lecturers from the Division of Chinese Medicine at RMIT University (Donald and Penner 
1994; Maciocia 1994; Jingfeng, Jian et al. 1995). 
Based on the practitioner experience and the classical references, a series of questions were 
developed using a Likert scale to characterize the different dimensions of a Chinese medicine 
diagnosis. Zang Fu Syndromes: Differential Diagnosis and Treatment (Donald and Penner 
1994; Junying and Zhihong 1998; Xianmin, Junying et al. 1998)  
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This questionnaire divided asthma into three subgroups (lung, spleen and kidney) according 
to TCM differentiation. The ‘Lung pattern’ questions related to enquiries about signs and 
symptoms involving the ‘Lung organ’ and its fu partner according to TCM, ‘Large Intestine’. 
The ‘Spleen pattern’ questions were linked to signs and symptoms of the ‘Spleen organ’ and 
its associate fu organ, the ‘Stomach’. The ’Kidney pattern’ questions involved the ‘Kidney’ 
and its associate fu organ, the ‘Bladder’. 
The questionnaire used a graded scaling system for symptoms so that:  
• “Zero (0) or None” referred to no symptoms  
• “One or Mild” referred to symptoms experienced once in a while that did not effect daily 
life. 
• “Two or Moderate” referred to symptoms that cause inconvenience in daily life; for 
example needing to carry a box of tissue around. 
• “Three or severe” referred to symptoms that hinder the performance of daily life such as 
reducing concentration in class because of wheezing. 
• “Four or very severe” referred to symptoms that severely effect daily life such as not 
being able to go to school or play sport.  
In addition to asking about symptoms the TCM questionnaire allowed the 
researcher/practitioner to include examination data including data about the observation of 
tongue body and its coating, and color, and for this information to be classified according 
to a numerical grading devised by the investigators. (See figure below). The coating could 
be classified as white or yellow. If a white or yellow coating was present the thickness of 
the tongue coating was classified as either, normal /thin (0) thiner than normal/thicker than 
normal (1), thick (2) or very thick or no coating (3). Tongue color was also examined in 
light of the other observations. For example when the tongue was very red it was 
considered grade1, if it was also dry another grade was added making it a grade 2, if it was 
also considered delicate or had no coatings or cracks, further grades were added (see chart 
below). Thus a red tongue with a thin, thick, yellow, white or no coating was graded 
accordingly. 
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Figure 8: Categorization and grading of tongue readings 
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 Grading Colour of the 
toungue’s body 
Marking 
0/Normal 
1/Mild 
2/Moderate 
Pale red 
Paler than normal red 
or darker than normal 
Plump red body 
Teeth mark 
edges around  
Sharp teeth 
marks on edges 
Thicker 
coating which 
easily scraped 
out
Coating 
thickness 
Thin normal 
coating 
Thick coating  
Color of the 
coating 
Thin normal 
white or light 
yellow 
No edge’s mark 
around tongue 
Little or no 
coating 
White or 
yellow 
Very white or 
very yellow 
Slippery & curdy 
and greasy 
looking  
 
Slippery 
&Excessive 
fluid and oily 
Neither too dry 
nor too wet. 
Moisture of 
toungue 
Yellow 
grayish  
Tender red 
body 
3/Severe 
Pulse Definitions 
Superficial pulse was considered to be easily felt by a light touch, but loses its strength 
when pressure is increased. 
Deep pulse was hardly felt by light touch but distinct under heavy pressure.  
Weak pulse was considered to be a deep pulse which extremely soft, and thready. 
Thready pulse like a very thin, sharp, or delicate thread but is very distinct and clear 
Rapid pulse was considered to be more than five beats per respiration. 
Faint pulse was considered an extremely thin soft and barely palpable even applying 
pressure. 
 
Figure 9: Catergorisation and grading of pulse readings 
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Grading 
3/Severe 
Faint pulse (thin soft barely palpable 
even when applying pressure) or hasty 
and swift 
0/Normal 
1/Mild 
2/Moderate 
Moderate, soft forceful and with a 
uniform rhythm  
 
Superficial (easily felt by a light 
touch but loses its strength when 
pressure is increased and tense  
Without strength, thready 
5 times per respiration 
4 beat per respiration or 
more than 5 pulses per 
respiration 
3 times per respiration 
Not Palpable or 7to 8 times 
per respiration 
Rate Character 
The pulse was graded according to a number of variables (see figure above). A pulse could 
be considered as superficial and thready, or weak at the same time and was graded 
accordingly. 
Each pulse and tongue reading was recorded and added on the corresponding pattern 
section of the CRF. Once the questionnaire was completed and the observations of the 
pulse and tongue recorded on each questionnaire the total score for each pattern as well as 
the total score for the whole questionnaire was recorded in the CRF and then the data 
transferred to a computer program for analyzing. (See Figure 10 for the TCM 
questionnaires.   
Figure 10:  TCM enquires 
0= None (Does not have this symptom) 
1= Mild (Have the symptoms once a while and it does not effect daily life) 
2= Moderate (The symptom can cause inconvenience in daily life) 
3= Severe (The symptom effect the performance of daily duties) 
4= Very Severe (The symptoms severely effect the performance of daily duties 
 
  
Pattern  0 1 2 3 4 
  History findings      
1. Wheezing      
2 Cough      
3 Shortness of breath      
4 Difficult to inhale      
5 Paroxysmal cough with 
chocking 
     
6 Shallow breathing      
7 Nasal stuffiness/ blocked      
8 Headache      
9 Loose stool     
10 Low resistance to 
common cold 
    
 
11 Aversion to cold      
12 Sticky sputum      
13 Dislike to speak      
14 Spontaneous sweating      
15 Absent of sweating      
16 Distress sensation in 
epigastric region 
     
17 Lassitude      
 Examination findings      
18 Profuse sputum       
19 Gargling sound in the 
throat 
     
20 Fullness of chest       
21 Low voice       
22 Pale tongue      
23 White coating      
24 Yellow coating      
Lung 
deficiency 
25 Superficial pulse 
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 History Findings      
1 Abdominal distension after eating      
2 Poor appetite      
3 Abdominal pain relieved by pressing 
or warmth 
     
4 Dryness of the mouth and throat      
5 Thirst      
6 Heavy limbs      
7 Weakness Of Muscles      
 Examination Findings      
8 Pale complexion       
9 Pale plump tongue      
10 Slippery coating      
Spleen  
Deficiency 
11 Weak pulse      
 
1 History Findings      
 Soreness on the knees and lumbar 
region 
     
2 Cold limbs      
3 Dizziness/ vertigo      
4 Deafness      
5 Night sweating      
6 Afternoon fever      
7 Burning sensation in the chest, palm 
& feet 
     
8 Chronic cough      
9 Loose tooth      
 Examination Findings      
10 Malar flush      
11 Red tongue: 
Delicate with little fluid: 
     
12 Thready:         rapid Pulse:      
Total Score:      
Kidney 
deficiency 
Average Score:      
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2.1.3.7 Breath Holding Time: 
The subject was handed an electronic clock timer [JADCO China Made] and 
demonstrated how to perform this test. The steps are as follows: take a deep breath in, 
press the push button to start, hold your breath as much as you can then as soon as you 
feel a desire to breathe again push the stop button and breathe. The best of three tries was 
recorded in seconds on CRF.  
2.1.3.8 Environmental Allergen Test 
Skin prick tests were performed with 8 common aeroallergens on all study children using 
a lancet technique. Subjects were tested to 7-grass mix (Kentucky blue, Meadow Fescue, 
Orchid, Perennial Rye, Redtop, Sweet Vernal, Timothy, and Bermuda), Ragweed, Birch 
Bermula Plaintai Cypress, Ryegrass Dog Fur, Cat Fur, Dust Mites, and fungus. 
 
Testing was performed by the researcher, using a study specific protocol (Nelson, 
Rosloniec et al. 1993; Illi, Garcia-Marcos et al. 1998; Topuz 2005; Topuz 2005). A test 
was considered positive if the skin test resulted in a wheal with mean diameter (mean of 
maximum and 90-degree midpoint diameters) of at least 3 mm greater than a saline 
control. In order to determine the allergenic status of children a saline solution was used 
as a negative control, and histamine was used as positive control. The tests were 
performed on a second visit because of general regulation, which had been set for both 
studies. Largest wheal diameters were measured 10 to15 minutes after pricking. Asthma 
subjects were asked not to use their steroid medication 3 days prior to the test (Perrin, 
Dechamp et al. 1984; Wood, Phipatanakul et al. 1999; James 2002). 
 
The subjects were informed of the procedures of the test as follows: For finding out if 
you have allergy to any common environmental object I am going to do some simple 
testing on your arm. Firstly I am going to clean your arm with alcohol then I will mark 
your arm with a pen to write numbers on it. Then a drop of allergen extract is going to be 
placed onto the marked area of your skin. After that using a sterile lancet, a small prick 
will be made through the drop to allow a small amount of allergen to enter your skin. If 
you are allergic to the tested allergen, a small mosquito-like lump will appear at the site 
of testing over 15-20 minutes. It may itch and we can wash or put some cream on to stop 
the itching. 
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2.1.4 Procedure for Subjects Testing  
The asthmatic subjects were asked not to use bronchodilators four hours prior to their 
visit. Baseline variables and a QoL Questionnaire were completed by the subject 
followed by measurement of exhaled NO, spirometry testing before and after 
bronchodilator use. While waiting for the bronchodilator to take affect, an EDST was 
performed and TCM enquiry was carried out including examination of tongue and pulse. 
Finally, BHT was measured and an appointment date and time for a second visit was 
given. In the second visit the skin prick test was performed first followed by the tests, 
which was performed at fist visit again.  
2.1.5 Statistical Analysis on Non-Conventional Measures of Lung Function 
Since no past studies were located researching the same issues as this study, we assumed 
we would get a treatment effect with an effect size of 0.8. To achieve 80% power at a 
significance level of 5%, sample size tables provided by Cohen (1988) indicated that a 
sample size of 26 per group would be needed. We decided to have 30 in each group to 
overcome the drop outs. 
 
Analysis of the data was done via Pearson correlations between FVC and FEV1of 
spirometry and the results of each of the non-conventional tests plus correlation between 
each non-conventional test to detect if there is any association among conventional and 
also non-conventional findings as well as independent sample t- tests analyses was done 
between asthma and healthy group to find the significance difference if there is any. 
 
Statistical analyses were performed using SPSS for Windows Version 14. Systematic 
trends correlations between paired elements of groups across levels of a categorical 
variable were assessed using Pearson Correlation 2-tailed test. The critical level of 
significance adopted for each statistical test was 0.05 and also 0.01 in two levels. Missing 
variables were treated by simply opting to drop the variables 
2.2 Randomized Controlled Trial of Oralmat 
2.2.1 Objectives of Study for the Clinical Trials of Rye Grass Extract 
The objectives of the clinical trials of rye grass extract were:  
To assess the clinical effectiveness of the rye grass extract (Oralmat drops) in reducing 
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the requirements for bronchodilator medication and improving the quality of life of 
asthma sufferers as well as looking for changes in peak flow, and lung function as 
measured by spirometry. 
 
2.2.2 Trial Design for Rye grass Study 
It was intended to perform an accurate, randomized, double blind study of the use of the 
“Oralmat drops” for the treatment of mild-moderate childhood asthma. The study used a 
randomized, double blind, placebo controlled, parallel design with a two week run in and 
a 12 week intervention period.  
2.2.3 Study Population for Ryegrass Study 
It is essential to report that this study had been started in Monash University and 
transferred to RMIT. Both sets of data were used and concluded with this study. As a 
result 31 asthmatic subject’s data were from Monash study and five from our recruitment 
with a total of thirty six. We tried to do the same exact procedure for our participants as 
Monash University did. However we carried out the tests such as TCM, BHT, NIOXNO 
and EDST, which we used them for our non-conventional study. Subjects were selected 
to one of two groups using blocked randomization. One group received the active 
preparation, while the other group received a placebo preparation. After a baseline 
questionnaire and lung function assessment tests, subjects were required to fill out a daily 
diary of their peak flow readings, asthma symptoms and medication usage. After a 2- 
week run in period subjects were reassessed and entered in the intervention phase of the 
study. Both the trial subjects and the investigator were blinded. Three formal Exhaled NO 
measurements, assessments of lung function by spirometry and acupuncture meridian 
function tests plus TCM questionnaires and BHT along with a detailed asthma QoL 
questionnaire were performed for each subject. These were done at Week 0 (baseline), at 
Week 2 (after the run in period) and at Week 14 (at the end of the treatment period). 
2.2.3. 1 Statistical power calculations for ryegrass study 
It was estimated that the detection of treatment effects between 0.5 and 0.6 with a 
significance level of 5% and 80% power using a two tailed t test, required a sample size 
of between 45 and 64 (Cohen, 1988). 
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2.2.4 Subjects Sample –Inclusion and Exclusion Criteria for Ryegrass 
Study 
Subjects were recruited from the community as mentioned in section 2.1.2.3 also data 
was transferred from Monash University. The inclusion criteria were the same as 
inclusion criteria for asthma subjects on study1. Such as; they were previously diagnosed 
with asthma by a medical practitioner, their asthma diagnosis was confirmed by 
spirometry and they were using an inhaled β2 agonist three or more times a week. 
Nevertheless Subjects who were used Oralmat drops previously or had any upper 
respiratory tract infection, severe asthma attack or hospitalization for any reason in the 
previous 4 weeks also had any medical conditions other than asthma for which long term 
prescription medications were required, or had participated in another study for asthma 
treatment at the same time, were excluded from the study. 
2.2.5 Intervention 
The study involved administration of 2-4 drops of the active rye grass preparation or 
placebo applied under the tongue, twice daily, for the 12weeks intervention period. Two 
drops administered under the tongue twice daily after meals for children aged 8-12, and 
four drops for children aged 13-16. Participants were asked after each administration to 
record it in their daily diary. 
 
2.2.6 Outcome Assessment 
2.2.6.1 Baseline Variables  
Baseline variables included, date of birth, gender, height, weight, ethnicity, smoking 
status, length of illness, treatments utilized, prescription medication usage, over-the-
counter medication usage, use of other therapeutic modalities (physiotherapy, 
acupuncture etc.), any co-existing conditions. SPT for allergy was also performed. 
2.2.6.2 Outcome Measures 
Daily measures were peak flow meter readings; medication use; asthma symptoms; and 
adverse events (asthma attacks/ illness episodes). On three occasions; at baseline (Week 
0), after the run-in period (Week 2) and at the end of the intervention period (Week 14), 
subjects were also required to complete the following assessments: QoL (using an 
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Asthma QoL Questionnaire); exhaled NO Measurement; lung function testing via 
spirometry; EDST via Biograph device; TCM Questionnaires; and BHT. Other measures 
included compliance and health resource utilization which were recorded according to the 
following table. 
                                                                                                                                                                   
  
89
Table 4: Study assessment Time table 
 
 
 
Assessment 
Week 0 
(Start of 
run-in 
period) 
Clinic visit 
Week 2 
(start of 
treatment 
period) 
Clinic visit
Week 6 
Telephone 
follow-up 
Week 10 
Telephone 
follow-up 
Week 14 
(end of treatment 
period) 
Clinic visit 
Demographics X     
Other therapies X X X X X 
Medication use X X X X X 
Other medical conditions 
(Acute and chronic) 
X X X X X 
Health resource utilisation X X X X X 
Asthma medication use  
Diary check 
 X X X X 
Peak Flow  
Diary check 
 X X X X 
Symptom  
Diary check 
 X X X X 
Compliance   X X X 
Adverse events inquiry X X X X X 
QoL X X   X 
Exhaled NO  X X   X 
Spirometry X X   X 
Acupuncture Meridian 
Function Test 
X X   X 
BHT X X   X 
Skin prick test  X    
 
2. 2.6.3 Data Collection  
All data collection such as demographics QoLQ, Exhaled NO measurements spirometry 
test, acupuncture meridian function test, TCM enquiry BHT assessments as well as skin 
prick test were carried out respectively as clarified on the first study section 2.1.3.  
 
However in the first visit an asthma diary booklet and a Peak-flow meter were handed to 
each asthmatic participant (Pfeffer, Ellison et al. 1996). They were asked to record their 
PEFR twice a day morning and evening, and asthma medication use, any changes on 
symptoms, compliance and also adverse events inquiry in the first two weeks and record 
the, Oralmat drop use, twice a day on the diary book from the end of the week two until 
to week fourteen for a period of twelve weeks. 
 
On week six and ten a telephone call was made to the asthmatic participants to check if 
they were using their medications and the study drops and recording the information in 
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the diary. They were also asked about their asthma symptoms and any adverse events 
during that period. On each visit an appointment was given to the next visit. A reminder 
telephone call was made a day before the due visit. 
2.2.6.4 Statistical Analysis of Ryegrass Study Data 
It was considered that analysis should be performed on using two sample t-test for 
comparing two samples means and paired sample test to compare variables between base 
line and the end of the treatment week. Also Post hoc power analysis was used to find if 
the larger sample size was needed to achieve statistical significance.  
 
It was considered that between 50 and 70 subjects would be required to be able to detect 
a significant difference between the groups with 80% power and a significance level of 
5%. However, seven asthma subjects started and only five subjects completed the study 
in RMIT. In addition we had a thirty one participant’s data from Monash University 
which were combind and analysed together (n=36). 
 
Chapter Three: Results 
3.1 Study Population 
3.1.1 Study Population for Non-Conventional Measures of Lung Function 
Twenty-three children participated in this study. Seven children were diagnosed with 
mild to moderate asthma and sixteen children were non-asthma healthy children. 
3.1.2 Study Population for Effect of Ryegrass Extract on Mild to Moderate Asthma  
Thirty six children participated in this trial, all of them diagnosed with mild to moderate 
asthma. 
 
3.2 Group Statistics  
3.2.1 Statistics for Non- Conventional Measures Study 
 
 Table 5: Average height and weight of healthy nonasthma and asthmatic subjects 
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Average Healthy subjects height =153cm. Average Asthma subjects height 
=149.85cm
Average Healthy subjects weight=44kg. Average Asthma subjects weight=43.7kg. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Independent samples t- test on non-conventional measures of lung function 
study 
*: t-test involving unequal variances. 
 
Asthma group 
(N=7) 
Healthy group 
(N=16) 
 
variables 
 
Mean 
Standard  
Deviation 
 
Mean 
Standard  
Deviation 
 
t-value 
 
p-value 
Demographics       
Age 11.1 2.7 11.9 2.4 -0.70 0.48 
QoL       
Active QoL 28.0 4.3 26.8 5.6 0.48 0.6 
Passive QoL 18 2.6 20 3.2 -1.50 0.14 
Spirometry       
Pre bronchodilator-
forced Expiratory 
Volume in 1 second 
2.2 0.60 2.6 .73 -1.24 0.22 
Pre Bronchodilator 
Forced Volume 
Capacity 
2.6 0.6 2.7 0.7 -0.45 0.65 
Acupuncture 
meridian testing 
      
Biograph Energy level 
test1% 
45.6 25.3 41.2 17.5 0.45 0.65 
Energy level  test2% 60.6 28.8 50.0 27.4 0.72 0.48 
Breath-Holding Time* 27.1 9.4 42.0 22.4 -1.67 0.036 
TCM questioning       
TCMQ Lung Score 14.6 2.3 6.0 3.3 6.07 0.000 
TCMQ Spleen Score 3.6 2.0 3.5 2.0 0.34 0.97 
TCMQ Kidney Score 4 2 3.3 1.6 0.91 0.37 
Airways Fraction of 
exhaled NO (FENo )* 
80.5 60.7 18.5 11.6 -2.68 0.036 
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3.2.1.1 The Statistical test for differences between asthma group and non-asthma 
healthy group on non-conventional measures of lung function assessment 
Most of the variables did not show any significant differences except: Airways NO level 
which showed a significant difference between the asthma and the healthy group 
(p=0.036). TCM test for the lung questionnaires showed a significant difference 
(p<0.0001). Also on the BHT there was a significant difference between the groups 
(p=0.036) (Table 6). 
 
Table 7: Pearson Correlation between Active QoL and other outcome measures on Co- trials for combined subjects, healthy as well as asthma 
subjects (2-tailed) 
 
 
 
 For Combined subjects 
(n= 23) 
For Healthy subjects 
(n=16) 
For Asthma subjects 
(n=7) 
 Correlation P- Value Correlation P- Value Correlation P- Value 
Active QoL        
Passive QoL 0.0.14 0.060 0.326 0.218 -0.34 0.44 
PreBronchodilator FEV1 -0.53** 0.010 -0.63** 0.008 -0.09 0.86 
PreBronchodilator FVC -0.57** 0.004 -0.64** 0.007 -0.30 0.50 
Biograph measure on 
Energy Level test one 
0.28 0.21 0.30 0.28 0.26 0.56 
Biograph Average Energy 
Level test 2 
0.43 0.60 0.49 0.07 0.39 0.95 
Biograph measure Right 
Lung Score on Test 1 
-.28 0.20 -0.23 0.43 -0.47 0.28 
BHT -0.18 .0.40 -0.25 0.34 0.55 0.19 
Sum score of lung 
TCMQuestionning 
-0.15 0.49 -0.54* 0.028 0.33 0.45 
Sum score of Spleen 
TCMQuestionning 
-0.30 0.15 -0.56* 0.022 0.54 0.20 
Sum score of Kidney 
TCMQuestionning 
-0.43* 0.038 -0.44 0.08 -0.60 0.15 
Airways Fraction of 
exhaled NO (FENo )  
-0.41 0.86 -0.50 0.07 0.14 0.78 
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Table 8: Pearson Correlation between Passive QoL and other Outcome Measures on co-trials for combined subjects, healthy as well as asthma 
subjects (2-tailed) 
 
 
 
For combined subjects 
(n=23) 
 
For Healthy subjects 
(n=16) 
For Asthma subjects
(n=7) 
 Correlation P- Value Correlation P- Value Correlatio
n 
P- Value
 
Passive QoL 
 
      
Active QoL 0.14 0.49 0.32 0.21 -0.34 0.44 
PreBronchodilator Forced 
Expiratory Volume 1sec 
-0.10 0.65 -0.30 0.24 0.35 0.48 
PreBronchodilator Forced 
Volume Capacity 
-0.08 0.68 -0.27 0.29 0.37 0.41 
Biograph Measure Energy 
Level test one 
 
-0.34 0.12 -0.35 0.21 -0.31 0.48 
Biograph Measure Energy 
Level test 2 
0.07 0.75 0.28 0.33 -0.28 0.64 
Biograph  Measure Right 
Lung Score Test 1 
0.32 0.14 0.19 0.50 0.63 0.12 
BHT 0.29 0.17 0.22 0.40 0.13 0.76 
Sum score of Lung 
TCMQuestionning 
-0.615** 0.002 -0.720** 0.002 -0.28 0.54 
Sum score of Spleen 
TCMQuestionning 
-0.473* 0.023 -0.41 0.11 -0.59 0.16 
Sum score of Kidney 
TCMQuestionning 
-0.03 0.87 -0.21 0.42 0.74 0.56 
 Airways Fraction of exhaled 
NO (FENo ) 
-0.20 0.12 -0.14 0.64 -0.38 0.44 
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Table 9: Pearson Correlation between the pre.Bronchodilator forced expiratory volume in 1 second and other outcome measures on the co- 
trials for combined subjects, healthy as well as asthma subjects. (2- Tailed) 
 
 
 For combined subjects 
(n=23) 
For Healthy subjects 
(n=16) 
For Asthma subjects 
(n=7) 
 Correlation P- Value Correlation P- Value Correlation P- Value 
Active QoL 
 
-0.538** 0.010 -0.636** 0.008 -0.09 0.86 
Passive QoL 
 
-0.10 0.65 -0.30 0.24 0.35 0.48 
Pre Bronchodilator Forced 
Expiratory Volume 1sec. 
      
PreBronchodilator Forced 
Volume Capacity 
0.954** 0.000 0.98** 0.000 0.924** 0.009 
Biograph measurement Energy 
Level test one 
-0.24 0.29 -0.20 0.49 -0.28 0.59 
Biograph measure Energy 
Level test 2 
-0.25 0.30 -0.23 0.41 0.11 0.88 
Biograph measure Right Lung 
Score Biograph Test 1 
0.33 0.14 0.32 0.25 0.24 0.63 
BHT 0.30 0.17 0.21 0.43 0.64 0.17 
Sum score of lung  
TCM Questioning 
-0.00 0.97 0.47 0.06 -0.76 0.07 
Sum score of Spleen  
TCM Questioning 
-0.462* 0.030 0.543* 0.030 0.23 0.65 
Sum score of Kidney 
TCM Questionnaires 
0.10 0.63 0.14 0.58 0.30 0.56 
 Airways Fraction of exhaled 
NO (FENo ) 
-0.20 0.41 0.596* 0.044 -0.52 0.29 
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Table 10 Pearson Correlation between Biograph energy level on test 1and other outcome measures on co-trials for combined subjects, healthy 
as well as asthma subjects (2-tailed) 
 
 For combined subjects 
(n=21) 
For Healthy subjects 
(n=16) 
For Asthma subjects 
(n=7) 
 Correlation P- Value Correlation P- 
Value 
Correlation P- Value 
Active QoL 0.28 0.21 0.30 0.28 0.26 0.56 
Passive QoL 10.34 0.12 -0.35 0.21 -0.31 0.48 
Pre Forced Expiratory Volume 1sec. -0.24 0.29 -0.20 0.49 -0.28 0.59 
Pre Forced Volume Capacity -0.23 0.31 -0.26 0.35 -0.17 0.71 
Av Energy Level on test one       
Average Energy Level on test 2 0.623** 0.004 0.44 0.11 10.98** 0.002 
Right Lung Score on Test 1 -0.755** 0.000 -0.81** 000 -0.73 0.05 
Average BHT 0.04 0.85 0.03 0.91 0.33 0.46 
Sum score of lung  
TCMQ 
0.13 0.55 -0.15 0.59 0.51 0.23 
Sum score of Spleen  
TCMQ 
-0.11 0.60 -0.14 0.63 -0.14 0.75 
Sum score of Kidney 
TCMQ 
0.04 0.86 0.27 0.33 -0.32 0.47 
Airways Fraction of exhaled NO 
(FENo ) 
0.595* 0.012 0.03 0.92 0.90* 0.01 
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Table 11: Pearson Correlation between Breath Holding Time and other outcome measures on co-trials for combined subjects, healthy as well 
as asthma subjects (2-tailed) 
 
 
 
 
For combined subjects 
(n=23) 
For Healthy subjects 
(n=!6) 
For Asthma subjects 
(n=7) 
 Correlation P- Value Correlation P- Value Correlation P- Value
Active QoL -0.18 0.40 -0.25 0.34 0.55 0.19 
Passive QoL 
 
0.29 0.17 0.22 0.40 0.13 0.76 
Pre Forced Expiratory Volume 1sec. 0.30 0.17 0.21 0.43 0.64 0.17 
Pre Forced Volume Capacity 0.19 0.38 0.13 0.62 0.43 0.32 
Av Energy Level on test one 0.04 0.85 0.03 0.91 0.33 0.46 
Average Energy Level on test 2 0.09 0.70 0.14 0.61 0.36 0.54 
Right Lung Score on Test  
1 
-0.15 0.51 -0.18 0.52 -0.39 0.38 
BHT       
Sum score of Lung TCMQuestioning -0.40 0.5 -0.24 0.36 -0.08 0.86 
Sum score of  Spleen TCM Questioning
 
0.31 0.14 -0.37 0.15 0.22 0.62 
Sum score of Kidney TCMQuestioning 0.01 0.95 0.14 0.59 -0.06 0.89 
Airways fraction of exhaled NO(FENO) -0.22 0.35 0.574* 0.040 -0.08 0.88 
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Table 12: Pearson Correlation between TCM questionnaires used for lung score and other outcome measures on Co-trials for combined 
subjects, healthy as well as asthma subjects (2-Tailed) 
 
 For combined subjects
(n=23) 
 
For Healthy 
subjects 
(n=16) 
For Asthma 
subjects 
(n=7) 
 Correlation P- Value Correlation P- 
Value 
Correlation P- 
Value 
Active QoL -0.15 0.49 -0.548* 0.028 0.33 0.45 
Passive QoL -0.615** 0.002 -0.720** 0.002 -0.28 0.54 
Pre Bronchodilator Forced 
Expiratory Volume in 1sec. 
0.00 0.97 0.47 0.06 -0.76 0.07 
PreBronchodilator Forced Volume 
Capacity 
0.10 0.62 0.44 0.82 -0.20 0.66 
Biograph Energy Level test one 
 
0.13 0.55 -0.15 0.59 0.51 0.23 
Biograph Energy Level test 2 0.07 0.75 -0.46 0.09 0.52 0.36 
Biograph Right Lung Score Test 1 -0.18 0.43 0.02 0.92 -0.65 0.11 
BHT -0.40 0.58 -0.24 0.36 -0.08 0.86 
Sum score of lung  
TCMQuestioning 
      
Sum score of Spleen  
TCMQuestioning 
0.34 0.10 0.580* 0.019 -0.39 0.38 
Sum score of Kidney 
TCMQuestioning 
0.26 0.22 0.16 0.53 0.00 1.00 
Airways Fraction of exhaled NO 
(FENo ) 
0.611** 0.002 
 
0.13 0.67 0.37 0.46 
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Table 13: Pearson Correlation between Airways Expired NO (FENo) variables and other outcome measures on co -trials for combined 
subjects, healthy as well as asthma subjects (2-Tailed) 
                                      100 
 For combined subjects 
(n=23) 
For Healthy subjects 
(n=16) 
For Asthma subjects 
(n=7) 
 Correlation P- Value Correlation P- Value Correlation P- Value
Active QoL -0.04 0.86 -0.50 0.07 0.14 0.78 
Passive QoL -0.36 0.12 -0.14 0.64 -0.38 0.44 
PreBronchodolator FEV1. -0.20 0.41 0.596* 0.032 -0.52 0.29 
Pre Bronchodilator FVC -0.16 0.50 0.54 0.05 -0.71 0.11 
Biograph Energy Level on test one 0.595* 0.012 0.03 0.92 0.900* 0.014 
Biograph Energy Level test 2 0.41 0.12 0.06 0.86 0.78 0.21 
Biograph Right Lung Score  Test 1 -0.32 0.20 -0.05 0.87 -0.50 0.30 
BHT -0.22 0.35 0.574* 0.040 -0.08 0.88 
Sum score of Lung  
TCMQuestioning 
0.611** 0.005 0.13 0.67 0.37 0.46 
Sum score of Spleen  
TCMQuestionning 
0.08 0.71 0.26 0.37 0.00 0.98 
Sum score of Kidney 
TCMQuestioning 
0.07 0.74 0.25 0.40 -0.62 0.18 
Airways Fraction of exhaled NO 
(FENO) 
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Table 14; Summary of the correlation tables derived from tables 5 to11. 
**: Correlations are significant at the 0.01 level 
*: Correlation is significant at the 0.05 level. 
 
 
  
Correlations 
Combined group 
whether 
correlated for 
(N=23) 
Healthy group 
whether 
correlated for  
(n=16) 
Asthma group 
whether 
correlated for  
(n=7) 
Spirometry Pre. 
Bronchodilator 
FEV1  
Yes** Yes** No 
Spirometry Pre. 
Bronchodilator 
FVC 
Yes** Yes** No 
TCM Lung Score No Yes* No 
TCM Spleen Score No Yes* No 
Table 
7 
Active QoL 
(AQoL) 
TCM Kidney Score Yes* No No 
TCM Lung Score Yes** Yes** No Table 
8 
Passive QoL 
(PQoL) TCM Spleen Score Yes* No No 
Asthma AQoL Yes** Yes** No 
TCM Spleen Score Yes* Yes* No 
Table 
9 
Spirometry 
pre 
bronchodilator 
forced 
expiratory in 1 
Second 
(Pre.FEV1) 
FENo No Yes No 
Biograph Energy 
level test 2 
Yes** No Yes** 
Biograph Lung 
Score 
Yes** No No 
Table 
10 
Biograph 
Energy level 
Test 1 
Airways NO level Yes* No Yes* 
Table 
11 
BHT FENo No *Yes* No 
QoL No Yes* No 
PQoL Yes** Yes** No 
TCM Spleen Score No Yes* No 
Table 
12 
TCM enquiry 
Lung Score 
FENo Yes** No No 
Spirometry FEV1  No Yes* No 
Biograph Energy 
level 
Yes* No Yes* 
BHT No Yes* No 
Table 
13 
Airways 
Fraction of 
exhaled NO 
(FENo) 
TCM Lung Score Yes** No No 
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Table 7 shows 2-tailed Pearson correlation between Active QoL and other outcome 
measures on Co- trials for combined subjects, healthy as well as asthma subjects. These 
results show that active QoL questionnaires scores had significant correlations (p<0.01) 
with spirometry Pre-FEV1 and pre-bronchodilator FVC for the combined and healthy 
groups. Also, significant correlations (p < 0.05) were obtained for the variables active 
QoL and TCM lung and spleen scores for the healthy group. The TCM kidney score 
significantly correlated (p<0.05) with the active QoL scores for the combined subjects. 
 
Table 8 demonstrates correlation between Passive QoL and other Outcome Measures on 
co-trials. Passive QoL was significantly correlated with TCM lung scores (p =0.002) for 
the combined group as well as the healthy group. The TCM spleen scores significantly 
correlated (p =0.023) with the passive QoL for the combined group.  
 
Table 9 shows correlation between pre-Bronchodilator FEV1 and other outcome 
measures on co-trials. Spirometry pre-FEV1 significantly correlated with active QoL for 
the combined group and the healthy group (p<0.01). It also demonstrated significant 
correlations with TCM spleen scores for the combined and healthy groups (p=0.03) In 
addition pre-FEV1 was significantly correlated with FENo (p=0.044) for the healthy 
group. 
 
Table 10 demonstrates correlation between Biograph Energy level on test 1 and other 
outcome measures on co-trials. It significantly correlated with Active QoL on healthy 
subjects (p=0.01) and also with FENo on combined and asthma groups (p≤0.01). 
 
Table 11 shows correlation between BHT and other outcome measures on co-trials for 
combined subjects, healthy as well as asthma subjects. BHT scores significantly 
correlated with airways NO on health group (p=0.04 only. 
 
Table 12 demonstrates correlation between TCM questionnaires used for lung score and 
other outcome measures. It significantly correlated with active QoL and passive QoL 
(p=0.002) on combined and healthy groups, also significantly correlated with FENo on 
combined group (p=0.002). 
 
Table 13 shows correlation between FENo variables and other outcome measures on 
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co-trials. It demonstrates a significant correlation with spirometry pre bronchodilator 
FEV1 on healthy subjects (p=0.032), and with biograph energy level test one score on 
combined and asthma subjects (p<0.05). It also significantly correlated with BHT on 
healthy subjects (p=0.04) and with TCM Lung score on combined subjects (p=0.005). 
 
Table 14 shows a Summary of 2- tailed Pearson Correlation between co -trials for 
combined subjects, healthy and asthma subjects, derived from tables 7 to 13 for easy 
comparison. 
 
3.2.1.2 Regression Analysis 
Table 15:  (Regression table) the dependent variable was preFEV1 and Predictors 
(Constant) were Biograph Energy level measurement BHT and Airways NO level 
measurements. Biograph and BHT have shown a level of significance. (Biograph 
energy level p=0.011 and BHT p=0.003). 
 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients t-value P-value.  Outcome 
Measures 
  B Std. Error Beta     
(Constant) 1.745 0.442   3.951 0.002 
EDSTT1% -0.023 0.008 -0.732 -2.950 0.011 
BHT 0.046 0.013 0.726 3.575 0.003 
FENO2 0.005 0.004 0.374 1.513 0.154 
 
The airways NO level did not significantly affect pre FEV1 (p=0.154). However, both 
biograph energy levels and breath holding time significantly influenced pre FEV1. 
Biograph energy levels had a negative influence on pre FEV1. This means that if you 
increased biograph energy levels, the pre FEV1 decreased (Table 15).  
Table 16: Number of Healthy and asthma subjects which reacted to the allergens 
 
 
 
 Negative 
control 
(Saline) 
Cat Dog Dust- 
mite 
Fungus Ryegrass Positive 
control 
(Histamine) 
Healthy Subjects  
(n=9) 
0 0 0 3 
(33%)
0 3 (33%) 9 (100%) 
Group 
A 
(n=18) 
3 (17%) 13 
(72%)
7 
(39%)
16 
(89%)
3 
(17%) 
14 
(78%) 
14 (78%) Asthma 
combined 
(n=36) 
Group 
B 
(n=18) 
2 (11%) 14 
(78%)
6 
(33%)
16 
(89%)
6 
(33%) 
16 
(89%) 
17 (94%) 
Sum of asthma 
subjects 
5 (14%) 27 
(75%)
13 
(36%)
32 
(89%)
9 
(25%) 
30 
(83%) 
31 (86%) 
Of the nine healthy subjects in the study who had the skin prick test, three had an 
allergic reaction to dust mite and three had an allergic reaction to ryegrass. From the 
above table, it appears that dust mites and rye grass produced the greatest allergic 
reactions for both the healthy subjects and the asthma subjects.  
 
The asthma subjects had more allergic conditions. Nevertheless; dust mite and ryegrass 
allergens are two allergens which are often found in healthy non-asthma subjects. A 
total of 14% 0f asthmatics did not have a reaction to the positive allergen (Histamine), 
at the same time there was a 14% allergic reaction to the negative control (saline) which 
is normally not expected (Table 16). 
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3.3 Group statistic for Rye Grass study 
Table 17: Group Comparison for active and placebo groups on ryegrass study used 
for QoL, spirometry and Diary scores on visit one (week 1)and visit 3 (week 
14)(Between Groups) 
A group  B group  t-value p-value Variable 
Mean Std.  
Deviation 
Mean Std.  
Deviation 
  
Demographics       
Age 11.50 1.98 11.06 2.77 0.55 0.58 
Height 151.33 11.73 146.39 18.17 0.97 0.33 
Weight 47.72 11.54 40.83 14.43 1.58 0.12 
QoL       
Week 1 Total Questionnaire Score 116.19 
(n=16) 
13.44 117.86 
(n=14) 
9.23 -0.39 0.69 
Week 14 Total Questionnaire Score 112.00 
(n=17) 
10.28 110.25 
(n=12) 
18.85 0.32 0.75 
Week 1 Active QoL (V1AQoL) 
 
27.06 
(n=17) 
4.25 26.73 
(n=15) 
4.72 0.20 0.83 
Week 14 Active QoL (V3AQoL) 
 
25.94 
(n=17) 
4.91 27.40 
(n=15) 
3.94 -0.91 0.36 
Week 1 Passive QoL (V1PQoL) 
 
18.59 
(n=17) 
2.89 17.20 
(n=15) 
2.59 1.42 0.16 
Week 14 Passive QoL (V3PQoL) 
 
17.06 
(n=17) 
2.48 18.07 
(n=14) 
2.33 -1.15 0.25 
Spirometry       
Week 1 Per-Bronchodilator forced 
Expiratory Volume in 1 second(V1 Pre- 
FEV1) 
2.31 
(n=17) 
0.67 2.23 
(n=18) 
0.86 0.30 0.76 
Week 1 Pre- Bronchodilator forced Volume  
Capacity (V1Pre-FVC) 
2.89 
(n=18) 
0.85 2.72 
(n=18) 
0.96 0.36 0.71 
 Week 1 Post Bronchodilator.  FEV1 2.67 
(n=15) 
0.77 11.00 
(n=15) 
7.20 -0.84 0.40 
Week 14 Pre- Bronchodilator forced 
Expiratory Volume in 1 second Pre (V3. 
FEV1) 
2.59 
(n=17) 
0.74 2.38 
(n=13) 
1.005 -0.31 0.75 
Week 1 Change on FEV1% 14.70 10.09 11.06 6.73 1.15 0.25 
Week 14 Change on FEV1% 8.39 9.47 78.53 254.77 -1.47 0.25 
Diary       
Week 1  Morning Diary Peak flow  304.2881(n
=18) 
107.64 237.23 
(n=16) 
134.14 1.61 0.11 
Week 14 Morning  Diary Peak flow  
 
325.52 
(n=15) 
79.81 266.50 
(n=14) 
138.48 1.41 0.16 
Week 1 Diary medication total puff 23.29 
(n=17) 
18.89 20.75 
(n=16) 
20.78 0.36 0.71 
Week 14 Diary medication total puff  21.82 
(n=17) 
26.18 17.57 
(n=14) 
23.13 0.47 0.63 
Week 1 Diary Symptom add scores 
 
3.82 (n=17) 4.39 3.50 (n=14) 3.50 0.22 0.82 
Week 14 Diary Symptom add scores 14.00 
(n=17) 
32.35 21.81 
(n=16) 
38.55 -0.63 0.53 
 
From the above table, it appears that there were no statistically significant differences 
in each of the variables for the two groups 
 
Table 18:  Paired t-tests comparing the variables between week 1 and week 14 for active and placebo groups on rye grass study. There is no 
significant result in either group. The P-values for both groups are<0.05.  
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Paired Differences for rye grass 
study variables between week 1 
and week 14 Group A Group B 
  Mean 
Std. 
Deviation t-value p-value Mean 
Std. 
Deviation t-value p-value 
PreBronchodilator. FEV1 - 
preBronchodilator FEV1
0.03 0.46 0.33 0.74 -0.12 0.57 -0.76 0.45 
Pre.Bronchodilator FVC. 
Pre.Bronchodilator FVC 
-0.91 0.46 0.33 0.74 -66.37 256.97 -1.00 0.33 
Post Bronchodilator FEV1 - Post 
Bronchodilator FEV1 0.08 0.32 1.02 0.32 -82.98 287.47 -1.00 0.33 
Average Morning Diary peak flow- 
Average Morning Diary peak flow  -10.48 28.19 -1.44 0.17 -21.12 42.27 -1.80 0.09 
Average Evening Diary peak flow- 
Average Evening Diary peak flow  9.61 64.61 0.59 0.56 -21.12 45.16 -1.68 0.11 
Diary medication total puffs - Diary 
medication total puffs 1.47 17.41 0.34 0.73 6.14 16.60 1.38 0.19 
Diary symp add scores -Diary symp 
add scores -4.68 25.32 -0.74 0.47 -7.28 26.14 -1.04 0.31 
Asthma QoL Questionnaire score -  
Asthma QoL Questionnaire score 4.18 14.86 1.12 0.27 4.54 10.61 1.42 0.18 
Active QoL (AQoL) – Active QoL ( 
AQoL) 1.11 5.40 0.85 0.40 -1.21 2.75 -1.65 0.12 
Passive QoL (PQoL) – Passive QoL 
(PQoL) 1.52 3.53 1.78 0.09 -0.46 2.93 -0.56 0.58 
                                                                                                                               
The paired t tests in table 18 showed no significant differences within each of the groups 
for variables compared between week 1 and week 14. However, it appears the study was 
under powered in that sample sizes were not large enough to detect a significant 
difference. Post hoc power analysis below indicated that sample sizes of larger than 85 
were needed for each group to have achieved statistical significance.  
 
Table 19: Post hoc analysis table to exhibit a required sample size for each group 
if 15% and/or 20% difference wanted to observe and also detectible difference 
with the present number of cases on base line variables (p=0.0 5 and power of 
80%). 
 
 
Base Line 
Variables 
Mean Std. Deviation 15% 0f base 
line mean 
N=16×SD²÷  
(15%Mean 
difference)² 
 
20% 0f base 
line mean 
N=16×SD²÷ 
(20%Mean 
difference)² 
% difference 
detectable  
By this study 
(16 per group) 
 
 
 
Pre FEV1 2.28 0.76 0.34 
 
82 0.45 64 33% 
PreFVC 2.78 0.89 0.42 74 0.55 43 32% 
 
Morning 
Diary 
PEFR  
272.7
3 
123.70  
40.9 
 
146.35  
54.5 
82.42 45% 
 Evening 
Diary 
PEFR  
280.6
6 
123.47  
42 
138.34 42 
56.13 
77.45 44% 
Diary 
Medicatio
n total 
puff 
22.06 19.55 3.3 561 4.4 315 88% 
W1 Diary 
Symptom 
add 
3.7 3.95 0.55 825 0.74 455 106% 
QoLQuest
ionnaire 
Score 
117 11.50 17.55 6.88  
23.4 
3.87 9.8% 
AQoL 26.9 4.40 4.03 19.15 5.38 10.74 16.39% 
PQoL 18.10 2.8 2.7 17.20 
 
3.6 9.67 15.5% 
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Chapter four: Discussion and Conclusions 
4.1 Discussion on Diagnostic Study 
The diagnosis of asthma is primarily based on clinical assessment although there are a 
number of different measures that can be used to assess disease severity such as 
questionnaires, pulmonary function tests, and biologic samples for markers of immune 
response and disease activity (Eggleston, Diette et al. 2005). Spirometry is currently the 
primary and the most widely used pulmonary function test (Ruppel 1997; Pierce 2005), 
however conventional clinical measures such as spirometry and PEFR, while providing 
valuable information about the status of the lungs, rarely capture the functional 
impairments (physical, emotional, and social) that are important to the patients in their 
everyday lives (Erhabor, Aghanwa et al. 2003). Spirometry and its associated measures 
does add a degree of rigor to objectively assessing and monitoring patients’ clinical 
condition and their response to treatment, and is commonly used in clinical research into 
asthma (Yin, Han et al. 2005; Yurdakul, Dursun et al. 2005). The  change in FEV1 after 
bronchodilator or response to histamine or methacholine challenge is considered to be 
diagnostic of reversible bronchial hyperreactivity (Sistek, Wickens et al.; Talini, 
Benvenuti et al. 2002; Carroll, Lenney et al. 2005) . 
 
In primary care, measures for lung function such as spirometry and PEFR are not 
routinely used for diagnosis but are used for assessing and monitoring patients’ 
condition and response to treatment. It is well recognized however that  symptoms do 
not necessarily correlate with lung function (Finkelstein, Lozano et al. 2000). This study 
was the first to examine a wide range of nonconventional measures of lung function 
including both objective and subjective measures, and suggests that patient centered 
measures such as QoL assessments, BHT and TCM assessments may be more sensitive 
than lung function measures in distinguishing between healthy and asthmatic subjects. 
The finding of statistically significant differences between asthmatic and nonasthmatic 
children in their NIOX NO, BHT measures and TCM enquiries along with the absence 
of a statistically significant difference between these groups in their FEV1 measures, 
suggests that patient-centered measures may provide useful information in clinically 
assessing asthmatic patients. The post hoc power calculation for the clinical trial further 
suggests that QoL measures may be particularly sensitive.  
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igate this.  
 
QoL measurement is one of the leading evaluations in the diagnosis, therapy and 
investigation of patients with asthma (Ferreira, Silveira et al. 2005) however QoL 
instruments need to be validated under local conditions before they can be accepted for 
application in a particular  community (Chhabra and Kaushik 2005). Our study used an 
asthma QoL questionnaire adapted from its UK version and validated to local conditions 
by Australian researchers (French, Christie et al. 1994; French, Carroll et al. 1998). It 
seems that this adaptation was appropriate as our post hoc power calculation revealed a 
low standard deviation in asthmatic children, giving our clinical trial the power to detect 
clinically significant changes in QoL with relatively few subjects. 
 
In this study FEV1 had a significant correlation with AQoL and TCM spleen and NIOX 
measures of (FENo) variables. However, it is clear that FEV1 does not directly 
correspond with other patient-centered measures and it has been demonstrated that there 
is a variable link between spirometry measures and patient perception with studies 
showing that improvement in FEV1 is not always related to improvement in patient’s 
feelings or lung function (Meszaros, Major et al. 2001). Furthermore a number of studies 
have demonstrated improvement in patient well being and functioning with no changes 
being observed in FEV1 (Ogaa, Nishimurab et al. 2005; Schatz, Mosen et al. 2005). It is 
interesting that while BHT was significantly different between the asthmatic and non 
asthmatic subjects, and correlated with TCM and NIOX, BHT did not correlate with 
FEV1 while TCM and NIOX did.  
 
The finding that active QoL was correlated with FVC and FEV1 for healthy subjects 
(Table 7) suggests that quality of life may be related to lung function for healthy people 
and also that improvements in FEV1 or FVC in healthy people may correspond to 
improved quality of life. This assertion may provide the basis for using breathing 
exercises in healthy people and adds support to proponents of yoga, Qi going and other 
breathing exercises who suggest that breathing exercises are important for general 
wellbeing. The lack of correlation between AQoL and FEV1 for the asthmatic group 
may be due to the small number of asthmatic subjects. Further study is required to 
invest
 
It is interesting that while active QoL correlated with FEV1 and FVC, passive QoL was 
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correlated with TCM enquiry. This suggests that the TCM enquiry may be more 
sensitive to overall wellbeing and internal organ function rather than physical activity. 
Again, the small numbers of subjects analyzed suggest that any conclusions from this 
study must be made cautiously and should be confirmed in larger studies. 
 
Asthma is considered by many to be primarily an inflammatory disease (Leem, Kim et 
al. 2005). NO measurement is considered to be an effective laboratory measure for 
detecting chronic airway inflammation (Bernard, Carbonnelle et al. 2005) and has been 
heralded as a new diagnostic tool for asthma (Steerenberg and van Amsterdam 2004; 
Zeidler, Kleerup et al. 2004). Assessing airway inflammation by quantitative 
measurements can strengthen the role of anti-inflammatory medication as first-line 
treatment of asthma, even in its mildest forms (Haahtela 2002). Our study using the 
NIOX system supports the usefulness of NO as a measure of asthma as we found that 
NO variables had a significant correlation with spirometry, biograph, BHT and TCM 
variables but not with QoL, (See Table 14). However, the NIOX system is costly to 
obtain and calibrate and requires a steady expiratory airflow which we found was 
difficult for young children to maintain. 
 
It is interesting that in this study NIOX not only correlated with spirometry but also with 
biograph readings, BHT and TCM enquiry. This may provide some validation for these 
measures and may indicate that these measures may be somehow related to airway 
inflammation. These nonconventional measures have the potential to add useful 
information to the assessment of lung function, however further studies are needed with 
larger sample sizes to confirm this.  
 
This study attempted to assess the correlation between conventional lung function 
measures and a set of questions and examination findings based on TCM theory. The 
TCM enquiry assessed the Lung and Large Intestine, Spleen and Stomach, Kidney and 
Urinary Bladder (three sets of related Zhang-Fu organs) according to the TCM 
diagnostic system along with the penetration of the disease into the body based on 
observations of the pulse and tongue. In this study TCM enquiry variables showed a 
significant difference between asthma and healthy groups with a p-value of <0.0000. 
TCM enquiry also had significant correlation with spirometry FEV1, QoL and airways 
NO variables. These findings suggest that TCM enquiry has the potential to provide 
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useful clinical information in the assessment and diagnosis of asthma. This potential 
however has not been fully utilized within western medicine. 
 
Within China, there has been a great deal of cooperation between TCM practitioners and 
Western medicine (Sidel and Sidel 1974; Hjelm, Hazlett et al. 2001; Li, Zhao et al. 
2006; Wang 2006). It has been suggested that TCM has a place in the treatment of 
bronchial asthma (Hsieh 1996; Joos, Schott et al. 2000), however TCM and Western 
medicine differ in their concepts of anatomy, physiology and systems of diagnosis. At 
present, it is not possible to reconcile them into a common language, however, it is 
possible for them to co-exist.  
Diagnostics is a vital element of TCM, serving as the connection between theory and 
clinical practice. It focuses on the patient as a whole person, and less on the symptoms. 
It also relies on the clinician's reading of the patient's symptoms and signs and there is 
scope for individual TCM practitioners to interpret TCM diagnosis in different ways. 
This is confirmed by a study in which forty patients with rheumatoid arthritis were 
assessed by three different TCM practitioners. Interestingly while this study found that 
there was considerable variability in the TCM diagnosis between different practitioners 
there was also considerable consistency between the TCM pattern diagnoses and the 
herbal treatment plans prescribed (Zhang, Lee et al. 2005).  
 
TCM emphasizes individualization of diagnosis and treatment. An important step in 
reconciling TCM and western medicine is the ability to standardize TCM diagnostic 
criteria. While TCM enquiry has not been previously standardized the current study, 
which is one of the first studies to attempt to quantify TCM diagnosis and correlate it 
with other measures, suggests that TCM enquiry including both questions and 
examination findings may provide useful clinical information. The standardized TCM 
questionnaire used in our study, which included information from historical questioning 
and clinical examination, displayed a remarkable ability to distinguish between 
asthmatic and healthy subjects as well as correlations with a number of other diagnostic 
measures. This suggests that such a standardized TCM enquiry, which requires no 
specialized equipment, may have more widespread application and may complement the 
use of other western diagnostic techniques. Further research is needed however to 
confirm and expand on this finding and standardized TCM enquiries such as used in this 
study may provide a tool for such future clinical research.  
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Acupuncture is a branch of TCM that has traditionally been used to treat asthma in 
China and is used increasingly for this purpose internationally. Electrodermal testing is 
an acupuncture-based approach and is claimed to be a device being able to refine 
homeopathic prescriptions (Lewith 2003). It has recently used as a diagnostic tool, 
mostly for allergic conditions. In this study, electro dermal testing did not show any 
significant difference between asthma and non asthma subjects, however it had a 
significant correlation with airways NO levels.  
  
Previous studies suggest that increased BHT is correlated with an increase in single-
breath diffusing capacity of the lung for CO in patients with airway obstruction 
(Graham, Mink et al. 1985) and that the duration of breath holding has significant 
implications in the performance of spirometry and peak flow measurements (Wanger, 
Ikle et al. 1996). Increased BHT is also correlated with increased NO concentration in 
exhaled air in normal people (Sato, Sakamaki et al. 1996), however there is no research 
about measurement of BHTT on asthma diagnosis despite its use by Buteyko practitioners 
to monitor asthma treatment.  
 
Breathing exercises and breathing retraining maybe useful in the management of asthma 
(Holloway and Ram 2004) and the biomechanical aspects of breathing along with 
breathing patterns may play an important role in symptom patterns and how they are 
experienced (Courtney and Cohen 2006). Our study suggests that BHT may provide 
useful information that can be used in combination with the clinical assessment system 
as a diagnostic technique on lung function assessment, especially in mild to moderate 
asthma conditions. However this is only a small study and further research on a larger 
scale is needed. It would be interesting for future studies to look at BHT as a measure of 
asthma as well as monitoring asthmatic symptoms.  
 
SPT is useful to identify triggers in allergic asthma (Bobb and Ritz 2003) and it is 
suggested that incorporating a SPT into the workup of subjects with suspected asthma 
can reduce the cost of this process significantly (Graif, Yigla et al. 2002). While 
knowledge of allergy and any associated allergens may help to reduce triggers for 
asthma, it does not have specific diagnostic value by itself and needs to be 
complemented with other diagnostic methods.  
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The finding that asthmatic subjects had more allergic conditions is consistent with other 
studies and confirms that dust mite and ryegrass allergens are major allergens which are 
often found in asthma subjects as well as healthy non-asthma subjects (Liam, Loo et al. 
2002; Akerman, Valentine-Maher et al. 2003; Cole Johnson, Ownby et al. 2004). The 
finding however that 14% of asthma subjects did not have reaction to the positive 
allergen (Histamine) was unexpected. This may be due to concurrent use of 
antihistamine for their allergic conditions as it was found that almost one third of 
asthmatic participants had allergic conditions such as hayfever, runny nose, sore eyes, 
rhinitis, eczema and acne and were using antihistamine preparations such as Avil 
(Pheniramine), Zyrtec (Cetirizine), Claratyne (Loratadine), Demazin 
(Chlorpheniramine). While subjects were instructed not to use oral steroid medication 
three days prior to the skin prick test and not to take antihistamine medication four hours 
prior to their attendance for the test, it is possible that this instruction was not adhered to. 
At the same time it was found that 14% of subjects tested had an unexpected reaction to 
the negative control (saline). It is uncertain how to explain this result. It is possible that 
this result may have arisen from data entry error despite the data being checked. It is also 
possible that experimental error, contamination, or mislabeling of reagents may have 
produced these results. SPT is generally considered to be reliable as long as a reaction to 
histamine is obtained (Christensen, Moelby et al. 1994). In our study one person did not 
have a reaction to histamine yet did have a reaction to rye grass and fungus. Again, after 
checking the data it was found that this participant had no reaction to positive or 
negative allergen but did react to ryegrass. 
4.1.1 Limitations of the Diagnostic Study 
The study on diagnostic measures involved only a small number of subjects and it is 
therefore difficult to extrapolate the results to the wider population. While it was 
intended to include more subjects, recruitment of subjects was difficult despite 
widespread advertising and the high prevalence of childhood asthma. This appears to be 
due to a number of reasons including: the restricted age range of participants, the need 
for parental/guardian involvement, the geographical location of the study, and the high 
incidence of cold and flu symptoms which excluded potential subjects. The results of 
this study must therefore be considered preliminary and any conclusions require 
confirmation in larger studies.  
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4.1.2 Conclusion on diagnostic study 
There is a statistically significant difference between healthy and asthmatic subjects in 
TCM and BHT and these non-invasive and inexpensive measures may be useful clinically. 
Further research is required to determine their potential use in asthma diagnosis. While a 
statistically significant difference was found between healthy and asthmatic subjects in 
their NIOX measures, this test requires expensive equipment that is difficult to use 
clinically with children and therefore its use in the clinical assessment of children may be 
limited. While TCM, NIOX and BHT may all be useful clinically more studies are required to 
determine their significance. 
4.2 Discussion on Clinical Trial 
While the study was not sufficiently powered to detect potentially clinically important 
effects of the ryegrass extract on FEV1 there was sufficient power to detect the significance 
difference for QoL. The finding that there were no statistically significant differences 
between the active and placebo groups for any of the outcome measures suggests that in the 
form and dosage used in this study, ryegrass extract  does not have therapeutic effect on 
children 8 to 16 years with mild to moderate asthma. 
 
It is interesting to note that not only was no effect seen due to the rye grass extract, there 
was also no placebo effect seen. Improvement in health due to the placebo response is an 
important and potentially measurable aspect of clinical encounters (Jacobs 2001) resulting 
from therapeutic potential of the doctor-patient relationship (Ovchinsky, Ovchinsky et al. 
2004). Furthermore it has been suggested that drug reactivity to personality factors may be 
due to the placebo affect (Capone, Brahen et al. 1976). The lack of any observable placebo 
effect in this study is in contrast to other studies examining different medicinal treatments 
for asthma but is consistent with studies of some complementary therapies for asthma such 
as homeopathy and acupuncture (See table 20) 
 
 
Table 20: Placebo and treatment effects seen in clinical trials of asthma  
Reference Article Title 
 
N Study design Primary 
outcome 
measure 
Result 
 
 
(Beeh, Beier et a
2006)  
Bimosiamose, an inhaled smal
molecule pan-selecting 
antagonist, attenuates late 
asthmatic reactions following 
allergen challenge in mild 
asthmatics: A randomized, 
double-blind, placebo -
controlled clinical cross-over-
trial 
12 Cross-over Spirometry 30% improvement with placebo 
(After allergen challenge following 
placebo treatment, there was 30% fa
from baseline in FEV1. In contrast, 
after allergen challenge following 
bimosiamose treatment the fall from
baseline reduced to 86%)  
(Niu, Chen et al. 
2006) 
 
Efficacy of sublingual 
immunotherapy with high-dos
mite extracts in asthma:  A 
multi-center, double-blind, 
randomized, and placebo -
controlled study in Taiwan 
145 Parallel Spirometry 40% improvement with placebo  
(Patients receiving Sublingual 
Immunotherapy (SLIT) improved 
their FVC, FEV1, and PEF as 
compared to baseline.  Asthma 
severity for SLIT group were 47% 
and for placebo group 60% at the en
of the study) 
(García-Robaina
Sánchez, Torre, 
Fernández-Calda
& Casanovas, 
2006) 
Successful management of 
mite-allergic asthma with 
modified extracts of 
Dermatophagoides 
pteronyssinus and 
Dermatophagoides farinae in a
double-blind, placebo-
controlled study 
54 Double-blind 
and placebo 
controlled 
Bronchial 
provocation 
test (BPT) 
spirometry 
FEV1 
No significant improvement with 
placebo. 
The results of the BPT expressed as 
the PD20FEV1 improved significant
after 1 year (from 10.05 to 11.06) 
while  
PD20FEV1 went from 43.50 to 41.00
in the placebo group. 
 
(Nickela, Kettler
et al. 2005) 
 
Effect of progressive muscle 
relaxation in adolescent female
bronchial asthma patients: A 
randomized, double-blind, 
controlled study 
61 Randomized, 
double-blind, 
controlled stud
FEV1 (L), 
 
1% (non significant) improvement in
the placebo group (initial FEV1 1.72
final 1.75) ,and 53.5% (significant) 
improvement in the active group 
(initial FEV1 1.61 final FEV1 2.15).
(Biernacki and 
Peake 1998) 
Acupuncture in treatment of 
stable asthma 
23 Cross-over Spirometry 
FEV1 and 
AQoL 
6% improvement in FEV1in the sha
group (1.89 to 2.01) compared to 7. 
% improvement in the active group 
(1.89 to 2.03) after 2 weeks.  
 
23% improvement in Qol in the sham
group (4.19 to 5.15) and 13.6% (4.1
to 4.76) improvement in the active 
group.  
(Tashkin, 
Kroening et al. 
1985) 
A controlled trial of real and 
simulated acupuncture in the 
management of chronic asthma
25 Cross over Spirometry No significant difference between or
within  groups 
(Christensen, 
Laursen et al. 
1984) 
Acupuncture and bronchial 
asthma 
18 Parallel PEFR All results seem in favor of 
Acupuncture, small sample size, 
 no definite conclusion 
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Regarding daily PEFR on the clinical trial there were no significant differences between 
the two active and placebo groups, and also no significant difference detected within each 
group for variables compared between week 1 and week 14. The post hoc analyses 
demonstrated that the study was under powered, as to perceive 20% difference 85 cases 
were needed; however with the present study with 16 subjects in each group, 44 to 45% 
difference could be detected in condition of such difference were present (See table 19). 
 
Parallel to other researchers it is believed that asthma control can be assisted by educating 
patients to use PEFMs (Janson 2005) and it is an important screening method for 
investigation and follow-up of the pulmonary function, PEF values can be easily 
calculated knowing one's age and height (Ljustina-Pribic and Roncevic 2005). 
 
In this study the use of PEF meters was demonstrated and explained to the children and 
parents. Some studies question the usefulness of the instruction and consider that it has 
never been validated in small children with asthma. (Slieker and van der Ent 2003). In 
most studies the age limit for young children was 4 years old however in Emeryk study 
the Lung Function Laboratory of the Children' Hospital in Lublin in the year 1992, PEF 
is not recommended for children younger than 6 (Emeryk, Jedrych et al. 1995). Truong 
suggests that PEF can be used in young children less than 7 years old. It is necessary to 
always use the same peak flow meter for a child (Truong, Iniguez et al. 1995). In this 
study the participant are believed to be capable of acceptable use of PEF meters and were 
issued identical PEFR meters. Though PEF measures are useful during symptomatic 
times to adjust management, daily use of PEF meters  does not seem useful by most 
families and is likely to be an unrealistic expectation for most children (McMullen, Yoos 
et al. 2002). 
4.2.1 Limitation of the Clinical Trials 
The clinical trial was limited by small numbers for similar reasons to the diagnostic 
study. Furthermore subjects were often taking long acting beta agonists which may have 
limited the ability to detect a change in lung function from the study medication. The 
asthmatic children in the diagnostic study were medicated and although they were asked 
to refrain from using long acting beta agonists and the like this was not always adhered 
to. The initial statistical power calculation suggested that if sizes of treatment effects are 
between 0.5 and 0.6, for a significance level of 5% and 80% power, sample sizes between 
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45 and 64 would be needed. We had only 36 participants (18 in each group), but despite 
this we still had power to detect difference in asthma active and passive QoL.  
4.2.2 Conclusion on Clinical Trial  
The ryegrass extract was no better than placebo in improving QoL or lung function in 
asthmatic children. As it is not possible to extrapolate the findings of this study to other 
populations, further studies using different populations or different doses may yield 
different results.  
 
4.3 Overall Conclusions and Implications for Future Research 
The use of inexpensive measures such as BHT and TCM enquiry may provide useful 
clinical information that can be used to assist in the diagnosis and monitoring of asthma, 
however further research is required in larger populations to confirm their use. BHT may 
be related to quality of life in healthy subjects although this requires confirmation in 
future studies. It is possible to standardize TCM history and examination and for this to 
provide clinically useful information. The use of the rye grass extract at the dose given in 
this study does not provide any clinical benefit for asthmatic children.   
 
Future research is warranteed to further investigate the relation of the NO with BHT and 
TCM enquiries on mild to moderate asthma conditions, relativity between BHT and QoL 
in healthy and asthmatic subjects, examination of the correlation between NO and BHT, 
TCM and EDST, standardization of the TCM enquiry, the effect of ryegrass extract on 
asthma in different age range and doses, and the diagnostic ability of EDST in a 
comprehensive way. 
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Appendix 1: 
 
 
 
Copy of Advertisements, letters and Media Releases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Do you have Asthma? 
Are you 8-16yrs old? 
 
The Department of Complementary 
Medicine, (Chinese Medicine Unit) of RMIT 
University (situated at Plenty Rd. West Bundoora 
Campus, Bundoora) is looking for volunteers 
to take part in a research study. 
 
We are looking at Natural Therapies 
For Asthma. 
 
If you take 3 or more doses of reliever medication 
per week (or someone you know does) and are 
interested… 
The study also requires 30 children of the same 
age who are non-asthmatic and healthy, to act as 
a control group, anyone interested to take part
 
Get your parent or guardian to give  
Sheena Maxwell a call on 9925-7584 
for more details. 
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Do you have Asthma? 
Are you 8-16 yrs old? 
 
The Department of Complementary  
Medicine, RMIT University  
(Situated at RMIT University  
Plenty Rd. Bundoora) are looking for  
Volunteers to take part in  
a research study. 
We are looking at  
‘Natural Therapies’  
for Asthma. 
 
Get your parent or guardian to give  
If you take 3 or more  
doses of reliever medication  
(eg. Ventolin) per week  
(or someone you know does)  
and is interested 
Please; 
Sheena Maxwell 
a call on 9925-7584 
for more details. 
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Do you consider having free lung function 
assessment and allergy testing? 
 
The Department of Complementary Medicine at RMIT University West Campus 
Bundoora Investigating  
“The usefulness of non-conventional measures for lung function”. 
 And needs young participants. 
If you are between 8 to 16 years old, and willing to 
participate in this study please ask your parents/Guardian to 
contact:  
The massage box 9925-7584 and give your contact number to 
organise an appointment for you. 
 
During this study you will have your lung function monitored and also have diagnostic tests 
including skin prick testing and lung function testings. The results of these tests may identify 
environmental triggers that you may be allergic to and these results can be made available to 
your medical practitioner to assist in the management of your health. 
 
 
MEDIA RELEASE 
 
 
CAN HERBAL MEDICINES ASSIST WITH CHILDHOOD ASTHMA? 
A clinical trial to be conducted by the Department of Complementary Medicine at 
RMIT University, hopes to determine whether an herbal medicine can help assist in 
easing the symptoms of asthma in children.  
 
Asthma currently affects as many as 25% of Australian children and even with the 
use of modern pharmaceuticals it can still cause significant illness. Asthma is a 
disease that greatly disrupts normal activities and may result in hospitalisation or 
even death in otherwise healthy children. 
 
Anecdotal reports and the results of a small trial suggest that a herbal medicine 
called ‘Oralmat Drops TM’, already available in Australia, may be able to assist in 
controlling asthma symptoms. The growing interest in this therapy has heightened 
the need for a methodical trial that meets international standards. 
 
Prof. Marc Cohen, Head of Department of Complementary Medicine at RMIT University’s will be conducting 
this trial and sees great benefit if the results are positive.   
 
The use of complementary medicines is continuing to grow in Australia and Prof. 
Cohen encourages its integration into patient care and health maintenance.  
 
“Oralmat Drops TM is a complementary medicine and is not proposed to substitute 
pharmacological medicines. However, if this herbal remedy is able to assist in 
controlling asthma symptoms then there are many people in our community who 
may benefit, so it is a very important trial” he said. 
 
Prof. Cohen is looking for around 70 people to take part in the trial. People with mild 
to moderate asthma between the ages of 8 and 16 years who are able to attend the 
RMIT University situated at Plenty Rd. Bundoora for assessments are invited to 
participate. People can leave their details on the trial message bank on 9925 7584. 
 
Release ends. 
 
For further information please contact: 
 
Sheena Maxwell 
RMIT University, Bundoora West Campus 
Building 202, level 4 
 
Tel: (03) 9925 7584, Fax (03) 9---- 
 
 
 
 
 
 
 
 
 
Do You Have Asthma? 
 
Volunteers are needed for a clinical 
trial into Complementary/Alternative 
Therapies for asthma, for children 
aged between 8 and 16 years. A free 
lung function test is included. 
 
If you are interested please call 
Sheena Maxwell on -9925-7584- 
 
 
 
 
  
 
Wanted: Children with asthma 
 
The Department of Complementary Medicine, at RMIT 
University, West Bundoora Campus (located at Plenty Rd. 
Bundoora) is seeking children with mild to moderate asthma to 
participate in a research study looking at the use of an herbal 
preparation to treat childhood asthma and also assessment of 
non-conventional measures of lung function.  Subjects aged 
between 8 and 16 years of age who currently require 3 or more 
doses of reliever medication per week to treat their condition 
are needed to volunteer for this trial.  The treatment involves 
the use of drops containing rye grass extract (or placebo) for a 
period of 12 weeks. Each participant will be required to use the 
drops twice a day and to fill out a daily diary.  Volunteers will 
need to attend an initial 90 minute interview inquiring about 
asthma details, quality of life, use of health resources and will 
also involve lung function test, nitric oxide assessment, 
electrodermal acupuncture meridian assessment, traditional 
Chinese medicine inquire and skin allergy testing. This 
interview will be repeated after 2 weeks and at the end of the 
12- week study period. 
 
If your child or anyone you know would be interested in participating 
in this study, please call the study coordinator Sheena Maxwell on 
message bank 9925 7584 at RMIT University. 
 
 
 
The study also requires 30 children of the same age who are 
non-asthmatic and healthy, to act as a control group. It would 
much appreciated if anyone interested to take part in this study 
please call Sheena Maxwell on the above number. 
 
 
Thank you. 
 
 
Prof Marc Cohen       A/Prof Charlie Xue   Sheena Maxwell 
  
 
Complementary Therapy for 
Children with Asthma 
 
 
 
The department of complementary medicine, Chinese medicine unit is looking for 
children aged between 8 and 16 years with mild to moderate asthma to participate in 
a research study looking at the use of a natural herbal preparation to treat asthma. 
Subjects will need to have been diagnosed with asthma and require 3 or more doses 
of reliever medication (such as Ventolin) per week.  The treatment involves the use of 
drops containing rye grass extract for a period of 12 weeks.  Each volunteer will be 
required to use the drops twice a day to treat their asthma and to fill out a daily diary.  
Volunteers will need to attend the study site at RMIT University West Bundoora 
Campus, Plenty Rd. Bundoora for an initial 90 minute interview consisting of lung 
function tests, skin allergy test, and questionnaires inquiring about quality of life and 
use of health facilities plus Traditional Chinese Medicine Questionnaire. This 
interview will be repeated after 2 weeks and at the end of the 14-week study period. 
 
If your child or anyone you know would be interested in participating in this study, 
please call the study co-coordinator Sheena Maxwell on Asthma Line 9925 7584 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Childhood asthma hope  
A clinical trial currently underway at RMIT University will determine if the herbal 
medicine, Oralmat Drops, can help control symptoms of childhood asthma – a 
debilitating and potentially fatal condition that currently affects one in four 
Australian children.  
 
RMIT University’s Head of Complementary Medicine, Professor Marc Cohen, 
says the growing interest in Oralmat Drops has heightened the need for a 
rigorous trial that meets international standards.  
 
While the complementary medicine is not intended to replace pharmacological 
medicines, Professor Cohen says many people could benefit if the herbal remedy 
proves effective in helping to control asthma symptoms.  
 
RMIT University Masters student Sheena Maxwell is working with Professor 
Cohen to conduct the trial.  
 
Children between the ages of 8 and 16 are required to participate in this study. 
For more information please call 9925 7584  
 
 
 
 
Childhood asthma hope 
 
A herbal treatment for the debilitating and sometimes deadly childhood 
asthma could be on the way if trials prove positive, RMIT University 
researchers say. 
 
A clinical trial currently underway at RMIT University will determine if the 
herbal medicine, Oralmat Drops, which is already available in Australia, is 
able to help control asthma symptoms. 
 
Asthma currently affects one in four Australian children and even with the 
use of modern pharmaceuticals it can still cause significant illness. Asthma 
is a disease that greatly disrupts normal activities and may result in 
hospitalisation or even death in otherwise healthy children. 
 
RMIT University’s Head of Complementary Medicine, Professor Marc 
Cohen, said the growing interest in ‘Oralmat Drops has heightened the need 
for a rigorous trial that meets international standards. 
 
“Oralmat Drops is a complementary medicine and is not intended to replace 
pharmacological medicines,” Professor Cohen said. 
“However if this herbal remedy is able to assist in controlling asthma 
symptoms then there are many people in our community who could benefit, 
so it is a very important trial.” 
 
RMIT University Masters student Sheena Maxwell will work with 
Professor Cohen to conduct the trial. 
 
Professor Cohen is looking for around 100 people to take part in the trial. 
People with mild to moderate asthma between the ages of eight and 16 who 
are able to attend the clinic at RMIT Bundoora for assessments are invited 
to participate. People can leave their details on a phone message bank (03) 
9925 7584.
Childhood asthma hope 
 
A herbal treatment for the debilitating and sometimes deadly childhood 
asthma could be on the way if trials prove positive, RMIT University 
researchers say. 
 
A clinical trial currently underway at RMIT University will determine if the 
herbal medicine, Oralmat Drops, which is already available in Australia, is 
able to help control asthma symptoms. 
 
Asthma currently affects one in four Australian children and even with the 
use of modern pharmaceuticals it can still cause significant illness. Asthma 
is a disease that greatly disrupts normal activities and may result in 
hospitalisation or even death in otherwise healthy children. 
 
RMIT University’s Head of Complementary Medicine, Professor Marc 
Cohen, said the growing interest in ‘Oralmat Drops has heightened the need 
for a rigorous trial that meets international standards. 
 
“Oralmat Drops is a complementary medicine and is not intended to replace 
pharmacological medicines,” Professor Cohen said. 
“However if this herbal remedy is able to assist in controlling asthma 
symptoms then there are many people in our community who could benefit, 
so it is a very important trial.” 
 
RMIT University Masters student Sheena Maxwell will work with 
Professor Cohen to conduct the trial. 
 
Professor Cohen is looking for around 100 people to take part in the trial. 
People with mild to moderate asthma between the ages of eight and 16 who 
are able to attend the clinic at RMIT Bundoora for assessments are invited 
to participate. People can leave their details on a phone message bank (03) 
9925 7584. 
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Appendix 2: Screening Form 
 
Rye grass Study and Lung Function Assessment by 
Conventional and Non-Conventional Measurements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol 1Code: SP#007 Project No:4-04 Maxwll                                    Subject Number         ???                                         
                                                                                                                     Subject Initial        ???                                   
 
 
 
Dated Screened----------------------- 
(dd/mmm/yy) 
 
Eligible/ Not Eligible 
The Complementary Medicine (Chinese Medicine Unit), RMIT University, West Bundoora Campus is 
running a research study Looking at a natural therapy to treat asthma in children. We are looking for 
children aged 8-16 years old who have diagnosed with asthma and currently require 3 doses of reliever 
medication per week, and also we need non-asthmatic healthy the same age children to evaluate with 
asthmatics subjects. Three visits need to be made to test lung function, ask questionnaires on quality of life 
and use of health assurance. A daily symptoms diary will need to be filled out by asthmatic subject with 
parental guidance. This herbal preparation will be given with normal asthma medication, not in place of. 
The Trial last 12 weeks +2 week run in at start. 
SCREENING FORM 
Ryegrass Study and Lung Function assessment by conventional 
and Non-Conventional Measurements 
 
 
Child’s Given Names (2):_____________________   _____________________ 
Child’s Surname: ___________________________________ 
 
Date of Birth: __  __/__ __ __/ __ __  (DD/MMM/YY)   Child’s Age___ __(years) 
 
Adress:_____________________________________________________________ 
            Postcode: __________ 
 
Sex:                        Male ?                                    Female ? 
 
Parent’s Guardian name: _______________________________________________ 
 
Telephone: (H) ___________________________ (W)   ______________________ 
                   (Mobile) ____________________Best time to call 
 
 
Local doctor/ treating health care professional contact 
details: 
 
Name:_________________________________________
Adress:________________________________________ 
___________________________Phone:_____________ 
______________________________________ 
 
 
 
Protocol 1Code: SP#007 Project No:4-04 Maxwll                                    Subject Number         ???                                         
                                                                                                                     Subject Initial        ???                                   
 
 
 
 
 
Office Use Only 
Source: How did you hear about the study? 
1. News paper advert 
2. Radio Publicity 
3. Saw Poster 
4. Friends told me 
5. Health care professional referral 
6. Other…………………………… 
(Please Circle) 
 
INCLUSION CRITERIA    Yes No  
1. Is the subject 8 to 16 years of age?…………………  ?  ? 
2. Has a medical practitioner previously 
diagnosed the subject with asthma?……………….  ?  ? 
3. Does the subject currently require (3) or more doses 
 of reliever medication per week?… 
Name of Relievers…………………………   ?  ? 
 
4. Is the subject able to attend for lung function 
 assessments on 3 visits at RMIT West Campus?                   ?  ? 
 
5. Is the subject able and willing, with guidance by  
parent/ guardian, to complete daily symptom diary?    ?  ? 
 
( If any of the “ No” boxes were ticked in this section , subject is not eligible for 
inclusion into the study) 
 
EXCLUSION CRITERIA                                     Yes            No 
1. Has the subject previously used Oralmat drops?           ?  ? 
 
2. Has the subject experienced a severe asthma attack                  ?  ? 
 
      within 6 weeks trial commencement? 
      (hospitalisation or emergency doctor attendance)                
 
3. Is subject taking oral steroids for asthma or have they     ?  ? 
 taken any in the last 4 weeks? Eg. Prednisolone  
4. Has subject had a cold or the flu in last 4 weeks?                      ?  ? 
 
 
Protocol 1Code: SP#007 Project No:4-04 Maxwll                                    Subject Number         ???                                         
                                                                                                                     Subject Initial        ???                                   
 
5. Has subject been in hospital for any reason in last 4wks?    ?  ? 
 
6. Does the subject have any other serious illness/condition     ?  ? 
that they are taking a prescription medication for?  
7. Is the subject currently on any other trial/study for       ?  ? 
asthma treatment? 
 
 (If any of the “Yes” boxes were ticked in this section, subject is not eligible for inclusion into 
this study.)                                                    
 
 
        
 
 
Inclusion Criteria for non-asthmatic normal subjects, 
 
          Yes                 No 
1. Aged between 8 to 16 years old                                          ?  ? 
 
2. No history of asthma or any kind of chronic disease          ?  ? 
3. Willing to participate in the study                                        ?             ? 
4. Give written consent by parent / guardian to                       ?  ? 
              their participation on the study 
 
 
Nots____________________________ 
 
Reasons for ineligibility______________________ 
 
        Interested in Future Research…………………        
                                                                   
 
                                                                         Signature of Interviewer 
 
__________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3: Plain Language Statements and Consent 
Form Letters
  
  
    
SCIENCE, ENGINEERING &   
TECHOLOGY PORTFOLIO    
  
 Complementary Medicine 
 Bundoora Campus 
 PO Box 71 
 Bundoora  3083 
 Victoria  Australia 
  
 Tel +61 3 9925 7440 
 Fax +61 3 9467 2794 
 E-mail marc.cohen@rmit.edu.au 
 
Child’s Plain Language Statement For 
A Clinical Trial of Ryegrass Extract and  
Assessment of Non- Conventional Measures of Lung Function 
 
INVESTIGATORS: Prof Marc Cohen, A/Prof Charlie Xue and Mrs Sheena Maxwell 
 
Dear Volunteer  
 
My name is Sheena Maxwell a Masters by research student in the Department of Complementary 
Medicine at RMIT University. I am investigating the use of herbal rye grass extract for asthma and 
the different tests used to measure asthma. This letter is to tell you information about the study. We 
will be giving each volunteer an active or inactive (placebo) treatment and testing their breathing and 
as well as asking them some questions. Neither the researchers nor the volunteers will know if they 
are getting the active or placebo treatment. 
 
If you agree to participate in this study we will ask you to: 
• Visit the clinic 3 times over a 14-week period to have some tests performed including some 
breathing tests, an allergy test as well as answer some general questions. 
• Take 2 to 4 drops of the given treatment 2 to 4 times each day and complete a diary of you 
symptoms, peak flow and medication use. 
• Answer some questions over the phone on 2 occasions during the study.  
 
During your participation in this study you will find out how well your asthma is being controlled 
and will also find out if you are allergic to common plants and animals. Your participation will also 
help the researchers find out if the herbal rye grass extract should be recommended more widely to 
help people with asthma.  
 
Participation in this study is voluntary, thus you may ask at any stage to stop being involved in the 
study or that a procedure be stopped at any time. All information collected about you will be kept 
confidential and no information about you will be released at any time.  
 
Any questions regarding the procedure of this research will be answered and explained at any time. 
Please contact Mrs. Sheena Maxwell on 94401862 if you have any questions concerning this project. 
 
Thank you for taking the time to read this form 
 
 
Prof Marc Cohen   A/Prof Charlie Xue    Sheena Maxwell 
 
Any questions or complaints about your child participation in this study may be directed to The 
Secretary of Human Research Ethics Committee, RMIT, 124 La Trobe St. Melbourne Vic. 3000. 
Tel: 99251745. 
 
SCIENCE, ENGINEERING &
TECHOLOGY PORTFOLIO  
Complementary Medicine 
Bundoora Campus 
PO Box 71 
Bundoora  3083 
Victoria  Australia 
 
Tel +61 3 9925 7440 
Fax +61 3 9467 2794 
E-mail marc.cohen@rmit.edu.au 
 
Child’s Plain Language Statement For 
Assessment of Non- Conventional Measures of Lung Function 
 
INVESTIGATORS: Prof Marc Cohen, A/Prof Charlie Xue and Mrs Sheena Maxwell 
 
Dear Volunteer  
My name is Sheena Maxwell a Masters by research student in the Department of Complementary 
Medicine at RMIT University. I am investigating the use of different tests used to measure 
breathing. This letter is to give you information about the study. If you agree to take part in this 
study we will ask you to visit our clinic 3 times over a 14-week period to have some tests 
performed including some breathing tests, an allergy test as well as answer some general 
questions about your health. 
 
About skin prick test 
During your second visit you will be asked to have a skin prick test. The test is to find out 
whether you are allergic to any common pollens or animals in the environment.  
While this test is safe, it can result in a small area of itchy skin similar to a mosquito bite if you 
are allergic to a test substance. There is also an extremely small risk of a larger allergic reaction. 
An experienced investigator will administer this test and procedures to manage an allergic 
reaction will be available if necessary. 
 
Airways nitric oxide test 
You will be asked to breath through a tube attached to a computer to measure the level of nitric 
oxide (a type of gas) in your breath.  
 
Spirometry test 
You will be asked to hold your breath then blow through a tube attached to a computer to find 
out how much air your lungs hold. You will then be asked to have a single dose of a drug that is 
used to treat people with breathing difficulties and you will then hold your breath and blow 
through the tube again to see if your lung size changes.  
 
Electro-dermal assessment of acupuncture meridian  
This is an Energy Measurement System that takes 5-10 minutes. It involves taking measurements 
on different points on your fingers and toes. There is no pain or unpleasant feelings associated 
with this test. 
 During your participation in this study you will find out about your breathing and if you are 
allergic to common plants and animals. Your participation will also help the researchers find out 
which tests are useful to monitor breathing. 
 
Your involvement in this study is up to you and you may ask at any stage to stop being involved 
in the study or that any test be stopped at any time. All information collected about you won’t be 
told to anybody else.  
If you have any questions you can ask your parent/guardian to ring me and talk to me about it. 
My name is Sheen a Maxwell and my number is 9925 7584 or 94401862.  
 
Thank you for taking the time to read this form. 
 
 
Prof Marc Cohen   A/Prof Charlie Xue    Sheena Maxwell 
 
Any questions or complaints about your child participation in this study may be 
directed to The Secretary of Human Research Ethics Committee, RMIT, 124 La Trobe 
St. Melbourne Vic. 3000. Tel: 99251745. 
 
 
 
  
RMIT HUMAN RESEARCH ETHICS COMMITTEE 
Prescribed Consent Form For Persons Participating In Research Projects Involving Interviews, 
Questionnaires, Focus Groups or Disclosure of Personal Information 
 
FACULTY OF LIFE SCIENCES 
DEPARTMENT OF  COMPLEMENTARY MEDICINE 
Name of participant:  
Project Title: Effect of ryegrass extract (Oralmat Drops) in the treatment of 
mild-moderate childhood asthma and 
 An Assessment of Non-Conventional Measures of Lung 
Function 
  
Name(s) of investigators:    (1) Marc Cohen Phone: 99257440 
(2) Sheena Maxwell Phone: 94401862 
 
1. I have received a statement explaining the tests/procedures and the interview/ questionnaire involved in this 
project. 
2.             I consent to participate in the above project, the particulars of which - including details of tests or                
procedures and the interviews or questionnaires have been explained to me. 
3. I authorise the investigator or his or her assistant to use with me the tests or procedures and administer a 
questionnaire referred to in 1 above.  
4. I acknowledge that: 
(a) Having read the Plain Language Statement, I agree to the general purpose, methods and demands of 
the study and that the possible effects of the tests or procedures have  been explained to me to my 
satisfaction. 
(b) I have been informed that I am free to withdraw from the project at any time and to withdraw any 
unprocessed data previously supplied.(unless follow-up is needed for safety). 
(c) The project is for the purpose of research and/or teaching. It may not be of direct benefit to me. 
(d) The privacy of the personal information I provide will be safeguarded. And only disclosed where I 
have consented to the disclosure or as required by law.  
(e) The security of the research data is assured during and after completion of the study.  The data 
collected during the study may be published,  No information which could identify me will  be 
used. 
Participant’s Consent 
 
Name:  Date:  
(Participant) 
 
 
Name:  Date:  
(Witness to signature)   
Where participant is under 18 years of age: 
 
I consent to the participation of ____________________________________ in the above project. 
 
Signature: (1)                                             (2) Date:  
(Signatures of parents or guardians) 
 
Name:  Date:  
(Witness to signature) 
Participants should be given a photocopy of this consent form after it has been signed. 
Any complaints about your participation in this project may be directed to the Secretary, RMIT Human Research 
Ethics Committee, University Secretariat, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is 
(03) 9925 1745.   
Details of the complaints procedure are available from : www.rmit.edu.au/council/hrec 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4: Case Report Form 
(CRF)
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Principal Investigator: 
Prof. Marc Cohen 
 
 
Complementary Department, School of Health Sciences, Chinese 
Medicine Unit, RMIT University 
 
 
 
 
Confidential 
 
Case Report Form 
 
 
A Randomized, Double Blind, Placebo controlled trial of ryegrass extract (Oralmat Drops) in the 
treatment of childhood asthma and Assessment of Non-Conventional Measures of Lung Function 
 
 
 
PROTOCOL NUMBER: SP#007  
& 
Project No: 4-04 Maxwell 
 
 
Schumacher Pharmaceuticals Pty Ltd 
A.B.N, 30 004 547 602 
252 Collins Street 
Melbourne 3000 
Victoria, Australia 
Ph: 613 03 9553 4314 
Fax: 613 03 9650 1205 
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Completion Guide Lines For Case Report Form(CRF) 
 
• Always use a black ball point pen when writing in CRF 
• Print neatly and legibly 
• Avoid use of abbreviations and acronyms whenever possible. Use only 
abbreviations that are clear and in standard medical use. 
• Enter subject’s number and initials in the space provided at the top of each 
CRF page. 
• Do not use the full name of subject in the CRF. 
• Box must be completed from left to right e.g. 12 written 0 0 1 2 
• Do not leave data box empty. Draw a line through and/ or state why data is 
missing. 
• Use the following abbreviations for missing information: 
 
-NO Not available/not applicable 
-ND Not Done 
-UNK/99 Unknown (e.g. for dates, if  the month is unknown record 
as 
 
• Record dates in DD/MM/ YY format e.g. 25 03 04 
• Record time in24 hour clock format (midnight= 0000) 
• When making correction, draw a single line through the incorrect value so that 
still legible date and initial the correction. Write the correct data as near as 
possible to the mistake. 
• Do not use correction fluid or tape in the CRF and do not write over an 
incorrect entry. 
• In medication table, record proprietary name for drug where possible (e.g. 
Ventolin, not salbutamol) and dosage in mg –convert if necessary. 
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STUDY SCHEDULE 
Assessment Time table Week 0 
clinic 
Visit 
Week 2 
Clinic visit  
Week 6 
Telephone 
follow-up 
Week 10 
Telephone 
follow-up 
Week 14 
Clinic 
Visit 
 
1 
Demographics √  
 
 
 
 
 
 
 
2 
 
Other Therapies 
 
 
√ 
 
√ 
 
√ 
 
√ 
 
√ 
 
3 
 
Medication Usage   
√ 
 
√ 
 
√ 
 
√ 
 
√ 
 
4 
Other Medical 
Conditions 
(Acute or Chronic) 
 
√ 
 
√ 
 
√ 
 
√ 
 
√ 
 
5 
Adverse Effect 
Enquiries 
 
 
√ 
  
√ 
  
√ 
6  Health resource utilisation √ √ √ √ √ 
7 Quality of Life 
Questionnaire 
 
 
√ 
 
√ 
   
√ 
8 Spirometry √  
√ 
   
√ 
9 Skin Prick Test 
 
  
√ 
   
10 Compliance   √ √ √ 
11 Peak Flow Diary Check  √ √ √ √ 
 
12 
Symptom Diary Check   
√ 
 
√ 
 
√ 
 
√ 
13 
 
 
Airway NO level 
Measurement 
 
√ 
 
√ 
   
√ 
14 Breath Holding Time  
√ 
 
√ 
   
√ 
 
15 
Acupuncture meridian 
function Test 
 
√ 
 
√ 
   
√ 
16 Asthma Medication use 
Diary Check 
 
 √ √ √ √ 
17 TCM Questionnaire √ √   √ 
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CRF: VISIT 1(WEEK 0) 
 
Date of Assessment   _ _   _ _   _ _(dd/mm/yy) Interviewer: __________________ 
 
INCLUSION CRITERIA For Asthmatic Subjects    
                                                                        Yes No   
1. Is the subject 8 to 16 years of age?………………….  ?  ? 
2. Has a medical practitioner previously 
diagnosed the subject with asthma?……………….   ?  ? 
3. Does the subject currently require (3) or more doses 
 of reliever medication per week?……    ?  ? 
4. Is the subject able to attend for lung function 
 assessments on 3 visits?…………………………….  ?  ? 
5. Is the subject able and willing, with guidance by  
parent/ guardian, to complete daily symptom diary?     ?  ? 
 
(If any of “No” boxes were ticked in this section, subject is not eligible for inclusion into this study.) 
 
EXCLUSION CRITERIA For Asthmatic Subjects  
1. Has the subject previously used Oralmat drops?                  ?  ? 
2. Has the subject experienced a severe asthma attack within 6 wks 
trial commencement (hospitalisation or emerge doctor attendance)?   ? 
3. Is  subject taking oral steroids for asthma or have they  
  taken any in the last 4 weeks? Eg. Prednisolone   ?  ? 
4. Has subject had a cold or the flu in last 4 weeks?   ?  ? 
 
5. Has subject been in hospital for any reason in last 4wks?  ?  ? 
 
6. Does the subject have any other serious illness/condition  ?  ? 
that they are taking a prescription medication for?  
7. Is the subject currently on any other trial/study for   ?  ? 
asthma treatment? 
 
 (If any of the “Yes” boxes were ticked in this section, subject is not eligible for inclusion into this 
study.)  
Is the subject eligible?     YES? NO? 
If NO, please state 
reasons____________________________________________________________ 
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CONSENT   
1) Has the parent consent form been signed?  Yes   ? No   ? 
If YES, date signed  _ _ / _ _ /_ _  (dd/mm/yy) 
 
Has the child consent form been signed?   Yes   ? No   ? 
If YES, date signed  _ _ / _ _ /_ _  (dd/mm/yy) 
 
 
Demographics  
Date of Birth   __ __ /__ __ / __ __ (dd/mm/yy)    Age __ __ 
 
 
 
Year diagnosed with asthma _______________ 
 
School year level or grade ________________________ 
 
 
Sex   ? Male  ?   Female 
 
 
Ethnicity    
Caucasian ?  Asian ?   
Aboriginal ?  Other ? …………………..   
    
 
 
Smoking  Do you currently smoke? Yes?  No? 
   ………………………………………………………………… 
 
 
 
Weight  ??? kg (rounded up)             Height   ??? cm (rounded up) 
(weight & height to be measured without shoes at time of spirometry) 
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Concurrent medications 
 
List all prescribed medications with their dosages at page 47 of CRF 
 
 
Asthma Therapies 
 
Do you currently use any of the following therapies for your asthma? 
 
Therapy 1=Yes 
2=No 
If yes, how often do you use this 
treatment? (indicate if per week/per 
month) 
Acupuncture   
Physiotherapy   
Homeopathy   
Chi Chung   
Yoga (breathing)   
Buteyko Breathing   
Other   
 
Adverse Events 
How have you been feeling lately? ………………………… 
……………………………………………… 
Yes  No 
Has the subject suffered any adverse event?    ? ? 
 If yes, please record on AE sheet on page 43 of CRF 
 
Quality of Life Questionnaire 
 
Choice of 2 booklets depending on participant age  1) green:: ages 8-11   ?   
        2) blue:: ages 12-16   ? 
(Questionnaire booklet in clear plastic pocket on next page) 
 
         Yes   No 
Has the QOL questionnaire been completed?   ?  ? 
Protocol Code: SP#007 & Project No: 4-04 Maxwell                                     Subject Number ???                        
 
Health Resource Utilization Survey 
 
Hospital Visits 
1. Have you visited a hospital casualty department or emergency room Yes No
 because of breathing, allergy or skin problems in the past 4 weeks? 
 
 1.1 If yes, how many times? 
 
2. Have you spent a night in hospital because of breathing, allergy or skin    
problems in past 4 weeks? 
 
2.1 If yes, how many days have you stayed in hospital because of 
breathing, allergy or skin problems in the last 4 weeks?  
 
2.2  In what sort of ward?  (circle letter) 
A) General Medicine       B) Chest Medicine          C) Rehabilitation 
     D) Intensive Care Unit       E) Other ………………………………………. 
 
Doctor Visits 
 
3. Have you been seen by a GP because of breathing problems, allergy or 
skin problems in the past 4 weeks? 
 Yes No
3.1 If yes, where were you seen & how often? 
  
A) At home (except for emergency visits)        No. of times  _____ 
      B) In the GP’s office or surgery        No. of times  _____ 
           C) At home for an emergency        No. of times  _____ 
 
4. Have you been to see a specialist (chest physician, allergy specialist, skin 
specialist, ENT doctor etc)  because of your breathing problems, allergy or 
skin problems in the past 4 weeks? Yes No
 
 4.1 If yes, how many times?  
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Yes No
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Other Practitioners  
 
5. Have you visited any of the following because of your breathing problems, 
allergy or skin problems in the last 4 weeks?   
 Yes No
Nurse           No. of times ____ 
Physiotherapist            No. of times ____ 
Practitioner of complementary medicine         No. of times ____ 
 
6. Have you had any clinical or laboratory tests because of your breathing, 
allergy or skin problems in the past 4 weeks? (excluding current study) 
Yes No 
6.1 If yes, which tests and how often? 
  a)  Respiratory function test No. of times   
  b)  Skin test for allergy  No. of times   
  c)  Blood test for allergy No. of times   
  d)  X-rays  No. of times   _____ 
e) Other  No of times    _____ 
 
School 
 
7. Have you taken any time off school because of your breathing, allergy 
Yes No  or skin problems in the past 4 weeks? 
 
 
7.1 If yes, how much time?      Days  
 
 7.2   If yes, when (date)? _________________ 
 
8. Have there been any days when you’ve had to give up activities  
 (e.g. sport, class time etc) because of your breathing, allergy or skin  Yes No
 problems in the past 4 weeks? 
 
8.1 If yes, how much time?        Days  
 
8.2 If yes, when (date)? _________________ 
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Airways Nitric Oxide Level 
 
SPIROMETRY 
 
Last Bronchodilator __________________________________________(type) 
 
          ___________________________________________(date & time) 
 
Spirometry result: 
(Printout of spirometry in source document) 
 
1.   Pre bronchodilator 
Best of 3 readings:  FEV1 ??.?? 
       FVC  ??.?? 
 
 
Post broncholdilator 
Best of 3 readings:  FEV1 ??.??  % Change?? 
       FVC  ??.?? 
 
 
 
Is 12%  reversibility in FEV1 present?………………………YES ?  NO ? 
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Nasal NO Concentration 
 
Lung NO Concentration 
 
Measured FENo (ppb) 
1. …………….. 
2. ……………. 
3. ……………. 
Average FENO (ppb). ………… 
Average VNO (nl/min)……………… 
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Breath Holding Time: _________________________/secs. 
 
 
 
 
 
Acupuncture Meridian Function Test 
 
Left Side Organs Right Side 
 Lung  
 ---------  
 Large Intestine  
 ------------ 
 
 
 Stomach  
 -----------  
 -----------  
 Spleen  
 Heart  
 Small Intestine  
 Bladder  
 Kidney  
 ---------  
 Pericardium  
 -------  
 -------  
 --------  
 Triple Warmer  
 Gall Bladder  
 Liver  
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Traditional Chinese Medicine enquires 
 (To be completed by a research assistant) 
Instrument 4 
0= None (Dose not have this symptom) 
1= Mild (Have the symptoms once a while and it does not effect daily life) 
2= Moderate (The symptom can cause inconvenience in daily life) 
3= Severe (The symptom effect the performance of daily duties) 
4= Very Severe (The symptoms severely effect the performance of daily duties) 
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Pattern Differentiation of asthma 
syndrome 
0 1 2 3 4 
1.  Wheezing      
2 Cough      
3 Profuse sputum      
4 Shortness of breath      
5 Difficult to inhale      
6 Proximal choking      
7 Shallow breathing      
8 Nasal stuffiness/ blocked      
9 Low resistance to common cold      
10 Aversion to cold      
11 Sticky sputum      
12 Dislike to speak      
13 Low voice      
14 Fullness of chest      
15 Gargling sound in the throat      
16 Spontaneous sweating      
17 Absent of sweating      
18 Distress sensation in epigastric region      
19 Lassitude      
20 Loose stool      
21 Headache      
22 Pale tongue      
23 White coating      
24 Yellow coating      
Lung deficiency 
25 Superficial pulse 
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 1 Abdominal distension after eating      
2 Poor appetite      
3 Pale complexion      
4 Abdominal pain relieved by pressing or 
warmth 
     
5 Dryness of the mouth and throat      
6 Thirst      
7 Heavy limbs      
8 Weakness Of Muscles      
9 Pale plump tongue      
10 Slippery coating      
Spleen  
Deficiency 
11 Weak pulse      
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1 Soreness on the knees and lumbar region      
2 Cold limbs      
3 Dizziness/ vertigo      
4 Deafness      
5 Night sweating      
6 Afternoon fever      
7 Malar flush      
8 Burning sensation in the chest, palm & feet      
9 Chronic cough      
10 Loose tooth      
11 Red tongue:          Delicate:  
 with little fluid: 
     
12 Thready:         rapid Pulse:      
Total Score:      
Kidney 
deficiency 
Average Score:      
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End of visit instructions 
 
Θ Has the participant been given a diary & instructions?  YES ? NO ? 
 
Θ Has the participant been given a peak flow meter shown how to use it? 
 YES ? NO ? 
 
 
 
NEXT APPOINTMENT: VISIT 2 (WEEK 2)  _________________________ 
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CRF: VISIT 2 (WEEK 2) 
 
Date of Assessment   _ _   _ _   _ _(dd/mm/yy) Interviewer: _____________________ 
 
 
Adverse Events 
How have you been feeling lately? ………………………… 
……………………………………………… 
 
Yes  No 
Has the subject suffered any adverse event?   ? ? 
 If yes, please record on AE sheet on page 43 of CRF  
 
 
 
Concurrent medications 
 
Any new medications/vitamins taken since last visit?                          YES?            NO? 
(If YES, list at Concurrent Medication Form on page 47 of CRF)  
 
Current Medical Conditions 
 
Any new medical conditions suffered/diagnosed since last visit?         YES?             NO? 
If Yes, please specify______________________________________________________________ 
_______________________________________________________________________________ 
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ASTHMA THERAPIES 
 
Have you started using any of the following therapies for your asthma? 
 
Therapy 1=Yes 
2=No 
If yes, how often do you use this 
treatment? (indicate if per week/per 
month) 
Acupuncture   
Physiotherapy   
Homeopathy   
Chi Chung   
Yoga (breathing)   
Buteyko Breathing   
Other   
 
Diary 
Has the subject’s diary been checked?    YES?   NO? 
 (Check Asthma Medication Use) 
 (Peak Flow) 
 (Symptom) 
 
 
Study drops 
Has the study preparation been given to subject and instructions given to subject & 
parent/guardian?                                                                 YES?      NO? 
 
Quality of Life Questionnaire 
 
Choice of 2 booklets depending on participant age        1) green:: ages 8-11       ? 
              2) blue:: ages 12-16       ? 
(Questionnaire booklet in clear plastic pocket on next page) 
 
                   Yes     No 
Has the QOL questionnaire been completed?  ?  ? 
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Health Resource Utilization Survey 
 
Hospital Visits 
1. Have you visited a hospital casualty department or emergency room 
Yes No
because of breathing, allergy or skin problems in the past 2 weeks? 
 
 1.1 If yes, how many times? 
 
 
2. Have you spent a night in hospital because of breathing, allergy or skin 
problems in past 2 weeks? Yes No
 
2.1 If yes, how many days have you stayed in hospital because of 
breathing, allergy or skin problems in the last 2 weeks?  
 
2.2  In what sort of ward?  (circle letter) 
A) General Medicine       B) Chest Medicine          C) Rehabilitation 
     D) Intensive Care Unit       E) Other ………………………………………. 
 
Doctor Visits 
 
Have you been seen by a GP because of breathing problems, allergy or 
skin problems in the past 2 weeks? 
Yes No 
If yes, where were you seen & how often? 
  
A) At home (except for emergency visits)        No. of times  _____ 
      B) In the GP’s office or surgery        No. of times  _____ 
           C) At home for an emergency        No. of times  _____ 
 
4. Have you been to see a specialist (chest physician, allergy specialist, skin 
specialist, ENT doctor etc)  because of your breathing problems, allergy or 
skin problems in the past 2 weeks? 
 
 4.1 If yes, how many times?  
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Yes No
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Other Practitioners  
 
5. Have you visited any of the following because of your breathing problems, 
allergy or skin problems in the last 2 weeks? 
 
Yes NoNurse           No. of times ____ 
Physiotherapist            No. of times ____ 
Practitioner of complementary medicine         No. of times ____ 
 
6. Have you had any clinical or laboratory tests because of your breathing, 
allergy or skin problems in the past 2 weeks? (excluding current study) 
 
6.1 If yes, which tests and how often? 
  a)  Respiratory function test No. of times   
  b)  Skin test for allergy  No. of times   
  c)  Blood test for allergy No. of times   
  d)  X-rays  No. of times   _____ 
e) Other  No of times    _____ 
 
School 
 
7. Have you taken any time off school because of your breathing, allergy 
  or skin problems in the past 2 weeks? 
 
7.1 If yes, how much time?      Days 
 
7.2   If yes, when (date)? _________________ 
 
8. Have there been any days when you’ve had to give up activities  
 (e.g. sport, class time etc) because of your breathing, allergy or skin  
 problems in the past 2 weeks? 
 
8.1 If yes, how much time?        Days 
 
 8.2 If yes, when (date)? _________________ 
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Yes No
Yes No
Yes No
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Airways Nitric Oxide Level 
 
 
Spirometry 
 
Last Bronchodilator __________________________________________(type) 
 
          ___________________________________________(date & time) 
 
 
Spirometry result: 
(Printout of spirometry in source document) 
 
1.   Pre bronchodilator 
Best of 3 readings:  FEV1 ??.?? 
       FVC  ??.?? 
 
 
Post bronchodilator 
Best of 3 readings:  FEV1 ??.??  % Change?? 
       FVC  ??.?? 
 
 
 
Is 12% reversibility in FEV1 present?………………………yes ?  no ? 
  
 
 
 
   
   
19
Lung NO Concentration 
 
Measured FENo (ppb) 
1…………….. 
2……………. 
3……………. 
Average FENO (ppb). ………… 
Average VNO (nl/min)……………… 
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Breath Holding Time: _____________________/secs.________ 
 
 
 
Skin prick test 
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Pollen Type 
 
Results 
Diameter 
of wheels 
mm. 
Pollen Type Results  
Diameter of 
wheels 
mm. 
1.Negative Control 
(Saline) 
 
 6. Birch Mix  
2. Ray grass  7. Mould Mix  
3.7 grass mix  8. Ragweed 
mix 
 
 
4. Cat Fur 
 9. Positive 
Control 
Histamine 
(10mg/ml) 
 
 
5. Dog Fur 
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Acupuncture Meridian Function Test 
 
 
Left Side Organs Right Side 
 Lung  
 ---------  
 Large Intestine  
 ------------ 
 
 
 Stomach  
 -----------  
 -----------  
 Spleen  
 Heart  
 Small Intestine  
 Bladder  
 Kidney  
 ---------  
 Pericardium  
 -------  
 -------  
 --------  
 Triple Warmer  
 Gall Bladder  
 Liver  
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Traditional Chinese Medicine enquires 
 (To be completed by research assistant) 
Instrument 4 
0= None (Dose not have this symptom) 
1= Mild (Have the symptoms once a while and it does not effect daily life) 
2= Moderate (The symptom can cause inconvenience in daily life) 
3= Severe (The symptom effect the performance of daily duties) 
4= Very Severe (The symptoms severely effect the performance of daily duties) 
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Pattern Differentiation of asthma 
syndrome 
0 1 2 3 4 
1.  Wheezing      
2 Cough      
3 Profuse sputum      
4 Shortness of breath      
5 Difficult to inhale      
6 Proximal choking      
7 Shallow breathing      
8 Nasal stuffiness/ blocked      
9 Low resistance to common cold      
10 Aversion to cold      
11 Sticky sputum      
12 Dislike to speak      
13 Low voice      
14 Fullness of chest      
15 Gargling sound in the throat      
16 Spontaneous sweating      
17 Absent of sweating      
18 Distress sensation in epigastric region      
19 Lassitude      
20 Loose stool      
21 Headache      
22 Pale tongue      
23 White coating      
24 Yellow coating      
Lung deficiency 
25 Superficial pulse 
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 1 Abdominal distension after eating      
2 Poor appetite      
3 Pale complexion      
4 Abdominal pain relieved by pressing or 
warmth 
     
5 Dryness of the mouth and throat      
6 Thirst      
7 Heavy limbs      
8 Weakness Of Muscles      
9 Pale plump tongue      
10 Slippery coating      
Spleen  
Deficiency 
11 Weak pulse      
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1 Soreness on the knees and lumbar region      
2 Cold limbs      
3 Dizziness/ vertigo      
4 Deafness      
5 Night sweating      
6 Afternoon fever      
7 Malar flush      
8 Burning sensation in the chest, palm & feet      
9 Chronic cough      
10 Loose tooth      
11 Red tongue:          Delicate:  
 with little fluid: 
     
12 Thready:         rapid Pulse:      
Total Score:      
Kidney 
deficiency 
Average Score:      
Protocol Code: SP#007 & Project No: 4-04 Maxwell                                     Subject Number ???                        
   
   
24
 
 
End of visit instructions 
 
Θ Is  the participant eligible to begin study medication based on the spirometry 
result?            
YES ?  NO ? 
 
If yes, has the participant been given the study drops & instructions?  
     
 
YES ?  NO ? 
 
 
 
 
 
 
 
 
 
NEXT CONTACT-WEEK 6 TELEPHONE CALL approximate  
 
date____________            _ 
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TELEPHONE FOLLOW UP 
(WEEK 6) 
 
Date of Telephone call  _ _   _ _   _ _(dd/mm/yy) Interviewer: ________________ 
 
 
Adverse Events 
How have you been feeling lately? ………………………… 
……………………………………………… 
 
Yes                  No 
Has the subject suffered any adverse event?   ?          ? 
 If yes, please record on AE sheet on page 43 of CRF  
 
 
 
Concurrent medications 
 
Any new medications/vitamins taken since last visit?                          YES?            NO? 
(If YES, add to Concurrent Medication Form on page47 of CRF)  
 
Current Medical Conditions 
 
Any new medical conditions suffered/diagnosed since last visit?         YES?             NO? 
If Yes, please specify______________________________________________________________ 
_______________________________________________________________________________ 
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ASTHMA THERAPIES 
 
Have you started using any of the following therapies for your asthma since visit 4 weeks 
ago? 
 
Therapy 1=Yes 
2=No 
If yes, how often do you use this 
treatment? (indicate if per week/per 
month) 
Acupuncture   
Physiotherapy   
Homeopathy   
Chi Chung   
Yoga (breathing)   
Buteyko Breathing   
Other   
 
 
Diary 
Is the subject or parent recording in diary every day?      YES?     NO? 
 (Check Asthma Medication Use, Peak Flow & symptoms for past day) 
 
 
Compliance of Study drops 
 
Quantity of drops used so far: ……………………………………………………………………….. 
 
 
Quality of Life Questionnaire 
 
Choice of 2 booklets depending on participant age        1) green:: ages 8-11       ? 
              2) blue:: ages 12-16       ? 
(Questionnaire booklet in clear plastic pocket on next page) 
 
                                 Yes   No 
Has the QOL questionnaire been completed?                    ?        ? 
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Health Resource Utilization Survey 
 
Hospital Visits 
1. Have you visited a hospital casualty department or emergency room 
Yes No because of breathing, allergy or skin problems in the past 4 weeks? 
 
 1.1 If yes, how many times? 
 
 
2. Have you spent a night in hospital because of breathing, allergy or skin 
problems in past 4 weeks? Yes No
 
2.1 If yes, how many days have you stayed in hospital because of 
breathing, allergy or skin problems in the last 4 weeks?  
 
2.2 In what sort of ward?  (circle letter) 
A) General Medicine       B) Chest Medicine          C) Rehabilitation 
     D) Intensive Care Unit       E) Other ………………………………………. 
 
Doctor Visits 
 
3. Have you been seen by a GP because of breathing problems, allergy or 
skin problems in the past 4 weeks? 
Yes No 
3.1 If yes, where were you seen & how often? 
  
A) At home (except for emergency visits)        No. of times  _____ 
      B) In the GP’s office or surgery        No. of times  _____ 
           C) At home for an emergency        No. of times  _____ 
 
 
 
4. Have you been to see a specialist (chest physician, allergy specialist, skin 
specialist, ENT doctor etc)  because of your breathing problems, allergy or 
skin problems in the past 4 weeks? Yes No
 
4.1 If yes, how many times?  
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Other Practitioners  
 
5. Have you visited any of the following because of your breathing problems, 
allergy or skin problems in the last 4 weeks? Yes No
 
Nurse           No. of times ____ 
Physiotherapist            No. of times ____ 
Practitioner of complementary medicine         No. of times ____ 
 
6. Have you had any clinical or laboratory tests because of your breathing, 
allergy or skin problems in the past 4 weeks? (excluding current study) 
Yes No 
6.1 If yes, which tests and how often? 
  a)  Respiratory function test No. of times   
  b)  Skin test for allergy  No. of times   
  c)  Blood test for allergy No. of times   
  d)  X-rays  No. of times   _____ 
e) Other  No of times    _____ 
 
School 
 
7. Have you taken any time off school because of your breathing, allergy 
Yes No  or skin problems in the past 4 weeks? 
 
 
7.1 If yes, how much time?      Days  
 
 7.2   If yes, when (date)? _________________ 
 
8. Have there been any days when you’ve had to give up activities  
 (e.g. sport, class time etc) because of your breathing, allergy or skin  
 problems in the past 4 weeks? 
 
8.1 If yes, how much time?  (hrs)      
Days 
 
 8.2   If yes, when (date)? _________________ 
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TELEPHONE FOLLOW UP 
(WEEK 10) 
 
Date of Telephone call  _ _   _ _   _ _(dd/mm/yy) Interviewer: ________________ 
 
 
Adverse Events 
How have you been feeling lately? ………………………… 
……………………………………………… 
 
 
Has the subject suffered any adverse event?    
 If yes, please record on AE sheet on page 43 of CRF  
 
 
 
Concurrent medications 
                                                                                                 
Any new medications/vitamins taken since last visit?                           
(If YES, add to Concurrent Medication Form on page 47 of CRF)  
 
Current Medical Conditions 
                                                                                                                                      
Any new medical conditions suffered/diagnosed since last visit?                            
If Yes, please specify______________________________________________________________ 
_______________________________________________________________________________ 
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Yes No
  
Yes No
  
Yes No
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ASTHMA THERAPIES 
 
Have you started using any of the following therapies for your asthma since visit 4 weeks 
ago? 
 
Therapy 1=Yes 
2=No 
If yes, how often do you use this 
treatment? (indicate if per week/per 
month) 
Acupuncture   
Physiotherapy   
Homeopathy   
Chi Chung   
Yoga (breathing)   
Buteyko Breathing   
Other   
 
 
Diary 
Is the subject or parent recording in diary every day?      YES?     NO? 
 (Check Asthma Medication Use, Peak Flow & symptoms for past day) 
 
 
Compliance of Study drops 
 
Quantity of drops used so far: ……………………………………………………………………….. 
 
 
Quality of Life Questionnaire 
 
Choice of 2 booklets depending on participant age        1) green:: ages 8-11       ? 
              2) blue:: ages 12-16       ? 
(Questionnaire booklet in clear plastic pocket on next page) 
 
                         Yes   No 
Has the QOL questionnaire been completed?                       ?        ? 
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Health Resource Utilization Survey 
 
Hospital Visits 
1. Have you visited a hospital casualty department or emergency room 
Yes No because of breathing, allergy or skin problems in the past 4 weeks? 
 
 1.1 If yes, how many times? 
 
2. Have you spent a night in hospital because of breathing, allergy or skin 
problems in past 4 weeks? Yes No
 
2.1 If yes, how many days have you stayed in hospital because of 
breathing, allergy or skin problems in the last 4 weeks?  
 
2.2.In what sort of ward?  (circle letter) 
A) General Medicine       B) Chest Medicine          C) Rehabilitation 
D) Intensive Care Unit       E) Other ………………………………………. 
 
Doctor Visits 
 
   
   
31
3. Have you been seen by a GP because of breathing problems, allergy or   
skin problems in the past 4 weeks? 
 Yes oN
3.1 If yes, where were you seen & how often? 
  
A) At home (except for emergency visits)        No. of times  _____ 
      B) In the GP’s office or surgery        No. of times  _____ 
           C) At home for an emergency        No. of times  _____ 
 
4. Have you been to see a specialist (chest physician, allergy specialist, skin 
specialist, ENT doctor etc)  because of your breathing problems, allergy or 
skin problems in the past 4 weeks? 
 
 
4.1 If yes, how many times?  
Other Practitioners  
 Yes No
Yes No
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5. Have you visited any of the following because of your breathing problems, 
allergy or skin problems in the last 4 weeks? 
 
Nurse           No. of times ____ 
Physiotherapist            No. of times ____ 
Practitioner of complementary medicine         No. of times ____ 
 
6. Have you had any clinical or laboratory tests because of your breathing, 
allergy or skin problems in the past 4 weeks? (excluding current study) 
 
6.1 If yes, which tests and how often? 
  a)  Respiratory function test No. of times   
  b)  Skin test for allergy  No. of times   
  c)  Blood test for allergy No. of times   
  d)  X-rays  No. of times   _____ 
e) Other  No of times    _____ 
 
School 
 
7. Have you taken any time off school because of your breathing, allergy 
  or skin problems in the past 4 weeks? 
 
 
7.1 If yes, how much time?      Days 
 
 7.2   If yes, when (date)? _________________ 
 
8. Have there been any days when you’ve had to give up activities  
 (e.g. sport, class time etc) because of your breathing, allergy or skin  
 problems in the past 4 weeks? 
 
8.1 If yes, how much time?        Days 
 
8.2 If yes, when (date)? _________________ 
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Yes No
Yes No
Yes No
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End of Week 10 phone call: 
 
Make appointment for 3rd (final) visit 
 
Appointment will be due around…………………………………………..  
 
 
 
Has an appointment been made for Week 14 visit…………YES ?  NO ? 
 
Date: _______________________  Time____________ 
 
Location________________________________________ 
 
Date Appmt slip sent: _______________   Initials _____________ 
 
 
 
Θ Remind parent to bring diary & left over drops to last visit 
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CRF: VISIT 3 (WEEK 14) 
 
Date of Assessment   _ _   _ _   _ _(dd/mm/yy) Interviewer: _____________________ 
 
 
Adverse Events 
How have you been feeling lately? ………………………… 
……………………………………………… 
 
Yes          No 
Has the subject suffered any adverse event?   ?      ? 
 If yes, please record on AE sheet on page 43 of CRF  
 
 
 
Concurrent medications 
 
Any new medications/vitamins taken since last visit?                          YES?            NO? 
(If YES, add to Concurrent Medication Form on page 47 of CRF)  
 
 
 
Current Medical Conditions 
 
Any new medical conditions suffered/diagnosed since last visit?         YES?             NO? 
If Yes, please specify______________________________________________________________ 
_______________________________________________________________________________ 
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ASTHMA THERAPIES 
Have you started using any of the following therapies for your asthma? 
 
Therapy 1=Yes 
2=No 
If yes, how often do you use this 
treatment? (indicate if per week/per 
month) 
Acupuncture   
Physiotherapy   
Homeopathy   
Chi Chung   
Yoga (breathing)   
Buteyko Breathing   
Other   
 
Diary 
Has the subject’s diary been checked for errors?  YES?   NO? 
 
Has the subject’s diary been collected?   YES?   NO? 
 
Left-over Study drops 
Has the study preparation been returned?                          YES?      NO? 
Left-over Quantity …………………………… 
 
Quality of Life Questionnaire 
 
Choice of 2 booklets depending on participant age        1) green:: ages 8-11       ? 
              2) blue:: ages 12-16       ? 
(Questionnaire booklet in clear plastic pocket on next page) 
 
                   Yes     No 
Has the QOL questionnaire been completed?  ?  ? 
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Health Resource Utilization Survey 
 
Hospital Visits 
Yes No
1. Have you visited a hospital casualty department or emergency room 
 because of breathing, allergy or skin problems in the past 4 weeks? 
 
 1.1 If yes, how many times? 
 
Yes No
 
2. Have you spent a night in hospital because of breathing, allergy or skin 
problems in past 4 weeks? 
 
2.1 If yes, how many days have you stayed in hospital because of 
breathing, allergy or skin problems in the last 4 weeks?  
 
a.  In what sort of ward?  (circle letter) 
A) General Medicine       B) Chest Medicine          C) Rehabilitation 
     D) Intensive Care Unit       E) Other ………………………………………. 
 
Doctor Visits 
3. Have you been seen by a GP because of breathing problems, allergy 
or 
Yes Noskin problems in the past 4 weeks? 
 
3.1 If yes, where were you seen & how often? 
  
A) At home (except for emergency visits)        No. of times  _____ 
      B) In the GP’s office or surgery        No. of times  _____ 
           C) At home for an emergency        No. of times  _____ 
4. Have you been to see a specialist (chest physician, allergy specialist, skin 
specialist, ENT doctor etc)  because of your breathing problems, allergy or 
skin problems in the past 4 weeks? 
   
 Yes NoIf yes, how many times?  
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Other Practitioners  
 
Yes No
5. Have you visited any of the following because of your breathing problems, 
allergy or skin problems in the last 4 weeks? 
 
Nurse           No. of times ____ 
Physiotherapist            No. of times ____ 
Practitioner of complementary medicine         No. of times ____ 
 
6. Have you had any clinical or laboratory tests because of your breathing, 
allergy or skin problems in the past 4 weeks? (excluding current study) 
Yes No 
6.1 If yes, which tests and how often? 
  a)  Respiratory function test No. of times   
  b)  Skin test for allergy  No. of times   
  c)  Blood test for allergy No. of times   
  d)  X-rays  No. of times   _____ 
e) Other  No of times    _____ 
School 
 
7. Have you taken any time off school because of your breathing, allergy 
Yes No  or skin problems in the past 4 weeks? 
 
 
7.1 If yes, how much time?      Days  
 
 7.2   If yes, when (date)? _________________ 
 
8. Have there been any days when you’ve had to give up activities  
 (e.g. sport, class time etc) because of your breathing, allergy or skin  Yes No
 problems in the past 4 weeks? 
 
8.1 If yes, how much time?        Days  
 
 8.2   If yes, when (date)? _________________ 
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Airways Nitric Oxide Level 
 
 
 
 
Spirometry 
 
 
Last Bronchodilator __________________________________________(type) 
 
          ___________________________________________(date & time) 
 
 
Spirometry result: 
(Printout of spirometry in source document) 
 
1.   Pre bronchodilator 
Best of 3 readings:  FEV1 ??.?? 
       FVC  ??.?? 
 
 
Post broncholdilator 
Best of 3 readings:  FEV1 ??.??  % Change?? 
       FVC  ??.?? 
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Lung NO Concentration 
 
Measured FENo (ppb) 
1…………….. 
2……………. 
3……………. 
Average FENO (ppb). ………… 
Average VNO (nl/min)……………… 
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Breath Holding Time: _____________________________ 
 
 
 
 
Acupuncture Meridian Function Test 
Left Side Organs Right Side 
 Lung  
 ---------  
 Large Intestine  
 ------------ 
 
 
 Stomach  
 -----------  
 -----------  
 Spleen  
 Heart  
 Small Intestine  
 Bladder  
 Kidney  
 ---------  
 Pericardium  
 -------  
 -------  
 --------  
 Triple Warmer  
 Gall Bladder  
 Liver  
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Traditional Chinese Medicine enquires 
 (To be completed by a research assistant) 
Instrument 4 
0= None (Dose not have this symptom) 
1= Mild (Have the symptoms once a while and it does not effect daily life) 
2= Moderate (The symptom can cause inconvenience in daily life) 
3= Severe (The symptom effect the performance of daily duties) 
4= Very Severe (The symptoms severely effect the performance of daily duties) 
 
CHINESE MEDICINE QUESTIONNAIRE 
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Pattern Differentiation of asthma 
syndrome 
0 1 2 3 4 
1.  Wheezing      
2 Cough      
3 Profuse sputum      
4 Shortness of breath      
5 Difficult to inhale      
6 Proximal choking      
7 Shallow breathing      
8 Nasal stuffiness/ blocked      
9 Low resistance to common cold      
10 Aversion to cold      
11 Sticky sputum      
12 Dislike to speak      
13 Low voice      
14 Fullness of chest      
15 Gargling sound in the throat      
16 Spontaneous sweating      
17 Absent of sweating      
18 Distress sensation in epigastric region      
19 Lassitude      
20 Loose stool      
21 Headache      
22 Pale tongue      
23 White coating      
24 Yellow coating      
Lung deficiency 
25 Superficial pulse 
 
 
 
     
1 Abdominal distension after eating      
2 Poor appetite      
3 Pale complexion      
4 Abdominal pain relieved by pressing or 
warmth 
     
5 Dryness of the mouth and throat      
6 Thirst      
7 Heavy limbs      
8 Weakness Of Muscles      
9 Pale plump tongue      
10 Slippery coating      
Spleen  
Deficiency 
11 Weak pulse      
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1 Soreness on the knees and lumbar region      
2 Cold limbs      
3 Dizziness/ vertigo      
4 Deafness      
5 Night sweating      
6 Afternoon fever      
7 Malar flush      
8 Burning sensation in the chest, palm & feet      
9 Chronic cough      
10 Loose tooth      
11 Red tongue:          Delicate:  
 with little fluid: 
     
12 Thready:         rapid Pulse:      
Total Score:      
Kidney 
deficiency 
Average Score:      
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NON SERIOUS ADVERSE EVENTS FORM 
Did the subject experience any non-serious adverse events during the study?      Yes ? No ?         If YES, Indicate below 
 
Further details ……………………………………………………………………………………………………………… 
      ………………………………………………………………………………………………………………… 
 
NON SERIOUS ADVERSE EVENTS FORM (continued) 
      43 
Non-serious 
Adverse Event 
Date of 
Onset 
Maximum 
Intensity 
Outcome Date of 
Resolution 
Action taken 
with study 
preparation 
as a result of 
the NSAE 
With-
drawal 
Relationshi
p to study 
preparatio
n 
Seriousnes
s 
Initials 
and 
Date of  
Entry 
Diagnosis(if known ) 
or signs / symptoms 
dd/mmm/yy 1=Mild 
2=Moderate 
3=Severe 
X=Not 
applicable 
R=Resolved 
S=Resolved 
with sequelae 
N=Not 
resolved or 
continuing 
dd/mmm/yy 0=None 
1=Dose 
adjustment 
2=Temporarily 
Interrupted 
3=Permanent 
discontinuation 
X=Not applicble 
Did the 
subject 
withdrawal as 
a result of this 
NSAE? 
 
Y=Yes 
N=No 
Relationship: 
1=Definitely, 
2=Probably, 
3=Possibly, 
4=Unrelated 
Does the AE 
meet the 
definition of 
serious? 
Y=Yes 
N=No 
If Yes, fill 
out an SAE 
form 
 
e.g.    Headache 
 
25 JAN 04 3 R 26 JAN 04 0 N 4 N NK 
28 JAN04 
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Did the subject experience any non-serious adverse events during the study?      Yes ? No ?          If YES, Indicate 
below 
 
Non-serious 
Adverse Event 
Date of 
Onset 
Maximum 
Intensity 
Outcome Date of 
Resoluti
on 
Action taken 
with study 
preparation 
as a result of 
the NSAE 
With-
drawal 
Relationshi
p to study 
preparatio
n 
Seriousness Initials 
and 
Date of  
Entry 
Diagnosis(if known ) or 
signs / symptoms 
dd/mmm/yy 1=Mild 
2=Moderate 
3=Severe 
X=Not 
applicable 
R=Resolved 
S=Resolved 
with sequelae 
N=Not 
resolved or 
continuing 
dd/mmm/y
y 
0=None 
1=Dose 
adjustment 
2=Temporarily 
Interrupted 
3=Permanent 
discontinuation 
X=Not applicble 
Did the 
subject 
withdrawal as 
a result of this 
NSAE? 
 
Y=Yes 
N=No 
Relationship: 
1=Definitely, 
2=Probably, 
3=Possibly, 
4=Unrelated 
Does the AE 
meet the 
definition of 
serious? 
Y=Yes 
N=No 
If Yes, fill out 
an SAE form 
 
e.g.    Headache 
 
25 JAN 04 3 R 26 JAN 
04 
0 N 4 N NK 
28 JAN 04 
 
 
         
 
 
         
          
 
 
         
 
Further details ……………………………………………………………………………………………………………… 
 
 
SERIOUS ADVERSE EVENTS FORM 
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Did the subject experience any serious adverse events during the study?      Yes ?     No?    If YES, Indicate below 
 
Serious 
Adverse Event 
Date of 
Onset 
Maximum 
Intensity 
Outcome Date of 
Resoluti
on or 
death 
Action taken 
with study 
preparation as 
a result of the 
NSAE 
Withdraw
al 
Relationsh
ip to study 
preparatio
n 
Seriousnes
s 
Signature 
And 
Date of  
Entry 
Diagnosis (if 
known ) or signs / 
symptoms 
dd/mmm/yy 1=Mild 
2=Moderate 
3=Severe 
X=Not 
applicable 
R=Resolved 
S=Resolved 
with 
sequelae 
F=Fatal 
N=Not 
resolved 
dd/mmm/yy 0=None 
1=Dose 
adjustment 
2=Temporarily 
Interrupted 
3=Permanent 
discontinuation 
X=Not applicable 
Did the 
subject 
withdrawal as 
a result of this 
SAE? 
 
Y=Yes 
N=No 
Is there a 
reasonable 
possibility 
that the SAE 
may have 
been caused 
by the study 
preparation? 
Does the AE 
meet the 
definition of 
serious? 
Y=Yes 
 
 
e.g.    
Anaphylaxis 
 
25 JAN 
04 
3 R 26 JAN 
04 
3 Y Y Y NK 
26 JAN 04 
 
 
 
         
 
 
 
         
 
Further details 
……………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………….. 
SERIOUS ADVERSE EVENTS FORM 
 
Did the subject experience any serious adverse events during the study?      Yes ?     No?    If YES, Indicate below 
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Serious 
Adverse Event 
Date of 
Onset 
Maximu
m 
Intensity 
Outcome Date of 
Resolutio
n or 
death 
Action taken 
with study 
preparation as 
a result of the 
NSAE 
Withdraw
al 
Relationsh
ip to study 
preparatio
n 
Seriousnes
s 
Signature 
And 
Date of  
Entry 
Diagnosis (if 
known ) or signs / 
symptoms 
dd/mmm/yy 1=Mild 
2=Moderate 
3=Severe 
X=Not 
applicable 
R=Resolved 
S=Resolved 
with 
sequelae 
F=Fatal 
N=Not 
resolved 
dd/mmm/yy 0=None 
1=Dose 
adjustment 
2=Temporarily 
Interrupted 
3=Permanent 
discontinuation 
X=Not applicable 
Did the 
subject 
withdrawal 
as a result of 
this SAE? 
 
Y=Yes 
N=No 
Is there a 
reasonable 
possibility 
that the SAE 
may have 
been caused 
by the study 
preparation? 
Does the AE 
meet the 
definition of 
serious? 
Y=Yes 
 
 
e.g.    
Anaphylaxis 
 
25 JAN 
04 
3 R 26 JAN 
04 
3 Y Y Y NK 
26 JAN 04 
 
 
 
         
 
 
 
         
Further details 
………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………….
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CONCOMITANT MEDICATIONS 
 
DATE DRUG 
 
DOSE INDICATION START 
DATE 
STOP 
DATE 
ON 
GOING 
INITIALS 
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CONCOMITANT MEDICATIONS Continued 
 
DATE DRUG 
 
DOSE INDICATION START 
DATE 
STOP 
DATE 
ON 
GOING 
INITIALS 
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End of visit instructions 
 
Θ Thank participant & parent for being part of the trial 
 
Θ Tell them about end of study letter (may take few months to be sent) 
 
STUDY TERMINATION FORM 
 
Has the subject completed the study according to the protocol?  
Yes    
No      
 
If No, select one of the following: 
  the subject did not wish to continue in the study 
  the subject developed a significant concurrent illness 
  other change in inclusion/exclusion criteria (please specify) 
 the subject did not comply with the protocol and/or study staff 
 unacceptable adverse events 
 other______________________________________________________ 
 
Additional comments 
_____________________________________________________________ 
 
_____________________________________________________________ 
 
_____________________________________________________________ 
 
 
Principal Investigator’s 
Signature:________________________________________________ 
 
Date:_______________
Protocol Code: SP#007, 4-04 Maxwell                                               Subject Number 
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Appendix 5 
Childhood Asthma Questionnaire Form B 
& 
Childhood Asthma Questionnaire Form C 



















  
 
 
 
 
Appendix 6: Daily Diary 
(Weeks: 1-14)
                                                               Herbal trial for asthma in children 
DAILY DIARY 
 
Weeks 1-14 
 
 
 
 
Subject Number………………       Initials……………. 
    
Date received diary  ___ / ___ / ___ 
 
 
 
 
 
 
 
General Instructions  
 
• You can start the diary the morning after your first visit to RMIT West Bundoora 
Campus 
 
During this trial you need to: 
 
1. Record the severity of your child’s asthma symptoms 
2. Weeks 3-14 - record when your child uses the trial drops by ticking in the box (or 
placing a ‘x’ in the box if the drops are missed) 
3. Record any asthma medications or other types of medications taken. 
4. Record any changes to your child’s health (eg: influenza, hayfever) or other 
general comments for each week at the bottom of the page. 
5. Record Peak Flow Measurements morning and evening 
 
 
Please note: 
* If your need more room you can write on the back of this booklet or on a separate piece of 
paper and attach it at the appropriate place. 
* If you forget to enter the details for one day on the chart, think back and try to fill them in as 
accurately as possible.  
* Please bring the Diary with you to every visit; it will be collected at the end of the trial. 
 
 
 
 
Asthma Study 
RMIT University, Complementary Medicine 
West Bundoora Campus, Chinese Medicine 
Clinical Trial Laboratory Level4 (202.4.58) 
RMIT University 
GPO Box 2476V Melbourne 3001 Vic. Investigator: 
Prof. Marc Cohen    Ph: 9925-7440 
Trial Co-ordinator: Sheena Maxwell Ph: 9925-7584 
 
If found please return to the above address 
                                                               Herbal trial for asthma in children 
Symptom Scores 
 
The symptom score for your child’s asthma is a single number ranging from 0 to 5.  An 
explanation of each number is given on every page of the diary. Please record the single 
number in the unshaded box under the appropriate day each morning.   
Symptoms of asthma include: 
 
♦ Difficulty in breathing, Wheezing, Chest tightness, and Coughing 
 
Other Medical Problems (Please write down any other medical problems, 
particularly any signs and symptoms of colds, infections, sore throat, runny nose 
etc.) 
 
Eg. DATE: 5/7/04 Runny Nose 
 
 
Medications 
 
All your Child’s asthma medications need to be recorded in the Diary.  Please record the 
name of the medication, it’s strength and the number of doses taken (that is the number 
of individual inhalations/tablets) since the last morning or evening record. 
Please also list the names of any other medications your child has taken, their strength 
in milligrams/micrograms per tablet/inhalation and number of doses taken.  The label on 
the box/bottle will have the strength.  
 
                                           Day           1        2       3       4       5          6          7 
 
 
 
 
 
 
 
 
 
 
Thanks again for assisting us with this medical research. 
Your time and effort are greatly appreciated!
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Name of asthma medication Strength                       Total no. of doses for day 
 Ventolin 100mcg 0 1 1 4 3 2 1 
          
 Pulimcort 200mcg 1 1 0 1 1 1 1 
          
OTHER MEDICATIONS Strength                      Total no. of doses for the day 
Panadol (Headache) 500mg 1 0 2 0 0 1 0 
         
If your require assistance with completing this Diary Card or a  
replacement, please call: 
? Sheena Maxwell on 9925-7584/9440-1862 
                                                               Herbal trial for asthma in children 
DIARY - WEEK 1 
 
SYMPTOM SCORES  DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 
How was your asthma last night? 
(Enter the number from list below that indicates how 
bad your  asthma was) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record). Name of asthma medication 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
OTHER (NON-ASTHM A) 
MEDICATIONS  
Strength  Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) 
(Place a x in box if not measured) 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 5 Day 7 
AM (L/min)        
PM (L/min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and symptoms 
of colds, infections, sore throat, runny nose etc) 
Date:  
Date: 
Date: 
Date: 
 
 
 
 
                                                               Herbal trial for asthma in children 
 
DIARY - WEEK 2 
 
SYMPTOM SCORES  DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 
How was your asthma last night? 
(Enter the number from list below that indicates how 
bad your  asthma was) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record). Name of asthma medication 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
OTHER (NON-ASTHM A) 
MEDICATIONS  
Strength  Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) 
(Place a x in box if not measured) 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 5 Day 7 
AM (L/min)        
PM (L/min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and symptoms 
of colds, infections, sore throat, runny nose etc) 
Date:  
Date: 
Date: 
Date: 
 
                                                               Herbal trial for asthma in children 
DIARY – WEEK 3 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
 
DIARY – WEEK 4 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
 
Day 1 
 
 
Day 2 
 
 
 
Day 3 
 
 
Day 4 
 
 
Day 5 
 
 
Day 6 
 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
DIARY – WEEK 5 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
 
DIARY – WEEK 6 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
 
DIARY – WEEK 7 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
 
DIARY-WEEK 8 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
 
DIARY – WEEK 9 
 
 
SYMPTOM SCORE  
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
 
1 
 
 
Day 2 
 
 
Day 3 
 
 
Day 4 
 
 
Day 5 
 
 
Day 6 
 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
 
DIARY – WEEK 10 
 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
DIARY – WEEK 11 
 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
DIARY – WEEK 12 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
DIARY – WEEK 13 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
                                                               Herbal trial for asthma in children 
DIARY – WEEK 14 
 
 
 
 
SYMPTOM SCORES 
W E E K B E GIN N I N G :  __  /  __  /  __   (ENTER DATE )      
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
Tick the box when you use the drops            a.m 
(If you miss a dose place a ‘ x ‘ in the box)           p.m 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
How was your asthma last night?  
(Enter the number that indicates how bad your 
asthma was –see code below) 
       
0= NO SYMPTOMS DURING THE NIGHT 
1=SYMPTOMS FOR ONE SHORT PERIOD DURING THE NIGHT 
2=SYMPTOMS CAUSING YOU TO WAKE ONCE OR WAKE EARLY 
3=SYMPTOMS CAUSING YOU TO WAKE TWICE OR MORE (INCLUDING WAKING EARLY) 
4=SYMPTOMS CAUSING YOU TO BE AWAKE FOR MOST OF THE NIGHT 
5=SYMPTOMS SO BAD THAT YOU DID NOT SLEEP AT ALL 
ASTHMA MEDICATIONS (Please list preventer and reliever medications) 
Strength   Total no. of puffs for the previous night (since last evening record) Name of asthma medication 
eg. Ventolin/Pulmicort  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
          
          
          
          
OTHER MEDICATIONS Strength Number of Doses taken 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
         
         
         
PEAK FLOW MEASUREMENTS (PEFR) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
AM (L/Min)        
PM (L/Min)        
OTHER MEDICAL PROBLEMS   (Please write down any other medical problems, particularly any signs and 
symptoms of colds, infections, sore throat, runny nose etc) 
Date: 
Date: 
Date: 
Date: 
  
 
 
 
Appendix 7 
 
Tables of Collected Data 
Patient_ID Random. NO Gender Age Height Weight V1.Pre.FEV1 V1. Pre FVC V1postFEV1
1 B 2 8 114 18 0.96 1.01 1.12
2 A 2 11 144 57 1.64 2.17 1.84
3 A 1 14 180 64 3.75 5.07 4.25
4 B 1 16 145 71 4.21 4.65 4.44
5 A 1 12 147 47 2.19 2.66 2.54
6 B 2 9 142 39 1.55 2.36 1.97
7 A 2 11 142 37 2.26 2.59 2.41
8 B 1 9 125 25 1.55 2.07 1.82
9 B 1 8 128 25 1.7 2.11 2.24
10 A 2 11 139 36 2.23 2.25 2.22
12 B 2 13 153 45 2.81 3.23 2.81
14 A 1 12 165 50 2.8 3.48 2.99
17 B 2 12 163 50 3.09 4.02 3.41
19 A 2 14 154 69 2.24 2.67 2.59
20 A 1 10 140 42 1.76 2.07 2.2
21 A 2 15 169 52 1.55 2.63 2.22
22 B 2 8 120 24 1.29 1.54 1.51
23 B 2 13 160 50 2.28 2.92 2.45
24 B 1 8 135 30 1.66 2.11 1.9
25 B 1 11 151 50 2.24 2.76 2.62
26 B 1 10 151 35 2.16 2.48 2.28
27 A 1 14 166 67 3.77 4.63 4.16
28 B 1 16 172 55 3.6 4.02 3.75
30 A 1 10 151 51 2.13 2.91 2.33
32 A 2 10 140 40 1.67 2.08 1.93
33 A 1 10 148 36 2.03 2.87 2.52
36 A 1 13 152 37 2.06 2.51 2.3
37 B 2 13 173 53 3.02 3.73 3.17
39 B 1 10 141 33 1.76 2.4 1.9
31a B 1 13 156 56 2.59 3.27 25.02
32a A 1 9 140 40 2.65 3.08 3.293
33a A 1 8 142 32 1.72 2.43 1.844
34a B 1 14 173 49 2.41 2.66 2.706
35a B 1 8 133 27 1.37 1.62 1.667
36a A 1 13 153 43 2.94 3.09 3.86
37a A 2 10 152 59 1,69 1.76 1.816
V1 Post FVC V3preFEV1 V3preFVC V3postFEV1 V3postFVC FEV1%ChangeV3FEV1%Change W1diapekflowam ave
1.12 18%
2.25 1.87 2.23 2.27 2.4 12% 22% 278.5714
5.26 4 5.33 4.44 5.39 13% 11% 344.2857
4.7 4.65 4.76 4.71 4.71 5% 1% 395
2.62 2.36 2.8 2.59 2.95 16% 10% 321.4286
2.39 1.59 2.08 2.08 2.57 27% 31% 115.5
2.62 2.38 2.64 2.45 2.64 7% 3% 329.2857
2.11 1.59 2.09 1.87 2.23 17% 18% 192.8571
1.88 1.86 2.3 1.93 2.23 11% 4% 190
2.27 2.24 2.39 2.3 2.41 1% 3% 290
3.23 2.64 3.09 2.94 3.36 0% 11% 395.7142
3.5 2.78 3.53 3.09 3.59 7% 11% 366.66
4.22 3.07 4.01 3.47 4.22 10% 13% 271.428
2.98 2.24 2.72 2.43 2.89 16% 8% 354.2857
2.46 1.85 2.18 1.95 2.21 25% 6% 296.66
3.21 0.188 2.94 2.33 3.1 43% 24% 280
159 1.13 1.46 1.34 1.61 17% 18% 187.1428
3.11 1.9 2.86 2.31 3.07 7% 21% 308.5714
2,2 1.74 2.07 1.87 2.11 14% 7% 263.33
3.08 17% 265.7142
2.6 5%
4.75 3.84 4.99 4.07 4.9 11% 6% 495.714
4.15 3.63 4.29 3.66 4.29 4% 1% 478.33
3.05 2.25 3.07 1.91 2.97 10% -15% 335
2.19 2.03 2.33 2.01 2.37 15% -1% 251.66
2.85 2.28 2.97 2.67 3.09 25% 17% 308.33
2.58 1.95 2.7 2.23 2.76 12% 14% 274.166
3.67 999 999 999 999 5% 999 0
2.35 1.76 2.33 1.95 2.37 8% 11% 252.142
33.23 2.23 339.2857
3.451 1.62 2.311 2.304 2.304 257.14
2.23 1.625 2.115 1.737 2.038 7.50% 6.90% 194
3.169 0
1.749 3.25 140.7
3.323 3.258 3.498 3.337 3.538 500
1.855 0
W1dipekflowpmaver W14diapeflowamaver W14di peflowpmaver W1ditotpf W14ditotpf W1diasympadscor W14disympadscos
0
284.285 252.85 253.33 46 34 1
348.571 381.42 378.57 28 28 9 1
400 490 507.14 12 4 2 2
350.833 364.28 345.71 70 102 3 2
137.5 155.71 132.85 13 0 11 4
333 371.66 376.66 0 0 0 99
199.2857 215 213.33 28 28 0 0
188.5714 213.33 214.16 0 0 4 1
306.2857 286.5 299 17 6 4 3
417.142 401.42 465 32 27 10 11
375 390 386.66 7 7 0 0
264.2857 371.42 371.42 14 28 2 3
349.5714 392.14 404.28 44 34 4 0
300 282.85 83.3 16 0 4 0
322.8571 333.3 356.6 16 34 17 19
198.5714 152.85 151.42 72 84 4 9
354.4285 328.57 359.28 35 40 5 16
250 262 272 8 4 2 99
242 238.57 245.71 58 4 6 3
0 99
472.142 504.28 511.66 28 32 5 0
481.66 500 496.66 14 14 0 0
320.7142 321 318.57 41 0 9 6
258.33 280 34 52 3 8
333.33 286.66 257.5 13 3 3 0
310.714 283 295 22 1 2 0
0 99
257.5 220 225 28 6 1 0
344.285 3 0 0 0
277.857 271.42 274.28 3 21 0 0
195 161.42 163.57 7 7 0 0
0 0
170 182.14 181.57 15 7 2 3
499 4 10 1 1
0 99
V1Quest score V3Quest score AQoLV1 AQoLV3 PQoLV1 PQoLV3 Negative Cat Dog Dustmte
120 28 17 0 0 0 7
111 105 20 17 18 18 0 8 0 8
98 113 23 26 20 16 0 3 2 6
112 110 18 24 17 22 0 1 2 2
107 97 22 25 25 15 0 6 2 6
125 133 32 30 15 20 0 3 0 11
114 115 29 28 19 20 0 0 1 4
109 100 28 25 17 14 0 2 0 6
125 117 34 33 18 20 0 1 0 7
135 119 33 33 20 19 0 0 0 11
98 89 22 25 17 16 0 7 0 12
111 94 23 26 21 18 3 2 1 6
110 102 24 24 22 21 1 4 2 2
89 113 21 30 19 20 1 3 3 16
126 104 31 29 17 16 0 0 0 0
110 109 24 23 21 15 2 3 3 8
125 142 28 30 19 18 0 1 1 11
109 96 21 23 20 18 0 13 4 0
31 30 18 15 0 3 0 9
121 98 26 30 11 16 0 0 0 3
114 1 3 0 7
103 112 26 23 19 17 0 2 0 7
0 2 0 18
125 102 32 16 15 11 0 2 6
126 128 29 24 12 17 0 5 0 8
123 130 28 32 17 18 0 0 0 8
112 26 22 19 21 0 5 0 8
21 26 19 18 0 4 2 9
128 128 31 34 16 17 0 6 0 4
82 21 20 0 0 0 13
126 128 32 30 15 15 0 3 0 11
116 115 30 32 20 15 0 9 3 13
125 31 31 18 18 0
129 126 26 25 14 0 5 3 3
0 9 0 15
139 108 31 25 19 19
Fungus RyeGrs Positive
0 3 6
0 15 4
0 3 3
2 2 4
0 6 2
0 5 4
0 0 2
0 3 7
1 2 3
0 3 0
2 14 5
1 0 0
1 6 12
2 5 5
0 6 0
0 3 5
0 5 3
1 6 5
0 3 3
0 0 6
1 3 3
2 2 4
0 10 5
0 4 7
0 2 3
0 2 3
0 4 5
0 2 3
0 9 4
0 7 13
0 9 7
0 0 13
0 4 4
0 11 7
